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We	  have	  seen	  great	  advances	  in	  our	  knowledge	  of	  the	  genetic	  regulation	  of	  various	  cancers	  
in	   recent	   years,	   thanks	   in	   large	   part	   to	   large-­‐scale	   genome	   sequencing	   efforts.	   As	   we	  
catalogue	  and	  characterize	  the	  genomic	  aberrations	  associated	  with	  cancers	  with	  increasing	  
detail	   and	   accuracy,	   we	   are	   faced	   with	   the	   challenge	   of	   having	   to	   cull	   bystanders	   from	  
biologically	  active	  drivers	  and	  establish	   relevant	  disease	  context	   in	  which	   these	  drivers	  are	  
rate-­‐limiting.	   To	   address	   this	   challenge,	   we	   have	   adapted	   a	   loss-­‐of-­‐function	   screening	  
approach	   to	   function	   in	   the	   context	   of	   an	   intact	   tumor	   microenvironment	   using	   patient-­‐
derived	   xenografts	   that	   more	   faithfully	   recapitulate	   the	   human	   disease	   compared	   to	  
established	   cell	   lines.	   Due	   to	   the	   relevant	   genetic	   heterogeneity	   between	   human	   tumors	  
with	   the	   same	   clinico-­‐pathological	   indications,	   we	   have	   integrated	   independent	   screening	  
approaches	  in	  a	  flexible	  platform	  for	  the	  interrogation	  of	  patient-­‐derived	  samples	  as	  well	  as	  
genetically-­‐defined	  mouse	  models	  in	  exactly	  the	  same	  experimental	  conditions.	  The	  goal	  of	  
this	   platform	   is	   to	   identify	   context-­‐specific	   genetic	   vulnerabilities	   and	   translate	   these	  
findings	   into	   drug	   discovery	   opportunities.	   As	   proof	   of	   concept	   for	   this	   approach,	   we	  
describe	  the	  development	  of	  an	  in	  vivo	  loss-­‐of-­‐function	  screen	  to	  systematically	  interrogate	  
epigenetic	   dependencies	   in	   pancreatic	   ductal	   adenocarcinoma	   (PDAC).	   In	   addition	   to	   the	  
well-­‐known	   genetic	   alterations	   (Kras,	   TP53,	   CDKN2A/p16,	   SMAD4),	   some	   epigenetic	  
mechanisms	   demonstrated	   to	   play	   a	   central	   role	   in	   PDAC	   evolution	   and	   progression.	   The	  
screening	  system	  utilizes	  tumor	  cells	  isolated	  from	  low-­‐passage	  PDAC	  xenografted	  tissue	  and	  
a	   lentiviral	   library	   of	   pooled	   shRNAs	   targeting	   236	   potentially	   ”druggable”	   epigenetic	  
regulators.	  The	  custom-­‐designed	  shRNA	   library	   (10	  shRNAs	  per	  gene)	  was	  engineered	  with	  
unique	   molecular	   barcodes	   that	   allow	   quantitation	   of	   each	   clone	   by	   massively	   parallel	  
sequencing.	  Hairpins	  are	  clustered	  according	  to	  their	  depletion	  or	  enrichment	  in	  comparison	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to	  a	  control	  population	  before	  transplantation.	  To	  date,	  we	  have	  completed	  a	  total	  of	  5	   in	  
vivo	  screens	  using	  diverse	  PDAC	  target	  cell	  models	  that	  have	   informed	  on	  novel	  epigenetic	  
dependencies.	  So	   far,	   the	  main	   limitation	   for	   the	  systematic	  exploitation	  of	   in	  vivo	   loss-­‐of-­‐
function	  screens	  to	  identify	  specific	  patient	  vulnerabilities	  come	  from	  the	  limited	  number	  of	  
human	  cells	  contributing	  to	  tumor	  establishment	  in	  a	  transplantation	  setting.	  The	  frequency	  
of	   these	   tumors	   initiating	   cells	   (TICs)	   is	   commonly	   estimated	   by	   time-­‐consuming	   limiting	  
dilution	  assays	  and	  may	  consistently	  vary	  between	  different	  tumor	  origins.	  With	  this	  in	  mind,	  
we	   have	   integrated	   in	   our	   platform	   a	   system	   based	   on	   scrambled	   barcoded	   libraries	   that	  
allows	   to	   directly	   assess	   the	   required	   coverage	   of	   screening	   libraries	   in	   each	   model	   and	  
adjust	  the	  shRNA	  screens	  for	  this	  factor.	  Our	  coverage	  study	  demonstrated	  to	  be	  a	  powerful	  
tool	  to	  identify	  the	  minimal	  number	  of	  cells/barcode	  required	  to	  sustain	  a	  complex	  library	  in	  
transplantation	   assay	   and	   at	   the	   same	   time	   a	   step	   forward	   to	   personalize	   the	   in	   vivo	  
screening	   patient	   by	   patient.	   We	   optimized	   a	   comprehensive	   data	   analytics	   pipeline	   and	  
developed	   a	   high-­‐throughput	   validation	   scheme	   to	   triage	   "hits"	   that	   emerge	   from	   each	  
screen.	   The	   most	   potent	   "hits"	   have	   been	   enrolled	   in	   both	   functional	   and	   clinico-­‐
pathological	  validation	  studies	  to	  determine	  the	  highest	  priority	  targets	  for	  this	  devastating	  
disease.	   Significantly,	   different	   components	   of	   the	   COMPASS	   histone	   H3	   Lys4	   (H3K4)	  
methyltransferase	   complexes	  were	   identified	   as	   candidates	   in	   our	   screens.	   COMPASS	   and	  
COMPASS-­‐like	   complexes	   are	   characterized	   by	   unique	   subunits	   composition,	   whose	  
identities	   provide	   insight	   into	   the	   different	   biological	   functions	   of	   these	   complexes.	   The	  
methyltransferase	  unit	  of	  the	  COMPASS	  complexes	  is	  directly	  involved	  into	  the	  methylation	  
of	   Lys4	   on	   histone	   H3,	   a	   commonly	   accepted	   sign	   of	   open-­‐chromatin	   and	   active	  
transcription.	   Chromosomal	   translocations	   involving	   MLL	   gene	   are	   frequent	   events	  
characterizing	   the	  Mixed	   Lineage	   Leukemia.	   In	   this	   disease,	   it	   has	  been	   shown	   that	   fusion	  
events	  with	  a	  variety	  of	  different	  partners	  compromise	  the	  MLL	  methyltransferase	  activity.	  
However,	  multiple	  members	  of	  the	  MLL	  family	  could	  be	  deregulated	  via	  different	  oncogenic	  
mechanisms	  in	  PDAC,	  as	  the	  genetic	  alteration	  in	  MLL2	  (amplification)	  and	  MLL3	  (mutation)	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suggested.	   Our	   platform	   represents	   an	   ideal	   starting	   point	   to	   understand	   the	   COMPASS	  
functionalities.	   So,	   a	  deeper	  understanding	  of	   genes	  and	  pathways	   regulated	  by	  each	  MLL	  
subunit	  in	  the	  context	  of	  PDAC	  is	  critical	  to	  better	  elucidate	  the	  molecular	  dynamics	  of	  this	  
disease	   and	   identify	   additional	   key	   points	   of	   vulnerability.	   Our	   study	   identified	   the	   core	  
different	   subunits	   of	   the	   COMPASS	   complexes	   (WDR5-­‐ASH2L-­‐RBBP5)	   as	   broad	   relevant	  
players	  in	  sustain	  PDAC	  progression,	  while	  the	  dependency	  on	  the	  MLL	  subunits	  appears	  to	  
be	   more	   context-­‐dependent	   and	   potentially	   consequent	   to	   specific	   genetic	   alterations.	  
Mechanistically,	   WDR5	   functions	   to	   sustain	   proper	   execution	   of	   DNA	   replication	   in	   PDAC	  
cells,	   as	   previously	   suggested	   by	   replication	   stress	   studies	   involving	   MLL1,	   a	   critical	   ATR	  
substrate,	   and	   c-­‐Myc,	   also	   found	   to	   interact	   with	   WDR5.	   By	   showing	   that	   ATR	   inhibition	  
mimicked	  the	  effects	  of	  WDR5	  suppression,	  we	  open	  up	  the	  possibility	  of	  testing	  inhibitors	  
currently	   in	   development	   for	   activity	   in	   this	   disease.	   These	   findings	   are	   proposing	   a	   new	  
layer	  of	   complexities	   in	   trapping	   the	  COMPASS	   complexes	  during	   tumor	  development	   and	  
unmasking	  unexplored	  directions	  for	  new	  therapeutical	  opportunities.	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Acronyms	  and	  Abbreviations	  
 
4-­‐OHT	  =	  4-­‐Hydroxytamoxifen;	  	  
ACA	  =	  Anti-­‐centromere	  antibodies;	  	  
Alb	  =	  Albumin;	  	  
BrdU	  =	  5-­‐Bromo-­‐2-­‐Deoxyuridine;	  	  
Cag	  =	  Gag	  promoter;	  	  
Cas9	  =	  CRISPR-­‐associated	  protein	  9;	  	  
CDF	  =	  Cumulative	  distribution	  function;	  	  
CDKi	  =	  CDK	  inhibitors;	  	  
CFA	  =	  Colony	  formation	  assay;	  	  
CRISPR	  =	  Clustered	  regularly	  interspaced	  short	  palindromic	  repeats;	  	  
CSC	  =	  Cancer	  stem	  cell;	  	  
DAPI	  =	  4',6-­‐diamidin-­‐2-­‐fenilindolo;	  	  
DOX	  =	  doxycycline;	  	  
dsRNA	  =	  double	  strand	  RNA;	  	  
ELDA	  =	  Extreme	  limiting	  dilution	  analysis;	  	  
FC	  =	  Fold-­‐change;	  	  
FDR	  =	  False	  discovery	  rate;	  	  
Flpo	  =	  Flippase;	  	  
Gag	  =	  Group-­‐specific	  antigen;	  	  
GEMM	  =	  Genetic	  engineered	  mouse	  model;	  	  
GFP	  =	  Green	  fluorescent	  protein;	  	  
GSC	  =	  Glioblastoma	  stem	  cell;	  	  
GSEA	  =	  Gene	  set	  enrichment	  analysis;	  	  
H3K27	  =	  Histone	  3	  Lysine	  27;	  	  
H3K4	  =	  Histone	  3	  Lysine	  4;	  	  
H3K4me3	  =	  Trimethylation	  of	  the	  Histone	  3	  Lysine	  4;	  	  
HMT	  =	  Histone	  methyltransferase;	  	  
HU	  =	  Hydroxyurea;	  	  
IC	  =	  Initiation	  complex;	  	  
ICGC	  =	  International	  cancer	  genome	  consortium;	  	  
IEG	  =	  Immediate	  early	  gene;	  	  
IRES	  =	  Internal	  ribosome	  entry	  site;	  	  
KINK	  =	  KrasG12D_LSL/+;	  Ink4aL/L	  	  background;	  
KP53	  =	  KrasG12D_LSL/+;	  Trp53L/L	  	  background;	  	  
Krt19	  =	  Cytokeratin	  19	  promoter;	  	  
LOF	  =	  Loss-­‐of-­‐function;	  	  
LSM	  =	  Lentiviral-­‐based	  somatic	  mosaic	  system;	  	  
miRNA	  =	  micro	  RNA;	  	  
MOI	  =	  Multiplicity	  of	  infection;	  	  
MRI	  =	  Magnetic	  resonance	  imaging;	  	  
mRNA	  =	  messenger	  RNA;	  	  
MT	  =	  Methyltransferase;	  	  
NGS	  =	  Next-­‐generation	  sequencing;	  	  
NlsCre	  =	  Cre	  recombinase	  gene;	  	  
NM	  =	  Number	  of	  molecules;	  	  
NSG	  =	  NOD/SCID	  gamma;	  	  
NT	  =	  Non	  targeting;	  	  
ORF	  =	  open	  reading	  frame;	  	  
OTE	  =	  Off-­‐target	  effect;	  	  
PCC	  =	  Premature	  chromosome	  condensation;	  	  
PCR	  =	  Polymerase	  chain	  reaction;	  	  
PDAC	  =	  Pancreatic	  ductal	  adenocarcinoma;	  	  
PDX	  =	  Patient-­‐derived	  xenograft;	  	  
PuroR	  =	  Puromycin	  resistance	  cassette;	  	  
R26	  =	  Rosa26	  gene	  locus;	  	  
RC	  =	  replication	  complex;	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Ref	  Cells	  =	  Reference	  cell	  population	  in	  studies	  with	  barcoded	  libraries;	  	  
RFP	  =	  Red	  fluorescent	  protein;	  	  
RISC	  =	  RNA-­‐induced	  silencing	  complex;	  	  
RNAi	  =	  RNA	  interference;	  	  
SD	  =	  Standard	  deviation;	  	  
shRNA	  =	  short	  hairpin	  RNA;	  	  
siRNA	  =	  small	  interfering	  RNA;	  	  
stRNA	  =	  small	  temporal	  RNA;	  	  
Tet	  =	  Tetracycline;	  	  
TF	  =	  Transcription	  factor;	  	  
TIC	  =	  Tumor-­‐initiating	  cell;	  	  
TMA	  =	  Tissue	  microarray;	  	  
TPC	  =	  Tumor	  perpetuating	  cell;	  	  
TSG	  =	  Tumor	  suppressor	  gene;	  	  
TSS	  =	  Transcriptional	  start	  site;	  	  
TU	  =	  Transducing	  units;	  	  
Tx	  =	  Tumor;	  	  
UTR	  =	  untranslated	  region;	  	  
Veh	  =	  Vehicle;	  	  
WRAD	  =	  WDR5-­‐RBBP5-­‐ASH2L-­‐DPY30	  complex;	  	  
WT	  =	  Wild-­‐type;	  	  
Xenograft	  I	  =	  Primary	  xenograft;	  	  
Xenograft	  II	  =	  Secondary	  xenograft;	  	  
γH2AX	  =	  Phospho-­‐H2AX.	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Introduction	  
	  
1.	  Pancreatic	  cancer	  	  	  
Pancreatic	  ductal	  adenocarcinoma	  (PDAC)	  is	  the	  most	  common	  cancer	  of	  the	  pancreas	  and	  
contributes	  to	  6.9%	  of	  all	  cancer	  deaths	  in	  the	  US,	  with	  an	  estimated	  48,960	  new	  cases	  and	  
40,560	  deaths	  in	  2015	  alone.	  Present	  estimates	  predict	  that	  >1.5%	  of	  the	  US	  population	  will	  
be	   diagnosed	   with	   PDAC	   in	   their	   lifetime	   (NCI/SEER	   2015).	   Moreover,	   there	   has	   been	   an	  	  
approximate	  14%	  increase	  in	  PDAC	  incidence	  compared	  to	  5	  years	  ago	  (estimation	  based	  on	  
SEER	   2015	   data).	   In	   keeping	  with	   this	   upward	   trend,	   it	   is	   projected	   that	   PDAC	  will	   be	   the	  
second	   leading	   cause	   of	   cancer	   death	   in	   the	   next	   15	   years,	   trailing	   only	   lung	   cancer1.	  
Unfortunately,	  the	  overall	  5-­‐year	  survival	  rate	  for	  PDAC	  patients	  is	  a	  dreadful	  ~6%.	  Major	  risk	  
factors	   for	   PDAC	   include	   smoking,	   diabetes,	   chronic	   pancreatitis	   as	  well	   as	   family	   history.	  
Early	  PDAC	  is	  often	  asymptomatic	  and	  there	  are	  no	  serological	  biomarkers	  in	  the	  clinic	  that	  
are	   specific	   for	   detecting	   precursor	   lesions	   in	   the	   general	   population,	   although	   promising	  
biomarkers	   are	   emerging.2	   It	   is	   estimated	   that	   it	   may	   take	   ~17	   years	   for	   a	   single	   tumor-­‐
initiating	   cell	   to	  develop	   into	  metastases,	   suggesting	   that	   there	   should	  be	  an	  emphasis	  on	  
biomarker	  discovery	  for	  early	  diagnosis3.	  
	  The	   standard	   of	   care	   for	   advanced	   PDAC	   has	   been	   either	   gemcitabine	   or	   its	   combination	  
with	  other	  agents	  (i.e.	  nab-­‐paclitaxel,	  erlotinib),	  which	  only	  provides	  very	  limited	  benefit4-­‐7.	  
FOLFIRINOX	  was	   approved	   recently	   for	   advanced	   PDAC	   and	   results	   in	   real	   responses,	   but	  
only	   in	   a	   subset	   of	   patients8.	   Approximately	   half	   of	   patients	   who	   progress	   on	   one	   of	   the	  
front-­‐line	   regimens	   receive	   second-­‐line	   therapy.	   For	   patients	   who	   progressed	   on	  
gemcitabine-­‐based	  therapy,	  a	  fluropyrimidine	  plus	  oxaliplatin	  regimen	  is	  standard,	  whereas	  
a	   gemcitabine-­‐based	   regimen	   is	   often	   chosen	   for	   patients	   who	   progressed	   on	  
FOLFIRINOX9,10.	   Even	  with	   aggressive	   treatment,	  median	   survival	   remains	   less	   than	  1	   year.	  
No	  standard	  of	  care	  treatment	  has	  been	  identified	  for	  patients	  who	  progress	  after	  second-­‐
line	  treatment7,8.	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Chemotherapy	   has	   proven	   disappointing	   in	   the	   treatment	   of	   PDAC,	   and	   a	   multi-­‐pronged	  
approach	   is	   being	   taken	   to	   identify	   new,	  more	   effective	   therapeutics.	   This	   includes	  more	  
potent	  chemotherapeutic	  drugs	  with	  improved	  delivery	  for	  solid	  tumors,	  as	  well	  as	  targeted	  
therapies.	   Currently,	   the	   only	   approved	   targeted	   therapy	   for	   PDAC	   is	   the	   EGFR	   inhibitor	  
erlotinib,	   which	   showed	   a	   modest	   survival	   benefit	   in	   combination	   with	   gemcitabine	  
compared	   to	   gemcitabine	   alone11.	   Given	   that	   up	   to	   90%	   of	   PDAC	   are	   estimated	   to	   have	  
overexpression	   of	   EGFR,	   drugs	   targeting	   EGFR	   continue	   to	   be	   investigated	   for	   this	  
disease12,13.	  	  
The	  genomic	  landscape	  of	  PDAC	  is	  dominated	  by	  oncogenic	  mutation	  of	  KRAS,	  present	  in	  up	  
to	  90%	  or	  more	  of	  cases14,15.	  Ample	   functional	  evidence	   from	  animal	  models	  suggests	   that	  
mutant	   Kras	   is	   critical	   in	   both	   PDAC	   initiation	   and	   in	   maintenance16,17.	   The	   characteristic	  
activating	   point	  mutation	   in	   this	   small	   GTPase	   has	   been	   profoundly	   challenging	   to	   inhibit	  
from	  a	  pharmacological	  perspective,	  and	  drugs	   intended	  to	   impede	  membrane	   localization	  
and	   activation	   by	   blocking	   prenylation	   have	   also	   failed18,19,20.	   Activating	  mutation	   in	   KRAS	  
results	   in	   constitutively	   active	   RAF/MEK/ERK	   and	   PI3K/AKT	   signaling,	   which	   drives	  
uncontrolled	   cell	   growth.	   As	   such,	   pharmacological	   targeting	   of	   these	   pathways	   is	   of	  
significant	   interest.	   So	   far,	   no	   single	   agent	   has	   yielded	   a	   clinical	   benefit,	   including	   the	  
MEK1/2	   inhibitor	   selumetinib,	   which	   is	   now	   approved	   for	   the	   treatment	   of	   metastatic	  
melanoma.	   Based	   on	   clinical	   trial	   results,	   it	   is	   widely	   held	   that	   simultaneous	   targeting	   of	  
multiple	  signaling	  cascades	  will	  be	  required	  to	  effectively	  block	  the	  KRAS	  signaling	  network.	  
Unfortunately,	   cumulative	   drug	   toxicities	   may	   diminish	   the	   clinical	   utility	   of	   such	   an	  
approach21	  .	  
Activating	   KRAS	   mutations	   is	   an	   early	   event	   in	   PDAC	   pathogenesis	   that	   is	   present	   in	  
pancreatic	   intraepithelial	   neoplasias	   (PanINs),	   the	   precursor	   lesion	   for	   PDAC15.	   (Fig.1)	  
Additional	  genetic	   inactivation	  of	  the	  tumor	  suppressors,	  CDKN2A,	  TP53,	  and	  SMAD4	  (each	  
present	  in	  >50%	  of	  PDAC)	  is	  associated	  with	  transition	  from	  PanINs	  to	  PDAC.	  Moreover,	  the	  
presence	   of	   Smad4	   and	   p53	   mutations	   in	   primary	   tumors	   correlates	   with	   increased	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propensity	   for	   metastatic	   dissemination.	   The	   pioneering	   development	   of	   a	   conditional	  
mutant	   Kras	   allele	   by	   Jacks	   and	   Tuveson	   enabled	   the	   first	   studies	   that	   demonstrated	   that	  
mutant	  Kras	  drives	  PanIN	  formation	  in	  association	  with	  local	  inflammation21,22	  .	  Moreover,	  it	  
has	  been	  shown	  that	  inactivation	  of	  CDKN2A,	  P53,	  and	  SMAD4	  synergizes	  with	  mutant	  Kras	  
to	  promote	  PDAC	  progression22-­‐25.	  	  
	  
A	  series	  of	  cancer	  genomics	  studies	  has	  expanded	  the	  PDAC	  mutation	  landscape,	  identifying	  
numerous	  less	  frequent	  genetic	  lesions.	  It	  is	  now	  clear	  that,	  in	  addition	  to	  the	  signature	  set	  
of	   mutations	   described	   above,	   PDAC	   tumors	   harbor	   recurrent	   genetic	   alterations	   in	  
chromatin	   regulators	   (e.g.	   ARID1A,	   ARID1B,	   KDM6A,	   MLL3),	   WNT	   pathway	   components	  
(RNF43),	   DNA	   damage	   genes	   (ATM,	   BRCA2),	   and	   other	   signaling	   pathways	   (e.g.	  
MAP2K4)26,27,28.	  However,	  none	  of	  these	  alterations	  are	  present	  in	  more	  than	  ~15%	  of	  PDAC.	  
Figure	   1.	   KRAS	   is	   a	  master	   regulator	   of	   pancreatic	   ductal	   adenocarcinoma	   initiation	   and	   progression.	   Constitutively	  
active	  KRAS	   (caused	  by	  KrasG12D	   or	  KrasG12V	  mutations)	   is	   sufficient	   to	   initiate	   the	  development	  of	  pancreatic	   intraepithelial	   neoplasia	  
(PanIN)	   and	   pancreatic	   ductal	   adenocarcinoma	   (PDAC).	   PanINs	   are	   classified	   into	   three	   stages	   of	   increasing	   cellular	   atypia	   and,	   in	  
humans,	   have	   been	   found	   to	   possess	   increasing	   numbers	   of	  mutations	   (common	  mutations	   are	   indicated	   in	   boxes).	   Changes	   in	   the	  
epithelium	  are	  matched	  by	  desmoplastic	  changes	  in	  the	  stroma.	  In	  mouse	  models,	  the	  human	  PanIN	  spectrum	  followed	  by progression	  
to	   PDAC	   has	   been	   recapitulated	   by	   activating	   mutant	   KRAS	   in	   embryonic	   pancreatic	   progenitors.	   Eliminating	   tumour	   suppressors	  
commonly	  inactivated	  in	  the	  human	  disease	  dramatically	  decreases	  PDAC	  latency	  (a	  limited	  set	  of	  examples	  is	  indicated).	  Mouse	  models	  
in	  which	  KRAS	  is	  activated	  specifically	  in	  some	  adult	  cell	  types	  have	  shown	  that	  both	  acini	  and	  insulin-­‐positive	  cells	  can	  give	  rise	  to	  PanINs	  
and,	  in	  some	  cases,	  PDAC	  depending	  on	  tissue	  damage	  and	  tumour	  suppressor	  inactivation.	  For	  these	  cell	  types,	  reprogramming	  into	  a	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In	   addition,	   studies	   of	   PDAC	   patients	   at	   autopsy	   have	   revealed	   that	   there	   is	   extensive	  
intratumoral	   genomic	   heterogeneity	  with	   only	   KRAS	  mutation	   being	   consistently	   detected	  
across	  different	  tumor	  clones.	  This	  strikingly	  high	  intratumoral	  heterogeneity	  has	  important	  
implications	   for	   the	   deployment	   of	   targeted	   therapeutics	   against	   these	   newly	   identified	  
pathways.	   Thus,	   agents	   targeting	   the	   founder	   mutations	   in	   PDAC	   (i.e.	   KRAS)	   may	   be	  
predicted	  to	  have	  the	  highest	  potential	  for	  clinical	  impact.	  However,	  this	  does	  not	  preclude	  
the	  possibility	  of	   targeting	   lower	  frequency	  mutations	  that	  may	  render	  subclasses	  of	  PDAC	  
cells	   sensitive	   to	   particular	   therapies.	   For	   example,	   approximately	   5%	   of	   PDAC	   harbor	   bi-­‐
allelic	   mutations	   of	   BRCA2,	   PALB2	   or	   other	   genes	   in	   the	   Fanconi	   anemia	   DNA	   repair	  
pathway,	   and	   these	   tumors	   are	   highly	   susceptible	   to	   double-­‐strand	   break-­‐inducing	   drugs,	  
such	   as	   platinum	   compounds29,30,31.	   As	   noted	   above,	   parsing	   the	   genome	   of	   PDAC	   from	  
emerging	   large	   scale	  datasets	   like	  TCGA	  and	   ICGC	   reveals	   the	  existence	  of	  numerous	   such	  
potential	   vulnerability	   nodes	   in	   PDAC,	   the	   vast	   majority	   of	   which	   remain	   untested	   and	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2.	  Epigenetics	  and	  pancreatic	  cancer	  
	  
All	  of	  the	  cells	  in	  an	  organism	  carry	  the	  same	  genome,	  but	  it	   is	  the	  regulated	  expression	  of	  
specific	  genes	  that	  allows	  cells	  to	  achieve	  diverse,	  stable	  phenotypes.	  The	  term	  "epigenetics"	  
describes	   heritable	   molecular	   modifications	   within	   cells	   that	   maintain	   the	   required	  
information	   to	   preserve	   a	   cellular	   phenotype	   across	   generations.	   A	   number	   of	   different	  
changes	  are	  used	  by	  cells	   to	  "remember"	  their	   transcriptional	  programming.	  These	   include	  
direct	   modifications	   of	   DNA,	   such	   as	   methylation,	   hydroxylation,	   formylation,	   and	  
carboxylation;	   variations	   in	   nucleosome	   occupancy	   and	   positioning;	   histone	   variants;	   and	  
histone	   post-­‐translational	   modifications,	   including	   methylation,	   acetylation,	  
phosphorylation,	  ubiquitylation,	  sumoylation,	  and	  at	  least	  11	  other	  modifications32,33.	  
While	  cancer	  has	  historically	  been	  considered	  a	  disease	  driven	  by	  genomic	  alterations,	   it	   is	  
now	   clear	   that	   epigenetic	   modifications	   of	   chromatin	   also	   play	   a	   key	   role	   in	   tumor	  
pathogenesis.	  Several	   lines	  of	  evidence	  underscore	  the	   importance	  of	  epigenetic	  control	   in	  
tumors.	   First,	   epigenetic	   silencing	   of	   tumor	   suppressor	   genes	   by	   promoter	   CpG	   island	  
hypermethylation	  has	  been	  documented	  and	  demonstrated	   to	  be	  mutually	   exclusive	   from	  
mutational	  inactivation	  of	  the	  same	  gene34,35,36.	  Second,	  epigenetic	  writers	  and	  readers	  have	  
both	   been	   shown	   to	   be	   required	   for	   tumor	   development	   in	   various	   mouse	  models37,38,39.	  
Third,	   evidence	   exists	   that	   tumor	   cells	   may	   acquire	   oncogene	   addiction	   to	   epigenetic	  
alterations,	  particularly	  DNA	  methylation40.	  Finally,	  whole-­‐genome	  sequencing	  of	  a	  number	  
of	  different	  cancers	  has	  catalogued	  recurrent	  somatic	  mutations	  in	  a	  vast	  array	  of	  epigenetic	  
regulators41.	  
The	   COMPASS	   complex	   (complex	   of	   proteins	   associated	   with	   Set1)	   was	   first	   identified	   in	  
yeast	   as	   a	   complex	   with	   specific	  methyltransferase	   (MT)	   activity	   for	   lysine	   4	   of	   histone	   3	  
(H3K4)42.	  Subsequently,	  six	  homologous	  complexes,	   including	  2	  COMPASS	  and	  4	  COMPASS-­‐
like	  complexes,	  were	  identified	  in	  humans	  that	  shared	  core	  components	  but	  form	  complexes	  
with	   different	   histone	   methyltransferases	   (HMTs;	   Set1A,	   Set1B,	   MLL1,	   MLL2,	   MLL3,	   or	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MLL4).	   All	   six	   HMTs	   have	   H3K4	   methylation	   activity	   in	   common	   due	   to	   a	   conserved	   SET	  
domain,	   resulting	   in	   “activating”	   marks	   on	   chromatin	   at	   actively	   transcribed	   regions43.	  
Despite	  this	  common	  function,	  the	  complexes,	  as	  well	  as	  the	  subunits	  within	  the	  complexes,	  
have	   a	   range	   of	   both	   redundant	   and	   non-­‐redundant	   roles,	   including	   methylation-­‐
independent	  roles,	  in	  cell	  development	  and	  differentiation44.	  
Recently,	   exome	   sequencing	   of	   PDAC	   patient	   samples	   by	   the	   ICGC	   has	   revealed	   loss-­‐of-­‐
function	   somatic	   mutations	   in	   three	   members	   of	   the	   chromatin-­‐modifying	   COMPASS-­‐like	  
complex	  family,	  MLL3,	  MLL4	  and	  UTX,	  at	  a	  cumulative	  frequency	  exceeding	  20%	  of	  cases	  and	  
a	   recent	  work	  by	  a	  collaborator	  at	  MD	  Anderson	  has	  produced	   in	  vivo	  data	   from	  a	  mouse	  
model	   of	   PDAC	   supporting	   tumor	   suppressor	   activity	   by	   MLL3	   in	   the	   context	   of	   mutant	  
Kras45.	   Moreover,	   numerous	   roles	   for	   COMPASS-­‐like	   proteins	   have	   been	   detailed	   in	   the	  
literature	  for	  many	  cancers,	  with	  the	  oncogenic	  effects	  of	  MLL1	  in	  hematologic	  malignancies	  
being	  particularly	  well	  characterized46.	  
The	   core	   COMPASS-­‐like	   subunits	   (WDR5-­‐RBBP5-­‐ASH2L-­‐DPY30),	   also	   known	   as	   WRAD,	  	  
complex	   with	   MLL2,	   MLL3,	   and	   MLL4	   as	   well	   as	   MLL1.	   MLL1	   and	   MLL2	   more	   closely	  
resemble	  Drosophila	  Trithorax	  protein	  and	  can	  complex	  with	  the	  tumor	  suppressor	  Menin47.	  
Conversely,	  MLL3	  and	  MLL4	  bind	  with	  the	  H3K7	  demethylase	  UTX	  (among	  others),	  and	  these	  
complexes	   have	   been	   shown	   to	   act	   as	   tumor	   suppressors	   in	   both	   hematological	  
malignancies	   and	   solid	   tumors48,49,50.	   Despite	   their	   different	   activities	   in	   the	   cell,	   all	   MLL	  
proteins	  can	  complex	  with	  the	  core	  WRAD	  proteins,	  and	  all	  have	  H3K4	  MT	  activity51,52.	  
MLL	  and	  the	  WRAD	  complex	  have	  been	   implicated	   in	  cell	  cycle	  control	  and	  execution,	  also	  
modulating	  their	  expression53,54,55.	  Most	  recently,	  it	  has	  been	  reported	  that	  MLL1	  association	  
with	  the	  WRAD	  complex	  is	  required	  for	  cells	  to	  progress	  through	  S	  phase,	  and	  that	  MLL1	  is	  a	  
substrate	  of	  ATR	  during	  the	  S-­‐phase	  checkpoint56.	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3.	  RNA	  interference	  (RNAi)	  discovery	  and	  biological	  implications	  
	  
The	   biological	   process	   of	   RNA	   interference	   (RNAi)	   was	   first	   discovered	   in	   Caenorhabditis	  
elegans	  as	  a	  response	  to	  double-­‐stranded	  RNA	  (dsRNA),	  which	  resulted	  in	  sequence-­‐specific	  
gene	  silencing.	  Starting	   from	  the	   initial	   findings	   in	  worms,	  Fire	  and	  colleagues	  proposed	  to	  
use	  antisense	  RNA	  as	  an	  approach	  to	  inhibit	  gene	  expression,	  demostarting	  that	  the	  double	  
strand	  DNA	  (dsRNA)	  was	  at	  least	  ten-­‐fold	  more	  potent	  as	  a	  silencer	  than	  sense	  or	  antisense	  
RNAs	   alone57,58.	   This	   discovery	   promoted	   the	   hypothesis	   that	   a	   number	   of	   previously	  
characterized	  mechanisms	   for	   silencing	  gene	  expression	  could	  be	  originated	  by	  a	   common	  
biological	  mechanism.	  Biochemical	  and	  genetic	  experiments	  were	  able	   to	  prove	  that	  RNAi,	  
co-­‐suppression	  and	  virus-­‐induced	  gene	   silencing	  are	  mechanistically	   similar,	   and	   that	  RNAi	  
gene	  silencing	  is	  shared	  by	  many	  eukaryotic	  organisms59,60.	  	  
Genetic	  studies	  in	  C.	  elegans	  and	  plants	  and	  biochemical	  studies	  in	  Drosophila	  generated	  our	  
present	   understanding	   of	   the	   mechanisms	   underlying	   dsRNA	   gene	   silencing.	   Basically,	  
injection	  of	  dsRNA	   into	  Drosophila	  embryos	   induced	   sequence-­‐specific	  post-­‐transcriptional	  
silencing61.	   Then,	   it	  was	  also	  demonstrated	   that	  Drosophila	  embryo	  extracts	  might	  also	  be	  
competent	  for	  RNA	  interference62.	  Reduction	  in	  luciferase	  synthesis	  from	  a	  synthetic	  mRNA	  
was	   observed	   in	   cell-­‐free	   lysates	   upon	   incubation	   with	   dsRNA	   and	   suggested	   that	   dsRNA	  
might	   drive	   the	   assembly	   of	   a	   nuclease	   complex	   that	   targets	   the	   homologous	   RNA	   for	  
degradation	  to	  induce	  gene	  silencing.	  
This	  nuclease	  complex,	  now	  known	  as	  RISC	  (RNA-­‐induced	  silencing	  complex),	  was	  extracted	  
from	  Drosophila	  S2	  cells	  in	  which	  RNAi	  response	  was	  simulated	  by	  treatment	  with	  dsRNA63.	  
Additional	   studies,	   proving	   the	   existence	   of	   “RNA	   guides”,	   corroborated	   the	   original	   RNAi	  
hypothesis	   that	   some	   dsRNA	   byproducts	   could	   drive	   the	   identification	   of	   substrates	   for	  
RNAi.	   In	   this	   direction,	   antisense	   RNAs	   with	   homology	   to	   genes	   being	   targeted	   by	   co-­‐
suppression	  were	  identified8.	  More	  than	  that,	  a	  ~25-­‐nucleotide	  RNA	  was	  discovered	  only	  in	  
plants	  experiencing	  specific	  gene	  suppression	  and	  homologous	  RNA	  products	  were	  observed	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during	   virus-­‐induced	   gene	   silencing.	   Similar	   small	   RNAs	   were	   produced	   from	   dsRNAs	   and	  
found	  in	  complex	  together	  with	  nuclease	  activity	  of	  RISC	  in	  Drosophila	  embryos63,64,65.	  
	  A	  model	  for	  RNAi	  was	  proposed,	   in	  which	  silencing	   initiates	  upon	  recognition	  of	  dsRNA	  by	  
machinery	   that	   converts	   the	   dsRNAs	   in	   ~21–25-­‐nucleotide	   RNAs66.	   These	   small	   interfering	  
RNAs	   (siRNAs)	  drive	   the	   identification	  of	   the	  homologous	  substrates	  being	  assembled	  with	  	  
an	   effector	   RISC	   machinary.	   The	   wide	   biological	   nature	   of	   dsRNA-­‐induced	   silencing	  
suggested	  that	   the	  central	  RNAi	  machinery	  potentially	  modified	   itself	   to	  answer	  to	  specific	  
biological	  requests	  in	  different	  organisms.	  
However,	  in	  all	  the	  organisms	  the	  dsRNA	  has	  to	  be	  cleaved	  to	  generate	  siRNAs.	  Experiments	  
oriented	  to	  the	  discovery	  of	  the	  enzyme	  involved	  into	  the	  initial	  RNAi	  step	  highlighted	  a	  new	  
RNase	   III	   ribonuclease	   family	  with	  unprecedented	   specificity	   for	  dsRNA.	  RNase	   III	   enzymes	  
can	  be	  divided	   into	   three	   classes	  based	  on	   structural	   domains:	   i)	   RNase	   III	   costituted	  by	  a	  
single	   catalytic	   domain	   and	   a	   dsRNA-­‐binding	   domain;	   ii)	   Drosha	   family	   nucleases	   contain	  
dual	   catalytic	   domains;	   and	   iii)	   a	   third	   family	   also	   contains	   dual	   catalytic	   domains	   and	  
additional	   helicase	   and	   PAZ	   motifs67,68,69.	   The	   third	   family	   was	   named	   Dicer	   and	   was	  
demonstrated	  to	  be	  	  evolutionarily	  conserved69,70.	  The	  tridimensional	  structure	  of	  the	  RNase	  
III	  catalytic	  domain	  sustained	  a	  model	  in	  agreement	  with	  generation	  of	  ~22-­‐nucleotide	  RNAs	  
by	  Dicer	  cleavage70.	  
RNAi	   is	   also	   constituted	   by	   RISC,	   the	   ribonuclease	   complex	   that	   recognizes	   and	   destroys	  
specific	   target	  mRNAs.	   Initally,	   the	   siRNA,	  which	   presumably	   identifies	   substrates	   through	  
base	   pairing,	   was	   identified	   as	   critical	   subunit	   of	   the	   RISC71.	   Cleavage	   is	   apparently	  
endonucleolytic,	  and	  occurs	  only	  in	  the	  region	  homologous	  to	  the	  siRNA.	  siRNAs	  are	  double-­‐
stranded	   duplexes	   with	   two-­‐nucleotide	   overhangs	   and	   phosphate	   termini,	   and	   this	  
configuration	  is	  functionally	  important	  for	  incorporation	  into	  RISC	  complexes72-­‐74	  .	  (Fig.2)	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Because	   base	   pairing	   interactions	   drive	   mRNA	   identification,	   the	   RNAi	   machinery	   can	   be	  
both	  dynamic	  and	  specific.	  Thus,	  the	  RNAi	  machinary	  has	  been	  adapted	  to	  numerous	  cellular	  
functions	   and	   organisms75.	   The	   normal	   gene	   regulation	   of	   endogenous	   levels	   could	   be	  
influenced	  by	  the	  RNAi	  mechanisms,	  as	  suggested	  through	  the	  analysis	  of	  plants	  and	  animals	  
containing	   dysfunctional	   RNAi	   components,	   even	   though	   this	   findings	   should	   not	   be	  
interpreted	   as	   proof	   that	   RNAi	   pathways	   independently	   regulate	   endogenous	   gene	  
expression.	   A	   possible	   mechanism	   emerged	   from	   the	   study	   of	   C.	   elegans	   containing	  
mutations	   in	   their	   single	   Dicer	   gene,	   DCR-­‐176.	   Interestingly,	   Dicer	   mutants	   displayed	  	  
alterations	   in	   developmental	   timing	   similar	   to	   those	   observed	   in	   let-­‐7	   and	   lin-­‐4	  mutants.	  
These	   loci	   encode	   small	   RNAs,	   which	   are	   synthesized	   as	   precursors	   and	   post-­‐
transcriptionally	   processed	   to	   a	   ~21-­‐nucleotide	   mature	   form.	   Additional	   studies	   have	  
confirmed	   that	   these	   RNAs	   are	   processed	   by	   Dicer77.	   The	   small	   temporal	   RNAs	   (stRNAs)	  
encoded	   by	   let-­‐7	   and	   lin-­‐4	   are	   negative	   regulators	   of	   specific	   protein-­‐coding	   genes,	   but	  
regulate	  expression	  at	   the	  translational	   level77,78.	  This	  generated	  the	  hypotesis	   that	  stRNAs	  
Figure	   2.	   Unlocking	   the	   potential	  
of	   the	   human	   genome	   with	   RNA	  
interference	  
Long	  dsRNA	  and	  miRNA	  precursors	   are	  
processed	  to	  siRNA/miRNA	  duplexes	  by	  
the	   RNase-­‐III-­‐like	   enzyme	   Dicer.	   These	  
short	   dsRNAs	   are	   subsequently	  
unwound	   and	   assembled	   into	   effector	  
complexes,	  RISCs,	  which	  can	  direct	  RNA	  
cleavage,	   mediate	   translational	  
repression	   or	   induce	   chromatin	  
modification.	  S.	   pombe,	  C.	   elegans	   and	  
mammals	  carry	  only	  one	  Dicer	  gene.	   In	  
D.	   melanogaster	   and	   A.	   thaliana,	  
specialized	   Dicer	   or	   DLC	   proteins	  
preferentially	   process	   long	   dsRNA	   or	  
miRNA	   precursors.	   7mG,	   7-­‐methyl	  
guanine;	   AAAA,	   poly-­‐adenosine	   tail;	  
Me,	  methyl	  group;	  P,	  5'	  phosphate.66	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and	  dsRNA	  could	   share	  only	   the	  processing	  enzyme	  Dicer.	  However,	  Mello	  and	   colleagues	  
discovered	   another	   piece	   of	   the	   puzzle,	   the	   requirement	   for	   Argonaute	   family	   proteins	   in	  
both	   stRNA	  biogenesis	  and	   stRNA-­‐mediated	   suppression.	  These	   findings	  opened	   the	  doors	  
for	   a	   new	  model	   in	   which	   the	   effector	   complexes	   constituted	   by	   siRNAs	   and	   stRNAs	   are	  
strictly	  related,	  but	  regulate	  expression	  by	  distinct	  mechanisms77.	  
A	  model	  that	  emerged	  to	  define	  RNA	  control	  of	  gene	  expression	  proposed	  that	  a	  similar	  RISC	  
complex	  is	  formed	  containing	  either	  siRNAs	  or	  stRNAs.	  Another	  model	  sustained	  that	  siRNAs	  
and	   stRNAs	   may	   recognize	   related	   but	   distinct	   complexes.	   In	   agreement	   with	   this	   model	  
siRNAs	   or	   exogenous	   hairpin	   RNAs	   fail	   to	   repress	   gene	   silencing	  when	  modified	   by	   single	  
mismatches	  with	   their	   substrates.	   In	   this	  direction,	  RISC	  complex	  could	  be	  considered	  as	  a	  
dynamic	   platform	   to	   structure	   different	   regulatory	   modules	   in	   a	   flexible	   way.	   The	   core	  
complex	  should	  be	  required	  to	  recognize	  the	  small	  RNA	  cleaved	  by	  Dicer	  and	  adoperate	  this	  
as	  a	  guide	  to	  search	  for	  its	  homologous	  substrate.	  As	  a	  consequence	  and	  in	  relation	  with	  the	  
kind	   of	   signal,	   different	   downstream	   functions	   are	   associated	   with	   the	   core:	   in	   RNAi,	  
nucleases	  should	  be	  joined	  to	  the	  RISC,	  whereas	  in	  stRNA-­‐mediated	  regulation,	  translational	  
repressors	   would	   join	   the	   complex.	   Inclusion	   of	   chromatin	   remodelling	   factors	   and	   other	  
adaptations	  could	  follow	  the	  initial	  effectors	  to	  accomplish	  the	  transcriptional	  silencing79,80.	  
	  
3.1	  RNAi	  as	  a	  solution	  for	  mammalian	  genetics	  
RNAi	   demostrated	   to	   be	   a	   powerful	   tool	   for	   investigating	   gene	   function.	   For	   a	   long	   time	  
exploitment	  of	  RNAi	   to	   interogate	  mammalian	  systems	  seemed	  to	  not	  be	   feasible,	  at	   least	  
until	   the	   first	   prove	   that	   the	   technology	   could	   work	   was	   obtained,	   thanks	   to	   the	  
demonstartion	  of	  RNAi	  in	  mouse	  embryos81,82,83.	  However,	  as	  mammalian	  somatic	  cells,	  but	  
not	  some	  embryonic	  cells,	  display	  nonspecific	  responses	  to	  dsRNA,	  RNAi	  appeared	  to	  be	  of	  
limited	   utility.	   Then,	   Tuschl	   and	   colleagues	   demostrated	   that	   siRNAs	   themselves	   could	   be	  
applied	  to	  cause	  effective	  silencing	  in	  many	  mammalian	  cells84.	  These	  small	  RNAs,	  chemically	  
synthesized	  mimicking	   the	  Dicer	  products,	   are	  presumably	   assembled	   in	   the	  RISC	   complex	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and	   target	   specific	   substrates	   for	   degradation.	   Fortunately,	   the	   siRNAs	   are	   too	   small	   to	  
activate	   nonspecific	   dsRNA	   responses	   such	   as	   the	   RNA-­‐dependent	   protein	   kinase	   (PKR)85.	  
Using	   a	   variety	   of	   standard	   transfection	   methods	   siRNAs	   can	   be	   easily	   introduced	   into	  
mammalian	  cells.	  The	  strength	  and	  timing	  of	  the	  interfering	  response	  is	  affected	  by	  several	  
parameters:	   the	   silencing	   response	   is	   primarly	   influenced	   by	   the	   overall	   efficiency	   of	  
transfection	  in	  the	  overall	  population.	  In	  individual	  cell,	  silencing	  is	  intrinsically	  related	  to	  the	  
amount	  of	  siRNA	  that	   is	  nternalized	  and	  on	  the	  potency	  of	  each	  siRNA	  against	   its	  target.	  A	  
weak	   siRNA	   can	   also	   be	   used	   to	   silence	   its	   target	   delivering	   a	   sufficient	   quantities	   of	   the	  
siRNA	   in	   the	  host	   cell.	  However,	  numerous	  undesired	  effects	   could	  be	  associated	  with	   the	  
use	  of	  large	  amount	  of	  reagent.	  
One	  limitation	  releated	  to	  the	  siRNA	  transient	  effects	  in	  mammals	  is	  the	  apparently	  lack	  of	  
the	  mechanisms	  that	  sustain	  the	  silencing	  amplification	  present	  in	  worms	  and	  plants.	  More	  
recently,	  different	  groups	  have	  proven	  that	  short	  hairpin	  RNAs	   (shRNAs)	  can	  be	  applied	  to	  
manipulate	   gene	   expression	   in	   experimental	   settings86.	   The	   shRNAs	   are	   not	   100%	  
homogeneous	   in	   size	   and	  design,	  with	   stems	   ranging	   from	  19	   to	  29	  nucleotides	   in	   length,	  
and	   with	   various	   degrees	   of	   structural	   similarity	   with	   natural	   miRNAs.	   These	   interfering	  
RNAs	  can	  be	  expressed	  in	  vivo	  from	  RNA	  polymerase	  II	  (Pol	  II)	  or	  III	  (Pol	  III)	  to	  induce	  stable	  
suppression	   in	  mammalian	  cells.	  Because	   these	  shRNAs	  are	  encoded	  by	  DNA	  vectors,	   they	  
can	  be	  delivered	  to	  cells	  exploiting	  the	  different	  tools	  that	  have	  been	  developed	  for	  delivery	  
of	   DNA	   exogenous	   constructs87.	   These	   include	   standard	   transient	   transfection	   systems,	  
stable	   transfection	   and	   infection	   using	   viruses	   ranging	   from	   retroviruses	   to	   adenoviruses.	  
Expression	  can	  also	  be	  regulated	  by	  either	  constitutive	  or	  inducible	  promoter	  systems.	  	  
The	   easy	   way	   of	   stable	   RNAi	   systems	   generation	   increased	   the	   request	   and	   applications	  
beyond	  the	  utility	  of	  transient	  siRNAs.	  Specific	  phenotypes	  can	  now	  be	  evaluated	  over	  long	  
time	   spans.	   Stable	   infected	   cells	   can	   be	   used	   either	   for	   in	   vitro	   or	   in	   vivo	   purposes,	   for	  
example	  investigating	  the	  cooperative	  role	  of	  the	  microenvironment	  with	  the	  tumor	  cells	  in	  
xenograft	   models.	   RNAi	   can	   also	   be	   applied	   to	   rapidly	   produce	   hypomorphic	   alleles	   in	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transgenic	  mouse	  models.	  In	  addition,	  shRNAs	  could	  be	  coupled	  with	  existing	  high-­‐efficiency	  
gene	   delivery	   vehicles	   to	   develop	   RNAi-­‐based	   therapeutics.	   At	   the	   end,	   the	   stringent	  
specificity	   of	   RNAi	   technologies	   supported	   the	   possibility	   to	   direct	   the	   silencing	   effect	  
against	  a	  mutant	  allele,	  such	  as	  an	  activated	  oncogene,	  without	  affecting	  the	  normal	  allele.	  
In	  search	  for	  rules	  that	  could	  generate	  more	  effective	  and	  specific	  siRNAs,	  different	  groups	  
tested	  large	  numbers	  of	  siRNAs,	  sorting	  them	  into	  classes	  depending	  on	  their	  potency,	  and	  
then	   looking	   for	   features	   that	   characterized	   effective	   on-­‐target	   siRNAs	   from	   ineffective	  
ones88.	  siRNAs	  in	  which	  the	  helix	  at	  the	  5'	  end	  of	  the	  antisense	  strand	  has	  a	   lower	  stability	  
than	   the	   3'	   end	   of	   the	   siRNA	   are	   generally	   more	   effective	   silencers	   than	   those	   with	   the	  
opposite	  arrangement.	  Biochemical	   studies	   also	   showed	  unequal	   incorporation	  of	   the	   two	  
RNA	   strands	   of	   the	   siRNA	   into	   the	   RISC	   complex.	   So,	   the	   the	   effectiveness	   of	   an	   RNAi	  
response	   leaded	   by	   a	   siRNA	   is	   strongly	   dependent	   on	   its	   tridimensional	   structure	   and	  
associated	  with	   the	   step	  of	  RISC	  assembly,	   in	  which	   the	  asymmetry	   in	   the	  dsRNA	  must	  be	  
sensed	   and	   a	   single	   RNA	   strand	   must	   be	   selected	   for	   incorporation	   into	   the	   enzymatic	  
complex.	  
	  
3.2	  RNAi	  as	  a	  tool	  for	  genetic	  screens	  
The	   success	   in	   applying	   RNAi	   for	   interrogate	   single	   gene-­‐associated	   phenotypes	   has	  
promoted	   numerous	   efforts	   to	   translate	   this	   approach	   on	   a	   large	   scale	   for	   genetic	  
investigation.	  With	  the	  human,	  mouse	  and	  rat	  genomes	  sequenced,	  RNAi	  demostrated	  to	  be	  
the	   required	   mechanism	   by	   which	   this	   enormous	   amount	   of	   genetic	   information	   can	   be	  
translated	  into	  functional	  annotations.	  	  
3.2.1	  RNAi	  libraries	  
siRNAs	   libraries	   can	   be	   constructed	   in	   fundamentally	   different	   ways,	   including	   chemical	  
synthesis	   or	   enzymatic	   digestion	   of	   long	   dsRNAs90,91.	   On	   the	   other	   side,	   libraries	   can	   be	  
synthesized	  by	  constructing	  shRNA	  lentiviral	  vectors	  that	  target	  each	  gene	  of	  interest92.	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In	   the	   same	   way	   as	   siRNAs,	   demonstration	   in	   the	   feasibility	   of	   the	   approach	   came	   from	  
small-­‐scale	  studies.	  Generating	  a	  library	  for	  targeting	  the	  family	  of	  de-­‐ubiquinating	  enzymes,	  
it	  was	  possible	  to	   identify	   	  a	  new	  unprecedented	  function	  of	   the	  CYLD	  gene	   in	  suppressing	  
the	  activity	  of	  NF-­‐ B93.	  This	  result	  unequivocally	  confirmed	  that	  unbiased	  genetic	  screens	  can	  
generate	  not	  only	  new	  biological	  informations	  but	  also	  tangible	  advances	  for	  the	  treatment	  
of	   specific	   disease.	   Several	   groups	   have	   produced	   arrayed	   libraries	   from	   chemically	  
synthesized	   oligonucleotides	   that	   cover	   about	   10,000	   different	   human	   genes	   each69,94.	  
Another	  group	  has	  expoited	   the	  polymerase	  chain	   reaction	   (PCR)	   to	  produce	  a	   library	   that	  
encode	   shRNAs,	   and	   several	   other	   groups	   have	   developed	   new	  methods	   for	   constructing	  
random	   shRNA	   libraries	   based	   on	   complementary	   DNA	   or	   genomic	   DNA95-­‐98.	   Random	  
libraries	  are	  relatively	  cheap	  to	  be	  produced	  and	  can	  gurantee	  the	  coverage	  of	  an	  individual	  
gene	  with	  many	   different	   shRNAs.	   Nonetheless,	   these	   libraries	   have	   the	   limitation	   of	   the	  
number	  of	  genes	  that	  can	  be	  properly	  represented.	  On	  the	  other	  side,	  libraries	  synthesized	  
using	  chemical	  oligonucleotides	  are	  more	  expensive,	  but	  allow	  the	  introduciton	  of	  powerful	  
informatic	  methods	  to	  improve	  the	  shRNA	  design	  and	  exhibit	  tolerance	  in	  rapid	  modification	  
of	  the	  shRNA	  structure.	  More	  than	  that,	  synthetic	  libraries	  can	  be	  used	  either	  as	  mixtures	  or	  
as	   individual	   arrays,	   in	   the	   same	   way	   as	   siRNA	   libraries.	   Independent	   transfection	   and	  
phenotypic	  optimization	  of	   target	   cells	  must	  be	   carried	  out	   for	   large-­‐scale	   screening	  using	  
siRNA	  libraries.	  siRNA	  libraries	  may	  be	  used	  to	  the	  deep	  range	  of	  screening	  applications	  that	  
were	   generated	  by	   the	  pharmaceutical	   companies	   as	   cell-­‐based	  assays	   for	  drug	  discovery.	  
These	  methods	  consist	  of	  fluorescent	  reporter	  assays	  for	  various	  phenotypes	  and	  screens	  by	  
throught	   automated	   microscopy	   technologies.	   In	   the	   same	   way	   RNAi	   effectors	   can	   be	  
synthesized	   as	   microarrays	   and	   evaluated	   for	   their	   functions	   as	   a	   consequence	   of	   in	   situ	  
transfection99.	  shRNA	  libraries	  can	  be	  also	  applied	  in	  a	  similar	  way,	  as	  demonstrated	  by	  the	  
development	   of	   arrayed	   library	   for	   genes	   that	   are	   specifically	   involved	   in	   functions	   of	   the	  
proteasome100.	   Pools	   of	   shRNAs	  must	   be	   transduced	   into	   a	   selective	   cell	   line	   with	   a	   high	  
representation	  and	  a	   low	  multiplicity	  of	   infection	  (MOI	  =	  0.1–1.0).	  The	  high	  representation	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gurantees	   that	   each	   shRNA	   in	   the	   library	  has	   a	   reasonable	  possibility	   to	   function,	   and	   the	  
low	  MOI	  gurantees	  that	  the	  cells	  are	  transduced	  with	  only	  one	  shRNA,	  avoiding	  cooperative	  
effects	  among	  shRNAs.	  RNAi	  screening	  approaches	  generated	  the	  possible	  to	  discover	  new	  
gene	   functions	   or	   networks	   involved	   in	   a	   wide	   range	   of	   biological	   processes,	   including	  
mechanisms	   critical	   for	   signal	   transduction,	   cell	   viability,	   cell	   or	   organelle	   morphology,	  
organelle	  or	  protein	  localization	  and/or	  function,	  drug	  resistance,	  and	  responses	  of	  host	  cells	  
to	  pathogens.	  shRNA	  libraries	  are	  available	  as	  pool	  from	  several	  commercial	  providers,	  and	  
recently	  the	  DECIPHER	  open	  source	  RNAi	  screening	  project	  proposed	  free	  of	  charge	  access	  
to	  lentiviral	  shRNA	  pools	  (http://www.decipherproject.net).	  
3.2.2	  Off-­‐target	  effects	  and	  false	  postives/negatives	  	  
The	   initial	  excitement	  about	  RNAi	  screens	  was	  diminished	  by	  the	  demonstration	  that	  RNAi	  
approaches,	   like	   all	   screening	   technologies,	   are	   connected	  with	   false	  discovery	   rate	   (false-­‐
positive	  and	  false-­‐negative	  results).	  In	  RNAi	  tools,	  the	  most	  relevant	  caveat	  is	  false	  positives	  
that	   are	   generated	   by	   sequence-­‐specific	   off-­‐target	   effects	   (OTEs)101,102.	   In	   addition,	   meta-­‐
analyses	  to	  facilitate	  the	  estimation	  of	  false	  discovery	  rates	  were	  helped	  by	  the	  deveopment	  
of	  RNAi	  screen	  data	  sets.	  These	  databases	  have	  also	  identified	  'frequent	  hitters',	  genes	  that	  
frequently	  score	  as	  positive	  hits	  across	  different	  screens,	  such	  as	  genes	  involved	  in	  essential	  
processes	  that	  might	  exert	  relevant	  but	  relatively	  broad	  as	  demonstrated	  for	  components	  of	  
the	   ribosome	  or	  proteasome.	  However,	   they	  have	   increased	   the	   information	  connected	   to	  
the	   specificity	   and	   relevance	  of	   primary	   screen	  hits.	   Sequence-­‐specific	  OTEs	  happen	  when	  
RNAi	   reagents	   recognize	   RNAs	   different	   from	   their	   intended	   target	   due	   to	   partial	  
complementarity.	   Applying	   sequence	   alignment	   is	   also	   possible	   to	   identify	   the	   subsets	   of	  
OTEs	   that	   are	   associated	   to	   the	   extended	   regions	   of	   complementarity	   between	   RNAi	  
reagents	  and	  genes	  other	  than	  the	  target,	  such	  as	  regions	  common	  to	  the	  target	  gene	  and	  its	  
paralogues.	  New	  methodologies	  for	  RNAi	  re-­‐annotation	  have	  been	  developed	  (ex.	  UP-­‐TORR	  
and	   GenomeRNAi)	   in	   order	   to	   facilitate	   the	   identification	   of	   RNAi	   triggers	   that	   no	   longer	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meet	  quality	  standards103,104.	  To	   further	   limit	  OTEs	   in	  RNAi	  screening	  approaches,	  new	  and	  
improved	  bioinformatic	  tools	  have	  recently	  been	  proposed	  and	  successfully	  applied.	  
3.2.3	  RNAi	  screening	  hits	  validation	  
The	   experimental	   approach	   more	   frequently	   used	   to	   validate	   RNAi	   screen	   hits	   is	   the	  	  
evaluation	  of	  multiple	  RNAi	  reagents	  for	  each	  gene,	  as	  different	  triggers	  have	  different	  seed	  
regions.	  In	  siRNA	  screens	  seven	  or	  more	  independent	  RNAi	  reagents	  per	  gene	  are	  arrayied.	  
In	  pooled	  shRNA	  screens,	  more	  than	  15	  constructs	  per	  gene	  are	  normally	  applied105,106.	  The	  
general	   startegy	   is	   oriented	   to	   increase	   as	   much	   as	   possible	   the	   number	   of	   independent	  
RNAi	  triggers	  per	  gene	  that	  reproduce	  the	  same	  phenotype,	  in	  order	  to	  maximize	  the	  chance	  
that	   the	   gene	   is	   a	   true	   hit	   in	   a	   screen.	   However,	   the	   experimental	   approach	   for	  
demonstrating	  the	  specificity	  of	  an	  RNAi	  reagent	  is	  to	  highlight	  that	  the	  displayed	  phenotype	  
can	   be	   rescued	   with	   the	   expression	   of	   an	   RNAi-­‐resistant	   version	   of	   the	   targeted	   gene.	  
Unfortunately,	  this	  rescue	  experiment	  could	  not	  be	  routinely	  performed,	  especially	  because	  
the	   interpretation	   of	   rescue	   experiments	   is	   complicated	   when	   rescue	   constructs	   are	  
expressed	  at	  non-­‐physiological	  levels101.	  Applying	  a	  comparative	  approach	  is	  also	  a	  potential	  
strategy	   to	   overcome	   species-­‐specific	   limitations,	   such	   as	   incomplete	   genome	   coverage	  of	  
screening	  reagents	  or	  sequence-­‐specific	  OTEs.	  The	  hits	  that	  emerged	  associated	  with	  cellular	  
processes	  and	  mechanisms	  in	  the	  data	  set	  of	  both	  species	  have	  a	  higher	  chance	  of	  being	  true	  
positive	  hits	   if	  gene	  ontology	  terms	  are	  consistently	  enriched.	  In	  addition,	  genes	  that	  score	  
as	   positive	   hits	   in	   both	   species	   can	   also	   be	   considered	  high	   confidence	   hits,	   because	   they	  
have	  been	  validated	  by	  different	  screen	  reagents,	  methodologies	  and	  organisms.	  
3.2.4	  Positive	  screens	  	  
siRNAs/shRNAs	  that	  are	  associated	  with	  a	  cellular	  phenotype	  that	  can	  be	  selected	  for	   (e.g.	  
increased	  survival,	  invasion	  or	  migration	  abilities)	  or	  isolated	  through	  can	  be	  considered	  for	  
positive	  screens107-­‐112.	  Using	  pooled	  libraries	  in	  positive	  selection	  approaches,	  the	  shRNA	  of	  
interest	   can	   be	   sequenced	   starting	   from	   the	   genomic	   DNA	   isolated	   from	   the	   isolated	   cell	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population.	  On	  the	  other	  way,	  deep	  sequencing	  can	  be	  applied	  to	  identify	  shRNAs	  that	  are	  
enriched	  in	  comparison	  with	  the	  reference	  population.	  So	  far,	  several	  strategies	  have	  been	  
proposed	  to	  identify	  the	  most	  promising	  hits	  sequencing	  the	  full	  hairpin,	  half	  of	  the	  hairpin	  
or	  the	  molecular	  barcode	  associated	  with	  the	  hairpin	  in	  some	  libraries113,114.	  
3.2.5	  Negative	  screens	  	  
Dropout	  of	  siRNA/shRNA	  sequences	   in	  the	  experimental	  population	  compared	  to	  a	  control	  
population	   characterize	   the	   negative	   screens.	   The	   phenotype	   associated	   with	   the	  
shRNA/siRNA	  of	  interest	  could	  result	  in	  cell	  death	  and	  the	  shRNA/siRNA	  would	  therefore	  be	  
significantly	  reduced	  or	  completely	  absent	  in	  respect	  of	  the	  control	  population115,116.	  So	  far,	  
shRNA	   pooled	   negative	   screens	   can	   only	   be	   performed	   applying	   microarrays	   or	   deep	  
sequencing	   detection	   strategies.	   Negative	   screens	   for	   synthetic	   lethality	   emerged	   from	  
classical	  genetic	  screens	   in	  yeast	  performed	  with	  the	  purpose	  of	   identifying	  two	  mutations	  
that	   result	   in	   lethality	   only	   when	   present	   in	   combination117.	   Synthetic	   lethal	   screens	  
obtained	  in	  the	  last	  years	  lot	  of	  attention	  from	  the	  onco-­‐biology,	  because	  they	  can	  be	  used	  
to	  discover	  the	  secondary	  genetic	  events	   (second	  hits)	   that	  can	  selectively	  kill	  a	  cell	  with	  a	  
primary	  oncogenic	  mutation.	  Rrecently,	  RNAi	  screening	  approaches	  have	  identified	  synthetic	  
lethal	  interactions	  with	  the	  RAS	  oncogene	  and	  the	  KRAS	  oncogene118,119.	  A	  slightly	  different	  
approach,	   known	  as	   chemical	   synthetic	   lethality	   screen,	   is	   focused	  on	   the	   identification	  of	  
genetic	   elements	   that	   cooperate	   with	   the	   effect	   of	   a	   chemical	   drug100.	   This	   strategy	   is	  
extremely	   informative	   to	   elucidate	   genetic	   networks	   that	   can	   have	   direct	   clinical	  
applications.	   In	  this	  direction,	  synthetic	   lethal	  RNAi	  screens	  have	  been	  exploited	  to	  identify	  
genes	  that	  are	  able	  to	  increase	  the	  sensitivity	  to	  a	  variety	  of	  chemotherapeutic	  drugs	  when	  
are	   targeted120-­‐124.	   The	   presence	   of	   residual	   gene	   activity	   upon	   RNAi	   knock-­‐down	   more	  
closely	  recapitulate	  the	  physiological	  situation	  that	  could	  be	  obtained	  with	  pharmacological	  
inhibitors	  than	  the	  knock-­‐out	  system	  which	  completely	  eliminates	  any	  gene	  activity100.	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So	  far,	  hundreds	  of	   large-­‐scale	  cell-­‐based	  RNAi	  screens	  have	  been	  performed	  in	  Drosophila	  
melanogaster,	  mouse	  and	  human	  cells.	  Recently,	  a	  further	  evolution	  of	  pooled	  RNAi	  screens	  
highlighted	   the	  use	  of	  molecular	   'barcodes'	   associated	  with	   individual	  hairpins	   to	   facilitate	  
the	  tracking	  of	  individual	  shRNAs	  behaviour	  in	  complex	  populations.	  	  
	  
3.3	  In	  vivo	  genetic	  screens	  using	  RNAi	  	  
RNAi	   screening	   approaches	   are	   now	   applicable	   to	   animal	   models	   due	   to	   the	   increasing	  
throughput	   and	   decreased	   costs	   associated	   with	   next-­‐generation	   sequencing	   (NGS).	   So,	  
individual	  shRNAs	  can	  be	  used	  as	  biological	  probe	  to	  interrogate	  specific	  cellular	  phenotypes	  
but	  also	  to	  understand	  in	  vitro	  or	  in	  vivo	  molecular	  details.	  In	  this	  direction,	  loss-­‐of-­‐function	  
(LOF)	  screens	  with	  pooled	  shRNA	  libraries	  have	  been	  successfully	  proposed	  in	  animal	  models	  
of	  different	  cancer	  types	  (ex.	  Leukemia,	  Breast,	  Glioblastoma)125-­‐130.	  Screens	  permormed	   in	  
lymphomas	  have	  highlighted	  that	  several	  genes	  are	  involved	  in	  functions	  that	  are	  not	  critical	  
in	   tissue	   culture	   conditions	   but	   are	   essential	   during	   cancer	   formation	   due	   to	   in	   vivo	  
cooperation	  with	  the	  host	  microenvironment
127
.	  This	  finding	  proves	  the	  unique	  feature	  of	  in	  
vivo	  RNAi	   screens	   and	   highlights	   the	   ability	   of	   these	   approches	   in	   investigating	   the	   tumor	  
cells’	   vulnerability	   in	  more	  physiological	   contexts	   compared	   to	   in	   vitro	   systems.	  An	   in	   vivo	  
RNAi	  screening	  experiment	  is	  based	  on	  the	  silencing	  of	  a	  panel	  of	  genes	  in	  a	  cell	  population	  
constituted	  by	  tumor-­‐initiating	  cells,	   the	  transplantation	  of	   the	   infected	  cells	   into	  recipient	  
hosts	  and	  the	  tumor	  formation	  as	  an	  endpoint	  (Fig.3).	  In	  these	  approaches,	  tumor-­‐initiating	  
cells	  (TICs)	   infected	  with	  pooled	  shRNA	  libraries	  sustain	   in	  vivo	   tumor	  proliferation	  and	  the	  
initial	  equal	  representation	  of	  single-­‐shRNA	  carrying	  cells	   is	  drifted	  toward	  tumor	  cells	  that	  
displayed	  a	  functional	  advantage	  due	  to	  the	  biological	  effect	  of	  the	  shRNA	  product.	  The	  TICs	  
can	   be	   generally	   defined	   as	   a	   population	   of	   cells	  with	   the	   unique	   feature	   of	   generating	   a	  
tumor	  in	  recipient	  animals,	  and	  so	  this	  definition	  includes	  the	  so-­‐called	  ‘cancer	  stem	  cells’.	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Basically,	   shRNA-­‐drived	   reduction	   of	   oncogenes	   level	   determine	   the	   depletion	   of	   the	   cells	  
carrying	   that	   specific	   shRNA.	   On	   the	   other	   side,	   shRNAs	   enriched	   in	   the	   final	   tumor	  
population	  could	  be	  considered	  hairpins	  that	  target	  putative	  tumor	  suppressor	  genes	  (TSGs).	  
Neutral	   shRNAs	   can	   be	   defined	   as	   hairpins	   that	   are	   not	   changing	   their	   representation	   in	  
comparison	   with	   the	   starting	   population	   and	   the	   number	   is	   largely	   influenced	   by	   the	  
duration	  of	  the	  experiment131.	  
	  
Figure	  3.	  Outline	  of	  an	  in	  vivo	  shRNA	  screen.	  	  
(a–d)	  shRNA	  library	  assembly,	  transfection	  and	  transduction	  (a–c),	  is	  followed	  by	  implantation	  of	  shRNA	  modified	  cells	  into	  recipient	  
animals	   (d).	   (d–f)	   Tumor-­‐enriched	   shRNAs	   are	   amplified	   from	   tissue	   or	   FACS-­‐purified	   cells	   by	   PCR	   (d,e)	   and	   counted	   to	   identify	  
enrichments	  and	  dropouts	  (f).131	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3.3.1	  in	  vivo	  RNAi	  screen	  procedures	  	  
Six	   main	   procedural	   steps	   should	   be	   taken	   into	   account	   for	   performing	   in	   vivo	   RNAi	  
screens131:	  
• Production	  of	  shRNAs.	  Individual	  shRNAs	  are	  primarily	  expanded	  as	  bacterial	  cultures	  
and	   then	   pooled	   together	   when	   the	   bacterial	   preparations	   are	   confluent.	   This	  
approach	   gurantees	   a	   fexible	   shRNA	   selection	   and	   permits	   individual	   validation	   of	  
successful	   amplification	   of	   bacterial	   cultures.	   At	   the	   end,	   this	   step	   attenuates	   the	  
chance	  of	  individual	  shRNA	  over-­‐growth,	  which	  may	  be	  responsabile	  for	  critical	  over-­‐	  
or	  under-­‐representation	  of	  specific	  shRNAs	  in	  the	  pooled	  library.	  
• Transfection.	   The	   pool	   of	   produced	   shRNAs	   is	   co-­‐transfected	   into	   HEK293T	   cells	  
together	  with	  second-­‐	  or	  third-­‐generation	  lentiviral	  packaging	  constructs.	  TICs	  of	  the	  
model	  of	   interst	  are	   infected	  at	  a	  multiplicity	  of	   infection	  (MOI).	  MOI	  must	  be	  <1	   in	  
order	  to	  gurantee	  that	  only	  one	  hairpin	  is	  integrated	  in	  one	  cell	  but	  not	  more.	  Then,	  
TICs	   are	   selected	   using	   puromycin	   (for	   pLKO.1	   lentiviral	   vectors)	   or	   fluorescent	  
reporters	  (ex.	  GFP,	  RFP)	  to	  remove	  the	  uninfected	  portion	  of	  the	  cell	  population.	  
• TIC	   implantation.	   Upon	   selection,	   TICs	   are	   transplanted	   into	   recipient	   hosts	   in	   a	  
number	   that	   is	   calculated	   taking	   into	   account	   the	   technical	   limits	   of	   the	   required	  
surgical	   procedure,	   the	   physiological	   requirement	   for	   the	   selected	   tumor	   to	  
ricapitulate	   the	   tumor	   of	   origin	   and	   the	   size	   of	   the	   selected	   library.	   At	   this	   step,	   a	  
representative	  portion	  of	  the	  TICs	  is	  collected	  as	  refrence	  cells	  to	  control	  for	  hairpin	  
representation	   before	   transplantation.	   If	   possible,	   in	   vitro	   screen	   should	   be	  
performed	   in	   parallel	   with	   the	   in	   vivo	   one,	   in	   order	   to	   allow	   the	   infected	   TICs	   to	  
proliferate	  under	  specific	  conditions	  of	  culturing.	  	  
• DNA	   extraction.	   At	   the	   appearance	   of	   tumor-­‐related	   symptoms	   or	   after	   in	   vivo	  
imaging	   with	   luciferase	   systems,	   animals	   are	   sacrified	   and	   the	   tumor	   is	   in	   toto	  
collected.	  shRNAs,	  integrated	  in	  the	  genome	  of	  the	  host	  cells,	  can	  be	  retrieved	  from	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genomic	  DNA	   or	   directly	   extracted	   from	   tumor	   biopsies	   or	   from	   viable	   tumor	   cells	  
that	  have	  been	  FACS-­‐purified	  to	  exclude	  host-­‐derived	  cells.	  
• Sequencing.	   Extracted	   genomic	   DNA	   from	   tumor	   cells,	   reference	   cells	   and	   tissue	   is	  
then	   subjected	   to	   PCR	   amplification	   cycles.	  Generally,	   a	   first-­‐step	  PCR	   is	   applied	   to	  
amplify	   the	   hairpins	   in	   the	   samples	   and	   a	   secondary-­‐step	   PCR	   is	   performed	   to	  
introduce	  the	  adapters	  for	  deep	  sequencing.	  At	  the	  end,	  PCR	  libraries	  are	  quantified,	  
mixed	  and	  sequenced.	  
• Data	  analysis.	  PCR	  product	  sequences	  are	  aligned	  to	  the	  reference	  list	  of	  the	  hairpins	  
present	   in	   the	   library,	   and	   each	   identified	   hairpin	   is	   counted	   and	   assigned	   to	   the	  
sample	   of	   origin	   (if	  multiplexed).	   Each	   hairpin	   is	   normalized	   in	   aech	   sample	   by	   the	  
sequencing	  depth	  (i.e.,	  total	  counts	  per	  sample)	  and	  by	  the	  relative	  abundance	  in	  the	  
reference	  cells.	  A	  final	  list	  of	  tumor	  enriched	  and	  reduced	  genes	  is	  then	  generated	  for	  
secondary	  validation.	  
3.3.2	  In	  vivo	  RNAi	  screen	  in	  human	  samples	  	  
The	   in	  vivo	  screens	  performed	  in	  mouse	  model	  systems	  opened	  the	  intriguing	  possibility	  of	  
expanding	   the	   same	   functional	   genomic	   studies	   to	   directly	   inform	   on	   human	   sample	  
vulnerabilities.	   The	   first	   attempt	   in	   this	   direction	   was	   proposed	   by	   Possemato	   and	  
colleagues,	  establishing	  an	   in	  vivo	  RNAi	  dropout	  screen	  on	  a	  breast	  cancer	  cell	   line132.	  They	  
were	  able	  to	  adapt	  the	  required	  steps	  to	  the	  human	  engraftment	  conditions	  and	  identified	  a	  
new	   serine	   biosynthesis	   pathway	   dependency	   for	   this	   disease.	   Following	   on	   this	  
breakthrough,	  Passik	  and	  colleagues	  extended	  the	  approach	  to	  melanoma	  samples	  shedding	  
light	   on	   the	   usefulness	   of	   DNA	   repair	   inhibition	   for	   the	   treatment	   of	   this	   disease	   and	  
highlighting	  different	  molecular	  points	  of	  vulnerability133.	  
However,	   the	   difficulties	   intrinsically	   connected	   with	   the	   nature	   of	   the	   xenograft	  
engraftment	   models	   limited	   the	   extensive	   application	   of	   the	   in	   vivo	   RNAi	   screening	  
technologies	  and	  step	  back	  the	  approach	  more	  as	  a	  biological	  tool	  than	  a	  medical	  resource.	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4.	  Patient-­‐derived	  xenograft	  (PDX)	  models	  in	  cancer	  discovery	  
	  
One	  of	  the	  most	  frequent	  reason	  for	  the	  high	  failure	  rate	  of	  new	  drugs	  in	  oncology	  is	  the	  lack	  
of	   pre-­‐clinical	  models	   that	   are	   able	   to	   fully	  mimicking	   the	   patient	   tumor	   heterogeneity.134	  
Even	   though	   the	   application	   of	   cancer	   cell-­‐line	   culture	   techniques	   pushed	   an	   acceleration	  
and	   expansion	   of	   cancer	   biology	   discovery,	   in	   reality	   the	   situation	   is	   that	   the	   chance	   of	  
translating	  these	  findings	   into	  clinical	  outcomes	  has	  been	   limited	  by	  the	  same	  models	   that	  
generated	  such	  relevant	  improvements.	  Several	  different	  explanations	  have	  been	  proposed	  
for	   this	   failure,	   for	   example	   the	   fact	   that	   cell	   lines,	   even	   when	   amplifieded	   in	   vivo,	   are	  
obtained	   from	  cancer	   cells	   that	  have	  adapted	   to	  proliferate	  without	  a	  physiological	   tumor	  
microenvironment,	  determining	  genetic	  profiles	   that	  are	  differents	   from	  the	  ones	   imposed	  
by	  the	  genetic	  pressure	  in	  patients135.	  In	  the	  same	  way,	  there	  are	  numerous	  evidences	  that	  
the	   genetic	   drift	   is	  more	   consistent	   between	   a	   primary	   tumor	   and	   the	   corresponding	   cell	  
line,	   than	   a	   direct	   patient-­‐derived	   xenograft,	   even	   after	   several	   generations135.	   So,	   even	  
though	   the	   chance	   of	   successfully	   transplant	   patient-­‐derived	   tumors	   has	   been	   established	  
some	   decades	   ago,	   these	   models	   for	   preclinical	   studies	   are	   just	   recently	   sistematically	  
characterized	  and	  applied	  for	  drug	  discovery	  purposes	  in	  oncology136–142.	  
The	   procedure	   for	   establishment	   and	   amplification	   of	   patient-­‐derived	   xenografts	   (PDXs,	  
Fig.4)	  has	  been	  deeply	  investigated	  and	  presented	  by	  multiple	  groups140–143.	  The	  approach	  is	  
very	   simple	  and	  based	  on	   the	   collection	  of	   fresh	   surgical	   tissue,	   fractionation	   into	   ~3	  mm3	  
pieces	  and	  subcutaneous	  or	  orthotopic	  transplantation	  into	  the	  flank	  of	  an	  immunodeficient	  
mouse.	   The	   primary	   mouse	   generation	   transplanted	   with	   the	   patient-­‐derived	   material	   is	  
termed	  F0,	  while	  the	  subsequent	  generations	  are	  numbered	  consecutively	  (F1,	  F2,	  F3	  and	  so	  
on),	  although	  some	  other	  groups	  have	  used	  the	  names	  G0,	  G1	  and	  so	  on143.	  The	  time	  span	  
required	  for	  tumor	  tumor	  formation	  in	  the	  primay	  generation	  is	  highly	  variable	  considering	  
tumor	  types,	  implantation	  site	  and	  recipient	  mouse	  strain,	  but	  generally	  it	  takes	  between	  2	  
months	   and	   4	   months,	   even	   though	   a	   	   failure	   of	   engraftment	   could	   not	   be	   considered	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definitive	  until	  6	  months	   from	  transplantation140.	  As	  a	  general	  approach,	   starting	   from	  the	  
third	  generation	   (F3	  or	  G3)	   the	  cohort	  can	  be	  expanded	   for	  drug	   treatment.	  However,	   the	  
only	   real	  parameter	   that	   should	  be	  considered	   to	  evaluate	   the	   reliability	  of	   the	  PDX	   is	   the	  
degree	  of	  divergency	  between	  the	  patient’s	  tumor	  and	  the	  corresponding	  xenograft	  in	  terms	  
of	  genetics	  and	  histology,	  two	  factors	  that	  are	  underestimated	  when	  results	  of	  therapeutic	  
studies	  are	  presented.	  (Fig.4)	  
	  
	  
4.1	  Engraftment	  in	  host	  recipients	  	  
The	   comparison	   among	   recipient	   strains	   or	   hosts,	   such	   as	   athymic	   nude	  mice,	   NOD/SCID	  
mice	   or	   NSG	   (NOD/SCID/IL2Rγnull)	   mice	   was	   not	   sistematically	   performed	   taking	   into	  
account	   the	   engraftment	   time	   span,	   engraftment	   rate,	   genetic	   landscape,	   or	   histological	  
profiles.	   The	   majority	   of	   studies	   highlighted	   engraftment	   rates	   of	   75%	   or	   above	   using	  
athymic	   nu/nu	   mice.	   The	   NOD/SCID	   mice	   are	   more	   often	   applied	   in	   F1145,146.	   Then,	   the	  
Figuere	  4.	  Establishing	  and	   testing	  of	  PDX	  models.	  Excess	  tumor	  specimens	  not	  needed	  for	  clinical	  diagnosis	  are	  obtained	  
from	   the	   consented	   patients	   (F0).	   Non-­‐necrotic	   areas	   of	   these	   tumors	   are	   sectioned	   into	   ~3	  mm
3	   pieces	   and,	   after	   processing,	  
implanted	   subcutaneously	   into	   anaesthetized	   5-­‐week	   to	   6-­‐week-­‐old	   female	   athymic	   nude	  mice.	   During	   the	   engraftment	   phase,	  
tumors	   are	   allowed	   to	   establish	   and	   grow	  and	   then	  are	  harvested	  upon	   reaching	   a	   size	  of	   1,500	  mm3	   (F1).	   Similar	   protocols	   are	  
employed	  for	  subsequent	  expansion	  cohort	  (F2)	  and	  treatment	  cohort	  (F3	  …	  Fn).	  Typically,	  biological	  assays	  are	  performed	  on	  tumors	  
in	  early	  generations	  (≤F5);	  these	  biological	  assays	  include	  drug	  efficacy	  studies,	  rational	  combination	  studies	  and	  the	  development	  of	  
predictive	  biomarkers	  for	  novel	  targeted	  therapies.	  If	  the	  developed	  biomarkers	  achieved	  accurate	  prediction	  in	  a	  validation	  set	  of	  
PDX	  models	   (or	   ‘xenopatients’),	   they	  might	   be	   translated	   into	   early	   phase	   clinical	   trials	   as	   tools	   for	   patient	   selection	   strategies.	  
Abbreviations:	  PDX,	  patient-­‐derived	  xenografts;	  RES,	  resistant;	  SEN,	  sensitive.143	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development	   of	   the	   NSG	   mice	   has	   increased	   the	   chance	   of	   reaching	   even	   higher	  
engraftment	   rates	   (close	   to	   95–100%).	   The	   NSG	   mice	   are	   characterized	   by	   a	   further	  
inhibition	  of	  the	  innate	  immunity	  by	  arresting	  the	  maturation	  of	  natural	  killer	  (NK)	  cells147.	  
	  
4.2	  Phenocopy	  the	  tumor	  of	  origin	  	  
The	   main	   advantages	   poited	   out	   for	   the	   PDX	   models	   is	   the	   ability	   of	   phenocopying	   the	  
original	   tumor	   architecture	   and	   histological	   features,	   even	   though	   there	   are	   still	   debates	  
about	   timing	   and	   extent	   the	   human-­‐derived	   microenvironment	   is	   preserved148.	   A	   new	  
promosing	   approach	   to	   bypass	   the	   disappearance	   of	   human-­‐derived	   microvasculature	  
applied	  tissue	  microarrays	  obtained	  from	  150	  PDX	  models,	  which	  were	  evaluated	  for	  a	  set	  of	  
vasculature-­‐associated	  genes	  demonstrating	  features	  of	  an	  angiogenic	  profile	  that	  could	  be	  
exploited	   for	   the	   identification	   of	   new	   therapies	   oriented	   towards	   the	   tumor	  
microenvironment148,149.	  Similar	  approaches,	  such	  as	  gene-­‐set	  enrichment	  analysis	  (GSEA)	  of	  
angiogenic	  and	  metastatic	  profiles,	  can	  be	  applied	  to	  circumvent	  the	  caveats	  releated	  to	  the	  
ability	  of	  human	  microenvironment	  recapitulation	  in	  PDX	  models150.	  
	  
4.3	  Transcriptional	  and	  mutational	  stability	  	  
	  	  
A	   relevant	   point	   associated	   to	   the	   PDX	   model	   stability	   is	   the	   extent	   of	   changes	   that	   the	  
methodologies	   of	   engraftment	   and	   amplification	   introduce	   to	   the	   genetic	   profile	   of	   the	  
tumors.	   Comprehensive	   genome-­‐wide	   gene-­‐expression	   analysis	   studies	   have	   highlighted	  
that	  PDX	  maximize	  the	  preservation	  of	  the	  key	  genes	  and	  global	  pathway	  activity	  in	  primary	  
tumors135,152.	   In	   this	   direction,	   studies	   performed	   in	   PDX	   models	   of	   non-­‐small-­‐cell	   lung	  
cancer	  (NSCLC)	  using	  unsupervised	  hierarchical	  clustering	  of	  genome-­‐wide	  gene-­‐expression	  
profiles	   demonstrated	   that	   9	   out	   of	   the	   17	   primary	   tumors	   clustered	   together	   with	   the	  
derived	   PDX	   models,	   with	   Pearson’s	   correlation	   coefficients	   ranging	   from	   0.78	   to	   0.95.	  
Notably,	   10	   of	   this	   17	   primary–PDX	   tumor	   pairs	   displayed	   correlation	   coefficients	   >0.90	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highlighting	  a	  high	  degree	  of	  similarity	  between	  the	  primary	  cancer	  and	  the	  corresponding	  
PDX	  model151.	   In	  the	  same	  way,	  10	  out	  of	  12	  primary	  pancreatic	  cancer	  PDX	  (F0	  versus	  F3)	  
tumors	  showed	  the	  same	  KRAS	  mutational	  and	  SMAD4	  expression	  status144.	  More	  than	  that,	  
some	  of	  the	  pancreatic	  cancer	  PDX	  models	  have	  been	  also	  selected	  to	   integrate	  the	  tumor	  
DNA	   content	   from	   the	   patient’s	   material	   for	   the	   pancreatic	   cancer	   genome	   sequencing	  
project152	   (Fig.5).	   Comparative	   studies	   of	   matched	   patient–PDX	  models	   applying	   genome-­‐
wide	   gene	   expression	   methodologies	   in	   colorectal	   cancer	   (CRC)	   and	   pancreatic	   ductal	  
adenocarcinoma	  (PDAC)	  were	  also	  recently	  presented.	  The	  third-­‐generation	  PDX	  model	  for	  
colon	   cancer	   and	   the	   fifth-­‐generation	   PDX	   model	   for	   pancreatic	   cancer	   displayed	   high	  
correlation	  of	  global	  gene	  expression	  when	  compared	  with	  their	  matched	  primary	  tumors.	  
	  
	  
4.4	  PDX	  as	  a	  platform	  for	  translational	  cancer	  research	  (co-­‐clinical	  trials)	  	  
It	   is	   pretty	   well	   established	   that	   one	   of	   the	   main	   limitations	   in	   oncology	   drug	   discovery	  
processes	  is	  the	  low	  rate	  of	  new	  compounds	  that	  are	  able	  to	  reach	  clinical	  approval.153	  The	  
reason	   for	   these	   unsuccesses	   is	   in	   part	   due	   to	   the	   fact	   that	   the	   conventional	   preclinical	  
models	  used	  to	  valiadate	  new	  drugs	  lack	  in	  predictive	  value154.	  So,	  rhe	  reason	  for	  diffusion	  of	  
PDX	  models	  is	   intensically	  connected	  to	  the	  fact	  that	  these	  models	  are	  better	  predictors	  of	  
Figure	  5.	  Comparison	  of	  genome-­‐wide	  gene-­‐expression	  profiles	  between	  primary	  patient	  tumors	  and	  PDX	  tumors. 
(a) Matched	  patient	  primary	  CRC	   tumor	   (F0)	  and	  PDX	   (F3).	  Genome-­‐wide	  gene-­‐expression	  profiles	  of	  a	  patient	  with	  CRC	  and	   their	  
matched	   PDX	  were	   profiled	  with	   Affymetrix®	   HuGene	   1.0	   ST	   arrays.	   (b)	  Matched	   patient	   primary	   PDA	   tumor	   (F0)	   and	   PDTX	   (F5).	  
Genome-­‐wide	  gene-­‐expression	  profiles	  of	  a	  patient	  with	  PDA	  and	  their	  matched	  PDX	  were	  profiled	  with	  Affymetrix®	  HG-­‐U133	  Plus	  
2.0	  arrays.	  High	  correlations	  were	  observed	   in	  both	  PDX	  models	  and	  their	  matched	  primary	  tumors.	  Abbreviations:	  CRC,	  colorectal	  
cancer;	  PDA,	  pancreatic	  ductal adenocarcinoma;	  PDX,	  patient-­‐derived	  tumor	  xenografts.143 	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the	  patient’s	  clinical	  outcome.	  Several	  studies	  have	  tested	  the	  response	  rate	  of	  drugs	  used	  
as	   standard	   of	   care	   in	   medical	   oncology	   in	   PDX	   models,	   particularly	   in	   colorectal	   cancer,	  
NSCLC,	   SCCHN,	   human	   breast	   cancer,	   and	   renal	   cell	   cancer	   (RCC).	   These	   reports	  
demonstrated	  that	  the	  response	  rates	  in	  PDX	  models	  match	  with	  good	  approximation	  with	  
those	   observed	   in	   the	   corresponding	   patients,	   both	   for	   targeted	   agents	   and	   for	   classic	  
cytotoxics.	  More	   recently,	  a	  prospective	   study	   in	  PDAC	  highlighted	  a	  new	  potential	   role	  of	  
PDX	   models	   as	   screening	   platforms	   for	   clinical	   trials.	   This	   study	   clarified	   that	   the	  
combination	  of	  nab-­‐paclitaxel	  and	  gemcitabine	  is	  effective	  in	  PDX	  models	  of	  PDAC,	  a	  result	  
perfectly	  in	  agreement	  with	  the	  efficacy	  of	  this	  combination	  in	  PDAC	  patients.	  This	  regimen	  
has	   recently	   confirmed	   to	   be	   able	   to	   determine	   a	   survival	   improvement	   for	   patients	  with	  
advanced	   PDAC,	   as	   demonstrated	   in	   a	   randomized	   phase	   III	   study,	   and	   is	   now	   under	  
evaluation	   to	   become	   a	   standard	   of	   care	   for	   this	   dramatic	   disease7.	   In	   the	   same	   way,	  
absence	  of	  antitumor	  efficacy	  in	  PDX	  models	  reflects	  negative	  results	  in	  clinical	  treatments.	  
These	  findings	  were	  confirmed	  in	  PDAC	  with	  agents	  such	  as	  the	  SRC	  inhibitor	  saracatinib	  and	  
the	  mTOR	  inhibitor	  sirolimus,	   for	  which	   lack	  of	  efficacy	   in	  PDX	  preclinical	  studies	  predicted	  
failure	   of	   the	   same	   strategy	   in	   the	   clinic156,156.	   Taking	   all	   these	   data	   together,	   it	   could	   be	  
easily	  understood	  why	  PDX	  models	  have	  now	  obtained	  a	  prominent	   role	   in	   the	  preclinical	  
phase	  of	  new	  anticancer	  drug	  development.	  One	  crucial	  advantage	  exerted	  by	  PDX	  models	  
in	   large	   preclinical	   studies	   is	   connected	   to	   the	   fact	   they	   contribute	   to	   clinical	   indications	  
prioritization,	   as	  well	   as	   identification	   of	   new	   biomarkers	   for	   potential	   drug	   efficacy157,158.	  
Preclinical	   studies	   in	   PDX	  models	   can	   also	   help	   in	   optimizing	   the	   clinical	   trial	   design.	   This	  
potential	   has	   been	   illustrated	   in	   studies	   involving	   cancer	   stem	   cell	   (CSC)	   drugs	   such	   as	  
inhibitors	   of	   the	   Sonic	   Hedgehog,	   Nodal/Activin,	   TGFβ,	   and	   Notch	   pathways159-­‐162.	   In	  
experiments	  with	  PDX	  models,	  these	  agents	  failed	  to	  cooperate	  with	  classical	  chemotherapy	  
in	  tumor	  regression	  but	  significantly	  delayed	  tumor	  growth	  and	  decreased	  tumor	   initiation	  
and	  relapse.	  So,	  the	  application	  of	  PDX	  models	  demonstrated	  to	  be	  critical	  to	  determine	  and	  
evaluate	  the	  effect	  of	  pharmacologic	  compounds	  on	  CSCs.	   In	  addition,	  these	  findings	  could	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be	  crucial	  for	  clinical	  trial	  design	  that	  are	  also	  oriented	  to	  consider	  the	  treatment	  of	  minimal	  
residual	  disease	  and	  to	  decide	  the	  appropriate	  setting	   in	  which	  to	  apply	  this	  approach.	  So,	  
PDX	  models	  may	   exert	   a	   fundamental	   role	   in	   drug	   efficacy	   studies	   and	   they	   could	   help	   in	  
selecting	  the	  populations	  of	  patients	  most	  likely	  to	  be	  sensitive	  to	  a	  new	  drug,	  as	  well	  as	  to	  
prioritize	  the	  development	  of	  new	  biomarkers.	  
	  
4.5	  Tumor-­‐Initiating	  Cell	  (TIC)	  frequency	  	  
The	  finding	  that	  phenotypically	  distinct	  cancer	  cell	  subpopulations	  are	  able	  to	  sustain	  tumor	  
growth	  in	  serial	  transplants,	  whereas	  the	  majority	  of	  tumor	  cells	  appear	  to	  be	  bystanders	  in	  
the	   process,	   has	   contributed	   to	   the	   arising	   of	   the	   cancer	   stem	   cell	   (CSC)	   concept	   in	  
tumorigenesis	  both	  in	  hematological	  and	  solid	  tumor	  malignancies163-­‐167.	  
Starting	  from	  the	  first	  experimental	  prove	  for	  the	  existence	  of	  a	  solid	  tumor-­‐initiating	  cell	  in	  
human	   breast	   cancers,	   the	   classification	   models	   corresponding	   to	   CSC	   have	   remained	  
complicated	  and	   the	   final	   link	  between	  CSC,	  normal	   stem	  cell	  populations,	  and	   the	   ‘cell	  of	  
origin’	  in	  cancer	  was	  not	  fully	  clarified163,164.	  So,	  even	  though	  a	  CSC	  involved	  in	  tumor’s	  origin	  
can	   probably	   originate	   from	   normal	   stem	   cells	   as	   a	   result	   of	   sequencial	   mutations	   that	  
confer	  oncogenic	  properties,	  the	  cell	  of	  origin	  in	  cancer	  and	  the	  predominant	  CSC	  present	  in	  
an	   evolved	   tumor	   may	   possess	   differing	   features	   releated	   to	   the	   point	   the	   tumor	   is	  
considerd164.	  To	  be	  precise,	  the	  CSC	  properties	  during	  disease	  development	  can	  change	  and	  
the	  identity	  can	  be	  different	  from	  from	  the	  cell	  of	  origin.	  
To	   cirumvent	   semantic	   misuderstandings	   connected	   to	   CSC	   concept,	   a	   different	   name	  
chosen	  for	  these	  cells	  is	  tumor	  perpetuating	  cells	  (TPCs),	  as	  these	  cells	  are	  characterized	  by	  
their	  ability	   to	   fully	   recapitulate	   tumors	  as	  demonstrated	  by	  serial	   transplantation	  of	  small	  
numbers	  of	  tumor	  cells	  with	  defined	  properties163,164.	  
It	  is	  now	  fully	  accepted	  that	  a	  relevant	  heterogeneity	  is	  associated	  with	  CSC	  sub-­‐populations.	  
Serial	  transplantations	  in	  limiting	  dilution	  are	  performed	  to	  quantify	  the	  tumor-­‐initiating	  cell	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frequency,	   estimated	   to	  be	  between	  1:100–1:20000	   for	   the	  majority	  of	   solid	   tumors167-­‐171.	  
Melanoma	  appears	   to	   represent	   an	   exception,	   because	  one	   in	   four	   cells	   is	   able	   to	   reform	  
tumors	  withwith	  the	  same	  features	  of	  the	  original	  tumor172.	  The	  concept	  that	  CSC	  must	  be	  
infrequent	   was	   originated	   by	   the	   results	   highlighting	   that	   normal	   stem	   cells	   generally	  
represent	   a	   small	   fraction	   of	   normal	   tissues.	   The	   relative	   infrequency	   of	   CSC	   in	   the	   initial	  
studies	  of	  AML	  also	  enforced	  this	  assumption173,174.	  However,	   the	  melanoma	  case	  suggests	  
that	  CSC	  can	  also	  be	  relatively	  frequent,	  depending	  on	  the	  indication,	  patient	  and/or	  stage	  of	  
disease.	  
Concers	   related	   to	   the	   CSC	   concept	   have	   been	   emerged	   as	   soon	   as	   the	   xenograft	   tumor	  
models	  were	  proposed,	  due	  to	  the	  fact	  that	  tumorigenicity	  can	  be	  obtained	  using	  a	  plethora	  
of	  distinct	  markers	  previously	  identified	  as	  specific	  for	  CSC	  (ex.	  CD44,	  CD133,	  and	  ALDH1A1).	  
These	   critics	   are	   primarly	   focused	   on	   experimental	   functional	   prove	   of	   tumor	   cell	  
heterogeneity	   and	   paucity	   of	   tumor-­‐initiating	   cells	   in	   solid	   tumors175-­‐179.	   Basically,	   the	  
features	   and	   frequencies	   of	   tumor-­‐initiating	   cells	   in	   mouse	   and	   rat	   tumors	   have	   been	  
highlighted	   applying	   autologous	   transplantation175-­‐178.	   However,	   human	   tumor	   cells	  
autologous	   transplantation,	   currently	   considered	   an	   unethical	   practise,	   displayed	   that	  
tumor-­‐initiating	   cell	   frequencies	   are	   consistently	   rare	   in	   well-­‐differentiated	   tumors	   and	  
require	   injection	  of	  more	  than	  1	  million	  cells	   for	  tumor	  formation179.	  These	  experiments	  of	  
autologous	  tumor	  cell	  transplantation	  robustly	  supported	  the	  notion	  that	  the	  CSC	  concept	  is	  
a	   real	   biological	   event	   and	   not	   only	   an	   artifact	   connected	   to	   the	   xenotransplantation	  
procedure.	   Further	   studies	   highlighted	   a	   strong	   connection	  between	   tumor	  differentiation	  
status	  and	  patient	  prognosis,	  proposing	  a	  clinical	  relevant	  relationship	  able	  to	  link	  the	  tumor	  
differentiation	  with	  the	  paucity	  of	  CSCs	  in	  less	  aggressive	  tumors,	  whereas	  CSCs	  seem	  to	  be	  
more	  represented	  in	  aggressive	  tumors	  or	  later	  stages	  of	  the	  disease180.	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4.5.1	  High	  TIC	  frequency	  -­‐	  Melanoma	  PDXs	  	  
	  
Until	   the	   last	   years,	   patients	   with	   advanced	   melanoma	   had	   limited	   therapeutic	   options.	  
Recently,	   the	   approval	   of	   the	   BRAF	   inhibitor	   vemurafenib	   and	   the	   CTLA-­‐4	   inhibitor	  
ipilimumab	  have	  opened	  new	  unexplored	   therapeutic	   directions.	   In	   this	   scenario,	   the	  PDX	  
models	  are	  capturing	  the	  attention	  due	  to	  their	  ability	   in	  defining	  resistance	  pathways	  and	  
rational	   combination	   strategies	   for	   the	   disease.	   Even	   though	   the	   establishment	   of	   PDX	  
melanoma	   models	   was	   proposed	   many	   years	   ago,	   there	   are	   no	   comprehensive	   studies	  
taking	  into	  account	  large	  numbers	  of	  models181,182.	  Preliminar	  experiments	  conducted	  with	  a	  
melanoma	  PDX	  model	  from	  a	  primary	  tumor	  and	  a	  matched	  metastatic	  lesion	  were	  used	  to	  
compare	  responses	  to	  anticancer	  drugs	  previously	  analyzed	  using	  cell	  lines	  derived	  from	  the	  
tumors	  and	  PDX	  models.	  Although	  the	  studies	  demonstrated	  consistency	  for	  the	  majority	  of	  
the	   responses,	   several	   different	   sensitivities	   were	   also	   detected181.	   Notably,	   a	   gene-­‐array	  
study	  executed	  using	  a	  panel	  of	  22	  melanoma	  PDX	  tumors	  was	  able	  to	  propose	  a	  predictive	  
gene	   signature	   to	   11	   standard	   cytotoxic	   agents,	   even	   though	   no	   further	   clinical	   validation	  
has	  been	  reported182.	  
Melanoma	   PDX	   models	   demonstrated	   also	   to	   be	   a	   useful	   tool	   for	   the	   identification	   of	  
melanoma	   tumor-­‐initiating	   cells.	   For	   instance,	   isolation	   and	   re-­‐implantation	   in	   limiting	  
dilution	   of	   ABCB5+	   cells	   from	   PDX	   models	   were	   able	   to	   regenerate	   the	   complete	   tumor	  
heterogeneity	   and	   depauperation	   of	   this	   specific	   subpopulation	   resulted	   in	   tumor	   growth	  
inhibition183.	   Another	   study	   presented	   the	   engraftment	   of	   a	   human	   uveal	  melanoma	   PDX	  
model	  in	  NOD/SCID	  mice	  with	  an	  successful	  rate	  close	  to	  28%	  and	  complete	  phenocopy	  	  of	  
the	   the	  primary	   tumor	   in	   terms	  of	  histology	  and	  genetic	  profiles184.	  More	   than	   that,	   upon	  
treatment	  with	  temozolomide,	  a	  standard	  chemotherapeutic	  agent	  for	  uveal	  melanoma,	  the	  
response	  of	  engrafted	  mice	  was	  consistent	  with	  the	  clinical	  outcome	  of	  the	  patients185.	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4.5.2	  Low	  TIC	  frequency	  -­‐	  Pancreatic	  cancer	  PDXs	  	  
New	  molecular	  and	  genetic	  methodological	  tools	  have	  highlighted	  a	  significant	  accelleration	  
in	   the	   scientific	   understanding	   of	   the	   complex	   genetics	   of	   PDAC.	  Whole-­‐exome	   sequence	  
analysis	   of	   primary	   PDAC	   tumors	   illustrated	   a	   set	   of	   11	   molecular	   pathways	   constantly	  
affected	   in	   this	   disease	   together	   with	   an	   average	   of	   63	   genetic	   alterations	   interesting	   an	  
individual	   tumor152.	   However,	   this	   accumulation	   of	   new	   genetic	   informations	   has	   not	   yet	  
been	  able	  to	  improve	  the	  clinical	  outcomes	  for	  PDAC	  patients.	  
Pancreatic	   cancer	   cell	   lines	   have	   been	   routinely	   applied	   for	   preclinical	   studies	   with	  
therapeutical	   candidates	   both	   in	   vitro	   and	   in	   vivo.	   However,	   xenografts	   obtained	  
transplanting	   in	   vitro	   stabilized	   cancer	   cells	   determine	   the	   development	   of	   tumors	  
characterized	  by	  masses	  of	  cancer	  cells	  with	  minimal	  stromal	   infiltration.	  So,	   these	  models	  	  
could	   not	   be	   considered	   able	   to	   recapitulate	   the	   human	   PDAC	   architecture	   and	   the	  
connections	  between	  stromal	  components	  and	  PDAC	  cells.	  In	  the	  same	  direction,	  it	  has	  been	  
demonstrated	   that	   the	   intratumoral	   perfusion	   is	   negatively	   affected	   by	   the	   desmoplastic	  
reaction,	  in	  a	  way	  that	  also	  the	  delivery	  of	  chemotherapeutic	  agents	  could	  be	  impacted	  and	  
the	   antitumor	   effects	   of	   a	   given	   therapeutic	   strategy	   could	   be	   overestimated	   in	   cell	   line-­‐
based	  models.186	   PDX	  pancreatic	  models	   are	  based	  on	   the	  engraftment	  of	   primary	  human	  
PDAC	  specimens	  in	  heterotopic	  or	  orthotopic	  anatomical	  locations.187,188	  The	  main	  feature	  of	  
these	   PDX	   models	   is	   the	   ability	   of	   recapitulating	   the	   original	   tumor	   architecture,	   even	  
though	  the	  human	  stroma	   is	   replaced	  during	  passaging	  by	  murine	  stroma.	  Orthotopic	  PDX	  
models	   display	   a	   more	   consistent	   amount	   of	   stromal	   elements	   and	   are	   more	   prone	   to	  
develop	   locoregional	   and	   distant	   metastases187,188	   (Fig.6).	   Pancreatic	   cancer	   PDX	   models	  
were	  initially	  developed	  with	  the	  focus	  of	  optimizing	  the	  strategies	  for	  the	  identification	  of	  
predictive	  and	  pharmacodynamic	  readouts	  for	  molecularly	  targeted	  therapies144.	  
	  	  	   38	  
	  
Howevern,	   these	   achievements	   should	   have	   faced	   a	   massive	   intratumoral	   heterogeneity,	  
especially	  taking	  into	  account	  gene	  and	  protein	  expression	  profiles.	  For	  example,	  the	  mTOR	  
inhibitors	   were	   evaluated	   in	   PDX	   models	   and	   they	   were	   able	   to	   inform	   on	   the	   higher	  
sensitivity	   of	   patients	  with	   high	   baseline	   expression	   of	   phosphorylated	   p70	   S6	   kinase,	   but	  
this	  finding	  failed	  the	  transplation	  step	  towards	  PDAC	  patients189.	  This	  failure	  could	  be	  due	  
to	   the	  parameters	  used	   to	  define	  a	  positive	   response	   in	   the	  PDX	  model	  or	   the	  numerouse	  
potential	   feedback	   loops	  that	  exist	   for	  the	  mTOR	  pathway.	  Another	  proposed	  strategy	  was	  
based	   on	   the	   coupling	   of	   tumor	   biopsy	   with	   ex	   vivo	   therapeutic	   treatment	   and	  
pharmacodynamic	   readout190	   .	   This	   approach	   elucidated	   that	   a	   polo-­‐like	   kinase	   (PLK)	  
inhibitor	   is	  able	  to	   inhibit	  tumor	  growth,	  especially	   in	  PDX	  models	  resistant	  to	  gemcitabine	  
treatment,	  and	  that	  cyclin	  B1	  can	  be	  considered	  a	  biomarker	  of	  efficacy191.	  Another	  strategy	  
that	   has	   been	   tested	   in	   PDAC	   is	   the	   treatment	   of	   a	   patient-­‐specific	   PDX	   with	   a	   panel	   of	  
approved	  drugs	  simultaneously	  with	  the	  first-­‐line	  therapy	  in	  the	  matched	  patient192.	  As	  soon	  
as	   the	   progression	   disease,	   the	   therapy	   demonstrating	   the	   most	   activity	   in	   their	   PDX	   is	  
proposed	  as	  therapeutical	  option.	  This	  approach,	  in	  combination	  with	  sequencing	  tools,	  was	  
able	  to	  prove	  the	  efficacy	  of	  a	  combined	  regimen	  of	  mitomycin	  C	  and	  cisplatin	   in	  a	  patient	  
displaying	  PALB2	  mutation193.	   Limitations	   to	   this	   intriguing	   system	  are	   connected	  with	   the	  
extreme	   variability	   in	   the	   engraftment	   success	   of	   the	   PDX	   and	   the	   requirement	   of	  
considerable	  resources.	  A	  further	  possibility	  could	  be	  represented	  by	  the	  complete	  genomic	  
profiling	   of	   a	   patient’s	   tumor	   soon	   after	   the	   surgical	   collection	   in	   order	   to	   facilitate	   the	  
Figure	   6.	   Pancreatic	   cancer	  
xenografts.	   (a)	   Direct	   xenograft	  
tumor	   established	   in	   a	   heterotopic	  
site	   (subcutaneous	   space)	   of	   a	  
NOD/SCID	   mouse.	   (b)	   Direct	  
xenograft	   tumor	   established	   from	  
injection	   of	   digested	   tumor	   (single	  
cells)	   into	   the	   pancreas	   of	   a	  
NOD/SCID	  mouse.	  Both	  heterotopic	  
and	  orthotopic	   tumors	  show	  tumor	  
gland	   formation	   and	   the	   presence	  
of	   peri-­‐tumoral	   stroma.	   Permission	  
from	   the	   M.D.	   Anderson	   Cancer	  
Center	   (MDACC)	   Institutional	  
Regulatory	   Board	  was	   obtained	   for	  
this	  study.187	  	  
	  	  	   39	  
targeted	  therapy	  selection	  of	  the	  PDX,	  and	  then	  coming	  back	  with	  the	  results	  to	  the	  patient	  
to	  direct	  the	  clinical	  decisions	  at	  the	  time	  of	  disease	  progression.	  
The	   stromal	   elements	   of	   the	   desmoplastic	   reaction	   tipically	   displayed	   in	   PDAC	   could	  
represent	   novel	   targets	   for	   improving	   the	   treatment	   of	   this	   disease.	   The	   prominent	   role	  
executed	  by	  the	  stroma	  in	  PDAC	  is	  highlighted	  by	  the	  findings	  that	  tumors	  cells	  engraftment	  
in	  PDX	  models	  requires	  expression	  of	  stromal	  genes	  and	  is	  associated	  with	  decreased	  patient	  
survival150.	   In	  PDAC,	  both	  genetically	  engineered	  and	  PDX	  models	  have	   illustrated	   that	   the	  
stromal	  components	  may	  play	  a	  crucial	  role	  in	  regulating	  gemcitabine	  uptake	  by	  the	  tumor	  
and	  can	  represent	  points	  of	  vulnerability	  to	  improve	  the	  therapy	  efficacy186,193.	   In	  the	  same	  
way,	   inhibitions	  of	   the	  hedgehog	  pathway	   could	  have	  an	  effect	   in	  modulating	   the	   stroma,	  
potentially	   due	   to	   the	   induction	   of	   apoptosis	   in	   pancreas	   stellate	   cells,	   with	   the	   result	   of	  	  
ameliorating	  the	  tumor	  vascularity186.	  Notably,	   treatment	  of	  pancreatic	  cancer	  PDX	  models	  
with	  a	  combination	  of	  gemcitabine	  and	  nabpaclitaxel	  affects	  the	  intratumoral	  desmoplastic	  
reaction	  with	  a	  consequent	  increase	  in	  intratumoral	  gemcitabine	  concentrations	  and	  growth	  
inhibition193.	   These	  experimental	   findings	  were	   translated	   into	  a	  phase	   I	   -­‐	   II	   clinical	   trial	  of	  
patients	   with	   advanced-­‐stage	   PDAC	   and	   suggested	   that	   PDX	   models	   can	   be	   also	   used	   to	  
propose	  therapeutical	  strategies	  directed	  to	  target	  the	  stromal	  elements	  in	  PDAC193.	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Aim	  of	  the	  project	  
	  
	  
The	   goal	   of	   this	   project	   is	   the	   identification	   of	   new	   potentially	   actionable	   molecular	  
vulnerabilities	   in	   the	   context	   of	   pancreatic	   ductal	   adenocarcinoma	   (PDAC).	   The	   lack	   of	  
effective	   therapies	   and	   the	   dramatic	   prognostic	   outcome	   classified	   new	   therapeutical	  
options	  for	  this	  disease	  as	  a	  high	  priority	  medical	  need.	  Adapting	  the	  classical	  in	  vivo	  shRNA	  
screening	  strategies	  to	  work	  with	  more	  predictive	  models,	  as	  the	  patient-­‐derived	  xenografts,	  
we	   aim	   to	   highlight	   new	   critical	   molecular	   dependencies	   that	   can	   be	   translated	   in	   more	  
robust	  drug	  discovery	  programs.	  Specifically,	  we	  decided	  to	  focus	  our	  attention	  on	  epigentic	  
mechanisms,	  normally	  preserved	  from	  mutational	  alterations	  in	  PDAC,	  in	  order	  to	  inform	  on	  
specific	   addictions	   associated	  with	   pancreatic	   cancer.	   In	   parallel,	   interrogating	   genetically-­‐
definied	  mouse	  models	   in	  the	  same	  experimental	  settings	  we	  could	   increase	  the	  chance	  of	  
associating	   epigenetic	   dependencies	   with	   the	   most	   frequent	   genetic	   landscapes	   in	   PDAC.	  
Furthermore,	   conjugating	   novel	   validation	   models	   with	   the	   classical	   ones,	   we’d	   like	   to	  
devolop	  a	   fast	   track	  pipeline	   for	   the	   rapid	  prioritization	  on	   the	  most	  promising	  chromatin-­‐
remodeling	  enzymes.	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Results	  
	  
1.	  Pancreatic	  cancer	  human	  xenografts	  and	  GEM	  models	  for	  in	  vivo	  screening	  	  	  
Transplantation	   of	   patient-­‐derived	   samples	   in	   a	   host	   recipient,	   known	   as	  
xenotransplantation,	   is	  a	  powerful	   tool	  to	  generate	  models	  able	  that	   faithfully	  recapitulate	  
the	   tumor	   of	   origin143,149,150.	   Compared	   to	   the	   transplantation	   of	   in	   vitro	   established	   cell	  
lines,	   patient-­‐derived	   xenograft	   models	   provide	   a	   new	   layer	   of	   complexity	   reflecting	   the	  
cellular	   heterogeneity	   of	   the	   original	   tumors	   and	   having	   avoided	   long	   term-­‐adaptation	   to	  
culturing	  in	  vitro.	  Numerous	  publications	  have	  shown	  that	  prolonged	  in	  vitro	  culturing	  drives	  
an	  artificial	   selection	  of	   sub-­‐clones	  and	   introduce	  a	   substantial	   genetic	  drift134,135.	   Some	  of	  
these	   issues	  were	   recently	   overcome	   through	   the	   establishment	   of	   adhesion-­‐independent	  
culturing	   methods	   (organoids),	   but	   despite	   these	   efforts	   the	   ability	   to	   phenocopy	   the	  
original	   tumor	   seems	   to	   be	   a	   unique	   feature	   of	   low-­‐passage	   xenotransplantation	  
approaches194.	  Analysis	  of	  expression	  profiles	  of	  patient-­‐derived	  xenograft	  models	  confirmed	  
that	   they	   maintain	   stability	   at	   least	   until	   the	   4th-­‐5th	   in	   vivo	   passage151.	   Patient	   derived-­‐
xenograft	  models	  to	  inform	  on	  patient	  vulnerabilities	  have	  been	  extensively	  exploited	  to	  test	  
the	   activity	   of	   experimental	   and	   approved	   oncology	   drugs,	   and	   it	   appears	   that	   at	   least	   in	  
certain	   instances	   they	   can	   predict	   clinical	   responses	   better	   than	   conventional	  
xenografts141,142.	   In	   order	   to	   enhance	   our	   ability	   of	   identifying	   genetic	   dependencies	   in	  
specific	   tumor	   contexts,	   we	   developed	   an	   in	   vivo	   screening	   platform	   in	   pancreatic	  
adenocarcinoma	  patient-­‐derived	  xenografts.	  	  
We	  first	  generated	  primary	  tumor	  derived	  xenografts	  (PDX)	  by	  transplanting	  small	  (approx.	  3	  
mm3)	   PDAC	   tumor	   pieces	   in	   each	   of	   five	   recipient	   mice.	   After	   this	   first	   enrichment	   step,	  
tumors	  were	   excised	   from	   the	   animals,	   pooled	   together	   and	   single-­‐cell	   preparations	  were	  
obtained	   by	   applying	   a	   combination	   of	   mechanical	   and	   enzymatic	   dissociation	   protocols	  
(Fig.7a).	  Purified	  single	  cells	  were	  seeded	  at	  high-­‐confluence	  on	  collagen	  I-­‐coated	  plates	  and	  
grown	  using	  an	  optimized	  culturing	  medium	  supplemented	  with	   cofactors.	  We	   limited	   the	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number	  of	  plate	  splitting	  to	  a	  maximum	  of	  3	  and	  introduced	  a	  “fibroblast-­‐off”	  approach	  to	  
eliminate	  mouse	  stromal	  cells.	  The	  purity	  of	  the	  PDX	  derived-­‐cultures	  was	  determined	  using	  
flow	   cytometry	   by	   estimating	   the	   percentage	   of	   human	   histocompatibility	   complex	   (HLA)	  





Figure	  7.	  Protocol	  for	  in	  vitro	  stabilization	  and	  characterization	  of	  PDX	  primary	  cells	  	  	  
(a)	  Scheme	  of	  the	  method	  established	  to	  isolate	  and	  amplify	  PDAC	  primary	  cells	  collected	  from	  PDX	  models;	  (b)	  Expression	  profiles	  of	  the	  	  
human	  (HLA)	  and	  mouse	  (Kd)	  major	  histocompatibility	  complexes	  in	  xenograft	  derived	  PDAC	  cells	  (MDA-­‐PATX43	  and	  MDA-­‐PATX53)	  at	  
passage	  3	  by	  flow	  cytometry	  (HLA-­‐APC,	  Kd-­‐PE);	  (c)	  Fluorescence	  intensity	  (Green)	  of	  MDA-­‐PATX53	  xenograft-­‐derived	  PDAC	  cells	  infected	  
with	  different	  dilutions	  (Non	  Infected,	  1	  μl,	  3	  μl)	  of	  a	  GFP-­‐pLKO.3G	  lentivirus.	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Before	   transplanting	   the	   isolated	   human	   cells	   in	   a	   secondary	   host,	   we	   verified	   not	   only	  
ability	  of	  the	  culture	  to	  be	  infected	  with	   lentivirus,	  but	  also	  the	  possibility	  to	  modulate	  the	  
infection	   rate	   (0,	   3	   and	   10	   μl	   of	   pLKO3.G-­‐GFP	   virus)	   (Fig.7c).	   Tumors	   harvested	   from	  
secondary	  xenografts	  were	  profiled	  for	  PDAC	  histological	  and	  histochemical	   features	  (H&E,	  
Cytokeratin	   19,	   Vimentin,	   10x)	   and	   compared	  with	   primary	   xenograft	   and	   patient-­‐derived	  
specimens	  to	  verify	  that	  the	  histological	  characteristics	  of	  the	  original	  tumors	  were	  as	  much	  
as	  possible	  maintained	  during	  this	  procedure	  (Fig.8).	  	  
	  
The	   architectural	   structure	   of	   the	   original	   PDAC	   tumors	   seemed	   to	   be	   conserved	   during	  
passaging	   in	  mouse	  recipients	  and	  the	  histological	  properties	  of	   the	   tissue	  were	  preserved	  
even	  after	  an	  in	  vitro	  step.	  	  
Using	   this	  method,	  4	  different	  PDAC	  xenograft	  models	   (MDA-­‐PATX43,	  MDA-­‐PATX50,	  MDA-­‐
PATX53	   and	   MDA-­‐PATX66)	   were	   generated	   and	   characterized	   for	   genetic	   alterations	  
(mutations	   or	   deletions)	   most	   frequently	   associated	   with	   pancreatic	   cancer:	   KRAS,	   TP53,	  
CDKN2A	   and	   SMAD4	   (Fig.9a).	   Sequencing	   analysis	   showed	   that	   KRAS	   mutations	   were	  
detectable	  in	  all	  the	  4	  PDX-­‐derived	  models,	  while	  TP53	  mutations	  were	  detected	  in	  only	  2	  of	  
them	  (MDA-­‐PATX50	  and	  MDA-­‐PATX66).	   In	  addition,	  3	  out	  of	  4	  PDX	  samples	  (MDA-­‐PATX43,	  
MDA-­‐PATX50	   and	   MDA-­‐PATX66)	   had	   deletions	   in	   CDKN2A	   and	   SMAD4	   genes.	   These	  
Figure	  8.	  PDX	  models	  able	  to	  phenocopy	  the	  pancreatic	  cancer	  of	  patients	  	  
Histological	   sections	   of	   PDAC	   diagnosed	   patients	   (Patient	   53,	   Patient43,	   10x)	   were	   stained	   with	   Hematoxylin	   and	   Eosin	   (H&E)	   and	  
compared	  with	  the	  sections	  collected	  from	  the	  matched	  PDX	  models	  (MDA-­‐PATX53,	  MDA-­‐PATX43).	  Primary	  (xenograft	  I)	  and	  secondary	  
(xenograft	  II)	  xenografts	  were	  stained	  for	  Cytokeratin	  19	  and	  Vimentin	  (10x).	  Bright-­‐fild	  images	  of	  the	  stabilized	  cells	  were	  taken	  during	  
in	  vitro	  amplification	  steps	  (20x).	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deletions	   were	   also	   confirmed	   at	   the	   level	   of	   protein	   expression	   by	   western	   blot.	  
Interestingly,	   PDX-­‐derived	   MDA-­‐PATX53	   cells,	   which	   reported	   no	   mutations	   or	   deletions	  
except	   for	   KRAS,	   showed	   absence	   of	   expression	   of	   the	   tumor-­‐suppressors	   p53	   and	   p16	  
(Fig.9b).	   These	  peculiar	   features	   could	  be	   related	   to	   the	   fact	   that	   the	  MDA-­‐PATX53	  model	  
was	   derived	   from	   a	   liver	  metastasis	   of	   a	   diagnosed	   PDAC	   tumor	   and	   not	   from	   a	   primary	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Figure	  9.	  Clinico-­‐pathological	  and	  mutational	  features	  of	  PDAC	  patient-­‐derived	  samples	  
(a)	  Clinico-­‐pathological	  (Sex,	  Age,	  Pathology,	  Stage,	  Metastasis	  Site)	  and	  mutational	  (Kras,	  TP53,	  CDKN2A,	  DPC4/Smad4)	  features	  of	  PDAC	  
xenograft-­‐derived	  samples	  (MDA-­‐PATX43,	  MDA-­‐PATX50,	  MDA-­‐PATX53,	  MDA-­‐PATX66);	  (b)	  Protein	  expression	  of	  p53,	  p16,	  SMAD4	  and	  β-­‐
actin	  in	  PDX-­‐derived	  cells	  (MDA-­‐PATX43,	  MDA-­‐PATX50,	  MDA-­‐PATX53,	  MDA-­‐PATX66).	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Upon	   transplantation	   in	   a	   secondary	   xenograft,	   PDX-­‐derived	   models	   displayed	   either	  
epithelial	   (MDA-­‐PATX43	   and	   MDA-­‐PATX53)	   or	   mesenchymal	   (MDA-­‐PATX50	   and	   MDA-­‐
PATX66)	   features.	   The	   contribution	   of	   mutant	   KRAS	   in	   sustaining	   the	   activation	   of	   its	  
downstream	  pathways	   in	  PDX-­‐derived	  cells	  was	  assessed	  by	   immunohistochemical	  staining	  
for	  the	  phosphorylation	  level	  of	  its	  downstream	  targets	  ERK1/2	  (Fig.10).	  	  
	  
With	   a	   very	   similar	   approach,	   primary	   cultures	   were	   also	   established	   starting	   from	   PDAC	  
genetic	  engineered	  mouse	  models	  (GEMMs):	  	  
• p48-­‐Cre,	  KrasG12D_LSL/+;	  	  
Figure	  10.	   In	  vivo	  characterization	  of	  PDX	  secondary	  xenografts	  generated	  transplanting	  PDAC	  stabilized	  primary	  
cells	  
Immunohistochemistry	  profiles	  (Cytokeratin	  19,	  Vimentin,	  human	  major	  histocompatibility	  complex	  (HLA),	  phospho	  ERK,	  10x)	  of	  the	  
secondary	   xenografts	   (xenograft	   II)	   generated	   transplanting	   the	   PDAC	   xenograft-­‐derived	   cells	   (MDA-­‐PATX43,	  MDA-­‐PATX50,	  MDA-­‐
PATX53,	  MDA-­‐PATX66)	  upon	  the	  stabilization	  step	  in	  vitro.	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• p48-­‐Cre,	  KrasG12D_LSL/+,	  Trp53L/L;	  	  
• p48-­‐Cre,	  KrasG12D_LSL/+,	  Ink4aL/L.	  	  
p48	  is	  a	  critical	  transcription	  factor	  in	  pancreas	  development	  and	  its	  expression	  is	  essential	  
to	  commit	  cells	  to	  a	  pancreatic	  fate195.	  To	  target	  the	  expression	  of	  mutant	  Kras	  in	  pancreatic	  
progenitor	   cells,	   a	   conditional	   allele	   was	   generated	   through	   genetic	   elements	   inhibiting	  
transcription	  and	  translation	  flanked	  by	  LoxP	  sites.	  Specifically,	  a	  Lox-­‐Stop-­‐Lox	  (LSL)	  cassette	  
was	   inserted	   into	   the	  mouse	   genomic	   Kras	   locus	   to	   contain	   the	  G-­‐A	   transition	   in	   locus	   12	  
(G12D)	   in	  order	   to	  drive	   the	  expression	  of	  mutant	  Kras	   in	  pancreatic	   tissue	  expressing	   the	  
Cre	   recombinase196.	   The	  p48-­‐Cre,	  KrasG12D_LSL/+	  model	   showed	  development	  of	   all	   the	   three	  
stages	   of	   pre-­‐neoplastic	   lesions	   (PanINs)	   associated	   with	   pancreatic	   cancer,	   but	   low-­‐
frequency	   progression	   to	   invasive	   and	   metastatic	   adenocarcinoma196,197.	   Single	   cell	  
preparations	  were	   isolated	   from	  pancreata	  of	  8	  weeks	  old	  mice	  and	   in	   vitro	   cultured.	   The	  
presence	   of	   mutant	   Kras	   in	   pancreatic	   cells	   drove	   over	   only	   a	   few	   passages	   oncogene-­‐
induced	   senescence,	   as	   assessed	   by	   β -­‐galactosidase	   assay	   (data	   not	   shown).	  
Spontaneously,	   some	   cells	   showed	   the	   ability	   to	   bypass	   senescence	   and	   proliferate.	   The	  
characterization	  of	   these	  cells	  highlighted	   the	   in	   vitro	   expression	  of	  mesenchymal	  markers	  
and	   the	   capacity	   of	   forming	   tumors	   with	  mesenchymal	   profiles	   when	   transplanted	   in	   the	  
pancreas	   of	   a	   recipient	   animal.	   This	   tumorigenic	   cell	   population	   was	   called	   p48-­‐Cre,	  
KrasG12D_LSL/+	   senescence-­‐escaper	   (Fig.11).	   As	   Kras	   mutations	   are	   not	   sufficient	   to	   induce	  
progression	  to	  the	  invasive	  stage	  of	  pancreatic	  adenocarcinoma,	  inactivation	  of	  either	  p53	  or	  
Ink4a	   has	   been	   used	   to	   generate	   combined	   models	   that	   progress	   to	   invasive	   PDAC198,199.	  
Pancreatic	   tumors	   were	   harvested	   from	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L	   and	   p48-­‐Cre,	  
KrasG12D_LSL/+,	   Ink4aL/L	   mouse	  models,	   processed	   for	   single	   cell	   isolation	   and	   established	   in	  
vitro	  as	  cell	  cultures.	  Orthotopic	  and	  subcutaneous	  transplantation	  of	  these	  cell	  populations	  
generated	   tumors	  with	   epithelial	   profiles	   for	   the	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L	   background	  
and	  mesenchymal	  ones	  for	  the	  p48-­‐Cre,	  KrasG12D_LSL/+,	  Ink4aL/L	  (Fig.11).	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Figure	  11.	  In	  vivo	  characterization	  of	  mouse	  allogarfts	  generated	  transplanting	  PDAC	  GEMM-­‐derived	  cells	  	  	  	  
Immunohistochemistry	   profiles	   (Hematoxylin	   and	   Eosin,	   Cytokeratin	   19,	   Vimentin,	   10x)	   of	   the	   allografts	   generated	  
translanting	   	   the	   PDAC	   mouse	   model-­‐derived	   cells	   (p48-­‐Cre,KrasG12D_LSL/+,p53L/L;	   p48-­‐Cre,	   KrasG12D_LSL/+,	   Ink4aL/L;	   p48-­‐Cre,	  
KrasG12D_LSL/+	  senescence-­‐escaper)	  upon	  in	  vitro	  stabilizaion.	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2.	  Developing	  methods	  for	  rapid	  in	  vivo	  assessment	  of	  tumor-­‐initiating	  cell	  
frequency	  	  
A	  number	  of	  parameters	  have	  to	  be	  carefully	  controlled	  when	  attempting	   to	   identify	  gene	  
products	  that	  are	  essential	  for	  in	  vivo	  tumor	  growth	  in	  a	  pooled	  screen	  approach131.	  In	  vivo	  
shRNA	   screens	   rely	   on	   the	   silencing	   of	   a	   library	   of	   targeted	   genes	   in	   a	   cell	   population	  
endowed	   with	   tumor	   engraftment	   capacity	   when	   implanted	   into	   recipient	   mice.	   Tumor	  
initiating	   cell	   (TIC)	   frequency,	   i.e.	   the	   ability	   of	   a	   tumor	   cell	   population	   to	   engraft	   and	  
propagate	  itself	  when	  implanted	  in	  vivo,	  varies	  dramatically	  between	  tumor	  types	  and	  must	  
be	   accurately	   determined	   to	   ensure	   faithful	   representation	   of	   complex,	   pooled	   shRNA	  
libraries168,173.	   The	   strategy	  most	   commonly	   applied	   to	   estimate	   TIC	   frequency	   in	   a	   cancer	  
cell	   population	   is	   based	   on	   in	   vivo	   transplantation	   upon	   extreme	   limiting	   dilution	   assay	  
(ELDA)168-­‐172.	   To	   more	   rapidly	   and	   accurately	   determine	   TIC	   frequency	   in	   PDAC	   xenograft	  
models,	   we	   first	   assessed	   the	   distribution	   and	   representation	   of	   a	   non-­‐targeting	   library	  
expressing	  12,500	  unique	  molecular	  barcodes	  in	  early	  passage	  tumor	  samples	  implanted	  in	  
recipient	  mice.	  The	  barcoded-­‐library	  was	  designed	  in	  a	  way	  that	  a	  molecular	  barcode	  of	  18	  
unique	  nucleotides	  is	  cloned	  in	  the	  pRSI17	  lentiviral	  vector	  (Cellecta)	  carrying	  a	  polycistronic	  
site	  with	  the	  puromycin	  resistance	  (PuroR)	  and	  RFP	  reporter	  gene	  (TagRFP)	  separated	  by	  the	  
2A	  peptide	  (Fig.12a).	  By	  "tagging"	  individual	  PDAC	  tumor	  cells,	  we	  could	  essentially	  track	  cell	  
fate	  by	  comparing	  clone	  representation	  in	  a	  reference	  population	  prior	  to	  implantation	  into	  
recipient	  mice,	  with	  that	  emerging	  after	   in	  vivo	  tumor	  establishment.	   If	  coverage	  (cells	  per	  
barcode)	   is	   sufficient	   to	   sustain	   library	   complexity	   in	   vivo,	   we	   would	   expect	   a	   normal	  
distribution	  when	   comparing	   barcode	   representation	   in	   xenografts	  with	   reference	   cells.	   If	  
library	   complexity	   is	   not	   covered	   within	   the	   experimental	   system,	   the	   distribution	   of	  
individual	  barcodes	  would	  be	  shifted	  compared	  to	  reference	  (Fig.12b).	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Through	  this	  effort,	  we	  could	  accurately	  determine	  the	  number	  of	  cells	  that	  are	  participating	  
in	   tumor	  engraftment	   (TICs).	   To	  highlight	   the	  power	  of	   the	   approach,	  we	   transduced	   cells	  
isolated	  from	  the	  early-­‐passage	  human	  PDAC	  xenografts	  (MDA-­‐PATX43,	  MDA-­‐PATX50,	  MDA-­‐
PATX53,	   MDA-­‐PATX66)	   and	   PDAC	   GEM	   models	   (p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L;	   p48-­‐Cre,	  
KrasG12D_LSL/+,	   Ink4aL/L;	   p48-­‐Cre,	   KrasG12D_LSL/+	   senescence-­‐escaper).	  We	   infected	   cells	   with	   a	  
lentiviral	   library	   expressing	   12,500	   unique	   molecular	   barcodes	   at	   a	   low	   multiplicity	   of	  
infection	  to	  ensure	  that	  each	  cell	  received	  a	  single	  viral	  integrant.	  The	  Poisson’s	  distribution	  
of	   lentiviral	   integrants	   suggested	   the	   ideal	   infection	   to	  maximize	   the	  number	  of	   cells	  with	  
only	  one	  integration	  as	  the	  one	  able	  to	  generate	  25-­‐30%	  infected	  cells	  (data	  not	  shown)200.	  
This	   infection	   rate	   was	   established	   sample-­‐by-­‐sample	   and	   confirmed	   by	   FACS	   analysis	  
through	   the	   fluorescent	   marker	   inserted	   in	   the	   lentiviral	   vector.	   The	   optimization	   of	   the	  
multiplicity	   of	   infection	   (MOI)	   was	   performed	   in	   patient-­‐derived	   cells	   applying	   three	  



















































































Figure	  12.	  New	  method	  for	  rapid	  in	  vivo	  assessment	  of	  tumor-­‐initiating	  cell	  (TIC)	  frequency	  	  	  
(a)	   Highlight	   of	   pRSI17	   lentiviral	   vector	   cloning	   site	   carrying	   the	   12.5k	   molecular	   barcodes	   and	   the	   downstream	   polycistronic	   site	  
carrying	  the	  puromycin	  resistance	  (PuroR)	  and	  RFP	  reporter	  gene	  (TagRFP)	  separated	  by	  the	  2A	  peptide;	  (b)	  Outline	  of	  experimental	  
design	  for	  in	  vivo	  TIC	  coverage	  study	  in	  patient-­‐derived	  and	  mouse	  models	  of	  pancreatic	  ductal	   adenocarcinoma	  (MOI=multiplicity	  of	  
infection,	  Ref	   Cells=Infected	  and	   selected	  cells	  before	  injection,	  Barcode=18	  unique	  nucleotides),	  representative	  analysis	  (Tumor/Ref	  
Log2	   ratio)	   of	   cells	   infected	  with	   a	   pool	   of	   unique	  molecular	   barcodes	   (18	   nucleotides)	   in	   the	   same	   transplantation	   setting	   of	   the	  
effective	  shRNA	  screen	  (i=model	  for	  covered	  complexity,	  ii=model	  for	  not-­‐covered	  complexity);	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Due	  to	  the	  previously	  shown	  higher	  reticence	  of	  mouse	  cells	  of	  being	  infected	  with	  lentiviral	  
vectors,	  we	  decided	   to	   increase	   the	   theoretical	   titers	   (0.3,	  0.6	  and	  1.2	  TU/cells)	  applied	   to	  
the	  PDAC	  GEM	  models	  for	  the	  MOI	  optimization	  study.	  Cytofluorimetric	  analysis	  of	  the	  RFP	  
positive	  cells,	  performed	  2	  days	  after	  infection,	  showed	  the	  optimal	  conditions	  for	  infecting	  
human	  or	  mouse	  cells	  respectively	  at	  0.3	  and	  1.2	  TU/cell	  (Fig.13).	  Further	  confirmations	  that	  
these	   established	   infections	   are	   able	   to	   maximize	   the	   number	   of	   cells	   with	   only	   one	  
integrant	  were	  performed	  introducing	  a	  qPCR	  system	  for	  MOI	  assesment201.	  This	  method	  is	  
based	  on	  the	  calculation	  of	  the	  number	  of	  molecules	  (NM)	  of	  a	   lentiviral	  component	  (Gag)	  
integrated	  in	  the	  genomic	  DNA	  of	  an	  infected	  cell	  population	  and	  the	  successive	  comparison	  
with	  the	  Albumin	  (Alb)	  gene,	  known	  to	  be	  present	  in	  the	  genome	  in	  2	  copies.	  The	  number	  of	  
molecules	   was	   determined	   applying	   a	   titration	   curve	   with	   known	   amounts	   of	   a	   lentiviral	  
vector	  carriyng	  a	  portion	  of	  the	  Albumin	  gene.	  A	  ratio	  close	  to	  0.5	  between	  Gag	  and	  Alb	   is	  

















0.15% 16% 14% 12.5% 20%
0.3% 30% 24% 22% 31% 4.5% 9% 5.8%
0.6% 9% 14% 9.1%
1.2% 15% 18% 16.3%
patc53 ni   
Tuesday, March 26, 2013   
doublets-
















patc53 ni G1: doublets-=20000> 
Region Count % Hist % All Mean
Total      23393 100.00 100.00 105.81, 56.60
doublets-      17091 73.06 73.06 128.46, 59.54
FSC/SSC
















patc53 ni G1: doublets-=20000>  (G1: doublets-)
Region Count % Hist % All Mean
Total      17091 100.00 73.06 121.16, 59.54
FSC/SSC      15254 89.25 65.21 114.94, 58.11
R3 rfp
R5 R6


























patc53 ni G1: doublets-=20000>  (G2: doublets- & FSC/SSC)
Region Count % Hist % All Mean
Total      15254 100.00 65.21 114.94, 11.56
R3          0  0.00  0.00  0.00,  0.00
rfp         74  0.49  0.32 163.30, 59.21
R5          2  0.01  0.01 17.00, 19.51
R6      15178 99.50 64.88 114.72, 11.33
patc53 015 d5   
Tuesday, March 26, 2013   
doublets-
















patc53 015 d5 G1: doublets-=20000> 
Region Count % Hist % All Mean
Total      25481 100.00 100.00 129.59, 56.46
doublets-      21935 86.08 86.08 143.34, 58.44
FSC/SSC
















patc53 015 d5 G1: doublets-=20000>  (G1: doublets-)
Region Count % Hist % All Mean
Total      21935 100.00 86.08 106.78, 58.44
FSC/SSC      19418 88.53 76.21 101.62, 58.61
R3 rfp
R5 R6


























patc53 015 d5 G1: doublets-=20000>  (G2: doublets- & FSC/SSC)
Region Count % Hist % All Mean
Total      19418 100.00 76.21 101.62, 159.11
R3          0  0.00  0.00  0.00,  0.00
rfp       3863 19.89 15.16 121.52, 742.49
R5          1  0.01  0.00 17.00, 21.54
R6      15554 80.10 61.04 96.69, 14.23
patc53 03 d5   
Tuesday, March 26, 2013   
doublets-
















patc53 03 d5 G1: doublets-=20000> 
Region Count  Hist % All Mean
Total      25501 100.00 100.00 129.56, 55.87
doublets-      22170 86.94 86.94 142.56, 57.83
FSC/SSC
















patc53 03 d5 G1: doublets-=20000>  (G1: doublets-)
Region Count % Hist % All Mean
Total      22170 100.00 86.94 106.47, 57.83
FSC/SSC      19532 88.10 76.59 100.83, 57.87
R3 rfp
R5 R6


























patc53 03 d5 G1: doublets-=20000>  (G2: doublets- & FSC/SSC)
Region Count % Hist % All Mean
Total      19532 100.00 76.59 100.83, 310.43
R3          0  0.00  0.00  0.00,  0.00
rfp       7464 38.21 29.27 116.16, 788.45
R5          1  0.01  0.00 17.00, 24.67








Figure	  13.	  MOI	  optimization	  study	  for	  infection	  with	  barcoded	  libraries	  
(Flow-­‐cytometry	  analysis	  for	  the	  RFP	  expression	  in	  MDA-­‐PATX53	  cells	  upon	  infection	  with	  different	  transducing	  units	  (Not	  Infected,	  
0.15	   TU/Cells,	   0.3	   TU/Cells)	   of	   the	   12.5k	   barcoded	   library,	   Day	   2	   post-­‐infection	   (Upper	   Panel),	   Summary	   of	   the	   RFP-­‐positive	   cells	  
(percentage)	   from	   PDAC	   xenograft-­‐derived	   (MDA-­‐PATX43,	   MDA-­‐PATX50,	   MDA-­‐PATX53,	   MDA-­‐PATX66)	   and	   GEM	   (p48-­‐
Cre,KrasG12D_LSL/+,p53L/L;	   p48-­‐Cre,	   KrasG12D_LSL/+,	   Ink4aL/L;	   p48-­‐Cre,	   KrasG12D_LSL/+	   senescence-­‐escaper)	   models	   upon	   infection	   with	  
different	  titers	  of	  the	  12.5k	  barcoded	  library:	  0.15	  TU/Cells,	  0.3	  TU/Cells,	  0.6	  TU/Cells	  and	  1.2	  TU/Cells,	  Day	  2	  post-­‐infection	  (Lower	  
Panel);	  




Prior	   to	   apply	   to	   our	   studies,	  we	   confirmed	   the	   reliability	   of	   this	   tool	   comparing	   the	  MOI	  
calculated	  through	  the	  qPCR	  method	  with	  the	  effective	  number	  of	  integrants	  that	  we	  were	  
able	  to	  detect	  by	  Southern	  Blot	  in	  isolated	  clones	  of	  infected	  A375	  cells	  (Fig.14b).	  The	  qPCR	  
system	  demonstrated	  that	  the	  above	  defined	  infection	  conditions	  (0.3	  and	  1.2	  TU/cells)	  are	  
able	   to	  maximize	   the	  number	  of	  cells	  with	  a	  single	   integration	   in	  human	  and	  mouse	  PDAC	  
models	   (Fig.14c).	   Upon	   controlled	   infection,	   cells	  were	   then	   selected	  with	   puromycin	   and	  
implanted	  subcutaneously	  into	  NSG	  mice.	  Tumors	  were	  isolated	  from	  mice	  and	  the	  barcodes	  
amplified	  from	  the	  genomic	  DNA	  by	  a	  2-­‐step	  PCR.	  We	  modified	  the	  secondary	  PCR	  in	  order	  
to	   allow	   the	   employment	   of	   a	   set	   of	   primers	   carrying	   Illumina	   adapters	   (P5	   and	   P7)	   to	  
Figure	  14.	  qPCR	  method	  for	  validation	  of	  the	  number	  of	  lentiviral	  integrants	  	  
(a)	  Titration	  curve	  generated	  amplifying	  known	  numbers	  of	  molecule	  of	  Albumine	  and	  GAG	  (lentiviral	  component)	  of	  a	  lentiviral	  vector	  
carrying	  a	  fragment	  of	  the	  Albumin	  gene.	  Threshold	  cycles	  were	  calculated	  for	  Albumine	  (CTAlb)	  and	  GAG	  (CTGAG)	  using	  the	  genomic	  DNA	  
extracted	   from	   infected	  cells	   and	   the	   same	  set	  of	  primers.	  Molecule	  numbers	  of	  Albumine	   (MNAlb)	   and	  GAG	   (MNGAG)	  were	  calculated	  
from	  the	  genomic	  DNA	  and	  titration	  curve	  comparison	  and	  used	  to	  determine	  the	  MOI	  applying	  the	  formula:	  MOI=	  (MNGAG/MNAlb)	  x	  2;	  
(b)	  Southern	  blot	  of	  viral	  integrants	  performed	  on	  genomic	  DNA	  collected	  from	  A375	  clones	  infected	  with	  a	  lentivirus	  at	  different	  MOIs	  
(NI=Not	  infected,	  1-­‐7=Infected	  clones).	  Comparison	  between	  number	  of	  integrants	  determined	  by	  Southern	  Blot	  (Bands)	  and	  qPCR	  (MOI)	  
methods;	  (c)	  Number	  of	  integrants	  calculated	  by	  qPCR	  (MOI)	  in	  PDAC	  xenograft-­‐derived	  cells	  infected	  with	  2	  different	  dilutions	  of	  virus	  
(0.3	  and	  0.6	  TU/Cell).	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facilitate	   the	   quantification	   of	   individual	   barcodes	   by	   next-­‐generation	   sequencing	   (NGS)	  
reducing	  the	  number	  of	  total	  cycles	  (Fig15a).	  To	  model	  optimal	  distribution	  of	  the	  complex	  
barcode	   library,	   we	   implanted	   different	   cell	   numbers	  with	   each	   barcode	   expressed	   in	   80,	  
240,	  or	  400	  individual	  cells	  (Fig.15b,c).	  	  
	  
The	  reads	  generated	  by	  the	  HiSeq2000	  were	  primarily	  filtered	  for	  a	  common	  portion	  of	  the	  
lentiviral	   integrant	   to	   remove	   the	   non-­‐specific	   errors	   produced	   during	   sequencing.	   The	  
positions	  of	   the	  18	  nucleotide	   sequences	  corresponding	   to	   the	  12,500	  molecular	  barcodes	  
were	  identified	  in	  the	  read	  string,	  trimmed	  and	  quantified.	  Upon	  normalization,	  the	  relative	  
number	  of	   counts	   (Log2)	   for	  each	   individual	  barcode	   in	   the	   tumor	  was	   compared	  with	   the	  
one	   in	   the	   reference	   cells	   before	   transplantation.	   The	   Log2	   ratio	   between	   tumors	   and	  
reference	   cells	   (Tumor/Ref	   Log2	   ratio)	   informed	   on	   the	   ability	   of	   the	   barcoded	   cell	  




























































































































































































Figure	  15.	  Amplification	  strategy	  of	  molecular	  barcodes	  and	  modulation	  of	  the	  TIC	  coverage	  	  	  
(a)	   Scheme	   of	   the	   barcode	   amplification	   to	   generate	   sequencing	   libraries	   from	   genomic	   DNA	   viral	   integrants	   (P5	   and	   P7=	   Illumina	  
adapters,	   Seq	   Primer=	   Sequencing	   Primer);	   (b)	   Agarose-­‐gel	   (2,5%)	   run	   of	   the	   barcode-­‐containing	   PCR	   products	   amplified	   from	   the	  
genomic	   DNA	   of	   MDA-­‐PATX53	   tumors	   (Tx1-­‐3)	   or	   reference	   cells	   (Ref	   Cells)	   infected	   with	   the	   12.5k	   barcoded	   library	   at	   different	  
coverages:	   80	   cells/barcode,	   240	   cells/barcode,	   400	   cells/barcode	   (Expected	   molecular	   weight	   =	   279	   bp);	   (c)	   Density	   plot	   of	   the	  
Tumor/Ref	  Log2	  ratio	  (Median	  between	  triplicates)	   for	  xenograft-­‐derived	  MDA-­‐PATX53	  cells	  infected	  with	  the	  12.5k	  barcoded	  library	  at	  a	  
increased	  TIC	  coverage:	  80	  cells/barcode	  (Left	  panel),	  240	  cells/barcode	  (Middle	  panel)	  and	  400	  cells/barcode	  (Right	  panel).	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Tumor/Ref	   ratio	  we	  were	   able	   to	   appreciate	   the	   distribution	   of	   the	   12,500	   barcodes	   as	   a	  
function	  of	  the	  change	  in	  representation	  (counts).	  	  
	  
A	  centered	  normal	  distribution	  is	  indicative	  of	  a	  complex	  library	  coverage	  (cells	  per	  barcode)	  
sufficient	  to	  represent	  each	  one	  of	  the	  barcodes	  in	  the	  established	  tumor.	  Alterations	  of	  the	  
Gaussian	   curve	   or	   in	   vivo	   disappearance	   of	   barcodes	   could	   be	   considered	   as	   a	   failure	   in	  
covering	   the	   number	   of	   the	   tumor	   initiating	   cells	   (TICs)	   that	   are	   participating	   in	   tumor	  
engraftment	  (Fig.15c).	  A	  ratio	  of	  80	  cells	  per	  barcode	  was	  sufficient	  to	  retain	  representation	  
of	  12,500	  different	  barcoded	  vectors	  in	  mouse	  PDAC	  implants	  derived	  from	  either	  the	  p48-­‐
Cre,	  KrasG12D_LSL/+,	  p53L/L	  or	  the	  p48-­‐Cre,	  KrasG12D_LSL/+	  senescence-­‐escaper	  models	  (Fig.16a-­‐c).	  	  
Figure	   16.	   Barcode	   distribution	   in	   TIC	   coverage	  
studies	  of	  PDAC	  mouse	  models	  	  	  
(a)	   Agarose-­‐gel	   (2,5%)	   run	   of	   the	   barcode-­‐containing	  
PCR	  products	  amplified	   from	   the	  genomic	  DNA	  of	  p48-­‐
Cre,KrasG12D_LSL/+,p53L/L	   and	   p48-­‐Cre,	   KrasG12D_LSL/+	  
senescence-­‐escaper	  tumors	  (Tx1,	  Tx2)	  or	  reference	  cells	  
(Ref	  Cells)	   infected	  with	  the	  12.5k	  barcoded	  library	  at	  a	  
coverage	   of	   80	   cells/barcode	   (Expected	   molecular	  
weight	  =	  279	  bp);	  (b)	  Density	  plot	  of	  the	  Tumor/Ref	  Log2	  
ratio	   (Median	   between	   replicates)	   from	   the	   p48-­‐
Cre,KrasG12D_LSL/+,p53L/L	   cells	   infected	   with	   the	   12.5k	  
barcoded	   library	   (coverage	   of	   80	   cells/barcode);	   (c)	  
Density	   plot	   of	   the	   Tumor/Ref	   Log2	   ratio	   (Median	  
between	   replicates)	   from	   the	   p48-­‐Cre,KrasG12D_LSL/+	  
escaper	   cells	   infected	   (in	   replicate)	   with	   the	   12.5k	  
barcoded	  library	  (coverage	  of	  80	  cells/barcode).	  








Conversely,	   for	   either	   PDX-­‐derived	  MDA-­‐PATX53	   or	  MDA-­‐PATX43	   samples,	   the	   number	   of	  
cells	  required	  to	  retain	  complexity	  was	  at	   least	  5-­‐fold	  higher	  (400	  cells/barcode)	  owning	  to	  
their	   lower	   TIC	   frequency	   (Fig.17a,b).	   Two	   additional	   human	   PDX-­‐derived	   models	   (MDA-­‐
PATX50	  and	  MDA-­‐PATX66)	  failed	  to	  provide	  a	  number	  of	  tumor-­‐initiating	  cells	  sufficient	  to	  
cover	   the	   complexity	   of	   a	   12,500-­‐barcode	   library,	   with	   the	   majority	   of	   barcodes	   being	  
randomly	  depleted	  during	  mouse	  tumor	  engraftment	  (Fig.17a,c).	  	  
To	   confirm	   the	   relative	   TIC	   frequencies	   as	   estimated	   by	   barcode	   representation,	   we	  
performed	   extreme	   limiting	   dilution	   assays	   (ELDA)	   on	   the	   same	  mouse	   and	   human	   PDAC	  
tumor	  models.	  Through	  ELDA	  transplantation	  of	  primary	  mouse	  PDAC	  tumors	  we	  estimated	  
Figure	  17.	  Barcode	  distribution	  of	  TIC	  coverage	  studies	  of	  human	  PDAC	  xenograft-­‐derived	  models	  	  	  
(a)	  Agarose-­‐gel	   (2,5%)	   run	  of	   the	  barcode-­‐containing	  PCR	  products	  amplified	   from	  the	  genomic	  DNA	  of	  MDA-­‐PATX43,	  MDA-­‐
PATX50	  and	  MDA-­‐PATX66	  tumors	  (Tx1,	  Tx2)	  or	  reference	  cells	  (Ref	  Cells)	  infected	  with	  the	  12.5k	  barcoded	  library	  at	  a	  coverage	  
of	  80	  cells/barcode	  (Expected	  molecular	  weight	  =	  279	  bp);	  (b)	  Density	  plot	  of	  the	  Tumor/Ref	  ratio	  (Median	  between	  replicates)	  
from	  the	  xenograft-­‐derived	  MDA-­‐PATX43	  and	  MDA-­‐PATX53	  cells	   infected	  with	  the	  12.5k	  barcoded	   library	  with	  a	  coverage	  of	  
400	   cells/barcode;	   (c)	   Density	   plot	   of	   the	   Tumor/Ref	   ratio	   (Median	   between	   replicates)	   from	   the	   xenograft-­‐derived	   MDA-­‐
PATX50	  and	  MDA-­‐PATX66	  cells	  infected	  with	  the	  12.5k	  barcoded	  library	  with	  a	  coverage	  of	  400	  cells/barcode.	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TIC	  frequencies	  in	  the	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  and	  the	  p48-­‐Cre,	  KrasG12D_LSL/+	  senescence-­‐
escaper	   models	   of	   1:27	   and	   1:19	   respectively.202,203	   Consistent	   with	   the	   results	   of	   our	  
barcode	   experiments,	   ELDA	   estimated	   a	   10-­‐20-­‐fold	   shift	   in	   TIC	   frequency	   between	  mouse	  
and	  human	  PDAC,	  and	  further	  confirmed	  the	  variability	  between	  human	  PDAC	  samples	  with	  
respect	   to	   TIC	   frequency	   (Fig.18).	   Taken	   together,	   these	   data	   suggest	   that	   the	   rapid	  
determination	   of	   barcode	   representation	   in	   these	   tumor	   explant	   models	   can	   accurately	  
predict	   TIC	   frequency	   compared	   to	   the	   time-­‐intensive	   ELDA	   transplantation	   assays.	   Using	  
this	  approach	  we	  can	  rapidly	  assess	  TIC	  frequency	  across	  patient-­‐derived	  PDAC	  tumors	  and	  
adjust	  barcode	  representation	  per	  cell	  to	  ensure	  adequate	  coverage,	  opening	  the	  possibility	  




	   	  
Figure	  18.	  Pancreatic	  cancer	  TIC	  frequency	  estimation	  by	  limiting	  dilution	  assay	  	  
Extreme	  limiting	  dilution	  analysis	  (ELDA)	  in	  PDAC	  mouse	  models	  (p48-­‐Cre,KrasG12D_LSL/+,p53L/L;	  p48-­‐Cre,	  KrasG12D_LSL/+,	   Ink4aL/L;	  p48-­‐
Cre,	  KrasG12D_LSL/+	  senescence-­‐escaper)	  and	  PDX-­‐derived	  cells	   (MDA-­‐PATX43,	  MDA-­‐PATX50,	  MDA-­‐PATX53,	  MDA-­‐PATX66).	   Tumor-­‐
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3.	  In	  vivo	  shRNA	  screens	  of	  new	  epigenetic	  vulnerabilities	  in	  human	  and	  
mouse	  PDAC	  models	  
	  
To	   identify	   candidate	   epigenetic	   mechanisms	   required	   for	   PDAC	   growth	   and	   survival,	   we	  
performed	  in	  vivo	  shRNA	  screens	  in	  two	  PDAC	  xenograft-­‐derived	  samples	  (MDA-­‐PATX53	  and	  
MDA-­‐PATX43)	  and	  three	  PDAC	  GEM	  tumor	  models	  (p48-­‐Cre,	  KrasG12D_LSL/+,	  Trp53L/L;	  p48-­‐Cre,	  




Figure	  19.	  In	  vivo	  shRNA	  screens	  for	  epigenetic	  vulnerabilities	  in	  human	  and	  mouse	  PDAC	  models	  
(a)	   Outline	   of	   experimental	   design	   for	   deep-­‐coverage	   shRNA	   screens	   in	   patient-­‐derived	   and	   mouse	   models	   of	   pancreatic	   ductal	  
adenocarcinoma	   (MOI=multiplicity	   of	   infection,	   Ref	   Cells=Infected	   and	   selected	   cells	   before	   injection,	   Barcode=18	   unique	  
nucleotides);	   (b)	   Highlight	   of	   pRSI17	   lentiviral	   vector	   cloning	   site	   carrying	   the	   2.4k	   shRNA-­‐coupled	   molecular	   barcodes	   and	   the	  
downstream	  polycistronic	  site	  carrying	  the	  puromycin	  resistance	  (PuroR)	  and	  GFP	  reporter	  gene	  (GFP)	  separated	  by	  the	  2A	  peptide.	  
Each	  shRNA-­‐coupled	  barcode	  was	  quantified	  by	  massively	  parallel	  sequencing	  and	  compared	  between	  matched	  samples	  (tumor/ref	  
log2	  ratio),	  Tumor-­‐essential	  genes	  were	  identified	  as	  depleted	  shRNAs,	  while	  tumor	  suppressors	  were	  enriched.	  Pie-­‐chart	  represents	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The	  workflow	  design	  was	  adjusted	  with	  the	  purpose	  of	  performing	  the	  shRNA	  in	  vivo	  screens	  
in	  exactly	  the	  same	  experimental	  setting	  previously	  applied	  for	  the	  TIC	  coverage	  studies.	  	  We	  
developed	   an	   shRNA	   library	   targeting	   236	   human	   or	   mouse	   epigenetic	   regulators.	   To	  
enhance	   the	   robustness	   of	   the	   screen	   and	   limit	   the	   potential	   for	   non-­‐specific	   off-­‐target	  
activity	   we	   employed	   10	   unique	   shRNAs	   per	   each	   gene	   in	   the	   library.	   Each	   shRNA,	  
constituted	   by	   2	   G/U	  mismatches	   in	   the	   passenger	   strand,	   a	   7	   nucleotides	   loop	   and	   a	   21	  
nucleotides	   targeting	   sequence,	   was	   cloned	   into	   the	   pRSI16	   lentiviral	   vector	   (Cellecta)	  
carrying	   a	   downstream	   polycistronic	   site	   with	   the	   puromycin	   resistance	   (PuroR)	   and	   GFP	  
reporter	   gene	   (GFP)	   separated	  by	   the	  2A	  peptide.	   The	  oligo	   corresponding	   to	  each	   shRNA	  
was	   synthesized	   with	   a	   unique	   molecular	   barcode	   (18	   nucleotides)	   for	   measuring	  
representation	  by	  NGS	  (Fig.19b).	  	  
The	  infection	  steps	  were	  performed	  mimicking	  the	  MOI	  optimized	  conditions	  (0.3	  TU/cell	  in	  
human,	   1.2	   TU/cell	   in	   mouse)	   we	   determined	   in	   each	   sample	   with	   the	   12,500-­‐barcode	  
library	   during	   the	   TIC	   coverage	   studies.	   The	   PCR	   amplification	   of	   the	   barcodes	   and	   the	  
sequencing	  data	  deconvolution	  and	  normalization	  were	  performed	   in	  accordance	  with	   the	  
methods	   explained	   above.	  We	   screened	   the	   PDX-­‐derived	  MDA-­‐PATX53	   and	  MDA-­‐PATX43	  
cells	   in	   replicate	  with	  ≈2,000	  cells/shRNA	  to	  ensure	   that	   library	  complexity	  was	  covered	   in	  
each	   transplanted	  mouse	   (Fig.20a,b).	  As	   suggested	  by	   the	  TIC	   coverage	   study	  with	  12,500	  
barcodes,	   the	   chosen	   shRNA	   library	  would	  not	   be	  maintained	   in	   the	  MDA-­‐PATX66	   tumors	  
with	  a	  coverage	  of	  ≈2,000	  cells/shRNA	  (Fig.20c).	  Replicate	  screens	  in	  the	  PDAC	  GEM	  models	  
were	  performed	  with	  ≈400	  cells/shRNA	  (Fig.21a-­‐c).	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Figure	   20.	   Results	   of	   in	   vivo	   shRNA	  
screens	   for	   epigenetic	   vulnerabilities	   in	  
human	  PDAC	  models	  
(a)	   PDX-­‐derived	   MDA-­‐PATX53	   cells	   were	  
screened	   in	   triplicate	   with	   2000	   cells/shRNA	  
(Upper	  panel,	  Tumor/Ref	  Log2	  ratio).	  Correlation	  
plots	   between	   replicates	   (Bottom	   panel,	   fold-­‐
change	  of	  relative	  counts,	  Pearson’s	  correlation	  
factor);	   (b)	   Replicate	   screens	   in	   the	   PDAC	  
xenograft-­‐derived	   MDA-­‐PATX43	   were	  
performed	  with	  2000	  cells/shRNA	  (Upper	  panel,	  
Tumor/Ref	   Log2	   ratio	   of	   relative	   counts).	  
Correlation	   plots	   between	   replicates	   (Bottom	  
panel,	  Fold-­‐change	  of	  relative	  counts,	  Pearson’s	  
correlation	   factor);	   (c)	   Replicate	   screens	   in	   the	  
PDAC	   xenograft-­‐derived	   MDA-­‐PATX66	   were	  
performed	  with	  2000	  cells/shRNA	  (Upper	  panel,	  
Tumor/Ref	   Log2	   ratio	   of	   relative	   counts).	  
Correlation	   plots	   between	   replicates	   (Bottom	  
panel,	  Fold-­‐change	  of	  relative	  counts,	  Pearson’s	  
correlation	  factor).	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The	  robustness	  of	  this	  screening	  approach	  was	  demonstrated	  comparing	  each	  replicate	  and	  
calculating	   the	   associated	   Pearson’s	   correlation	   factor.	   Among	   all	   the	   performed	   screens,	  
only	  the	  MDA-­‐PATX66	  replicates	  showed	  a	  very	  low	  correlation	  (R2=0.15-­‐0.25)	  (Fig.20-­‐21).	  
	  
Figure	  21.	  Results	  of	  in	  vivo	  shRNA	  screens	  for	  
epigenetic	   vulnerabilities	   in	   mouse	   PDAC	  
models	  
(a)	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  cells	  were	  screened	  in	  
triplicate	   with	   400	   cells/shRNA	   (Upper	   panel,	  
Tumor/Ref	   Log2	   ratio).	   Correlation	   plots	   between	  
replicates	   (Bottom	   panel,	   fold-­‐change	   of	   relative	  
counts,	   Pearson’s	   correlation	   factor);	   (b)	   Replicate	  
screens	   with	   the	   PDAC	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L	  
senescence-­‐escaper	   cells	   were	   performed	   with	   400	  
cells/shRNA	   (Upper	   panel,	   Tumor/Ref	   Log2	   ratio	   of	  
relative	   counts).	   Correlation	   plots	   between	   replicates	  
(Bottom	   panel,	   Fold-­‐change	   of	   relative	   counts,	  
Pearson’s	   correlation	   factor);	   (c)	   Replicate	   screens	  
with	   the	   PDAC	   p48-­‐Cre,	   KrasG12D_LSL/+,	   Ink4aL/L	   cells	  
were	   performed	   with	   400	   cells/shRNA	   (Upper	   panel,	  
Tumor/Ref	   Log2	   ratio	   of	   relative	   counts).	   Correlation	  
plots	   between	   replicates	   (Bottom	   panel,	   Fold-­‐change	  
of	  relative	  counts,	  Pearson’s	  correlation	  factor).	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To	   confirm	   an	   accurate	   coverage	   of	   each	   shRNA	   in	   the	   performed	   screens,	   we	   applied	   a	  
cumulative	  distribution	   function	   (CDF)	   to	   the	  Tumor/Ref	   ratio	  as	  a	   first-­‐line	   filter	   to	  detect	  
the	  top	  15-­‐30%	  depleted	  shRNAs	  (Fig.22a).	  	  
	  
For	   each	   sample,	   the	   cutoff	   (-­‐2/-­‐4	   Log2)	   determined	   by	   the	   CDF	   analysis	   demonstrated	   to	  
match,	  with	  good	  approximation,	   the	  Log2	  value	  of	   the	  -­‐2	  Standard	  Deviation	  (-­‐2SD)	   in	  the	  













Figure	  22.	  Identification	  of	  depleted	  shRNAs	  in	  human	  and	  mouse	  PDAC	  in	  vivo	  screens	  
(a)	  Cumulative	  distribution	  function	  for	  human	  PATX53	  (left	  graph)	  and	  mouse	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  mouse	  model	  (right	  
graph);	   (b)	   Overlapped	   Tumor/Ref	   ratios	   (Log2	   ratio)	   for	   the	   TIC	   coverage	   studies	   and	   the	   corresponding	   shRNA	   screens	   in	  
xenograft-­‐derived	  MDA-­‐PATX53	  (Left	  graph)	  and	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  mouse	  model	  (right	  graph),	  Log2	  ratio	  values	  for	  
the	  ±2	  Standard	  Deviations	  (SD)	  in	  the	  TIC	  coverage	  studies	  are	  highlighted	  in	  the	  graphs	  (dashed	  grey	  lines).	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To	   identify	   the	   top-­‐scoring	   “hits”	   in	   each	   screened	   PDAC	   model	   we	   associated	   robust	   Z-­‐
scores	  to	  each	  gene,	  taking	  into	  account	  the	  fold-­‐change	  of	  top	  3	  shRNAs,	  and	  ranked	  them	  
on	  the	  base	  of	  the	  corresponding	  p-­‐value	  (Fig.23).	  
	  
	  
A	  p-­‐value	  associated	  to	  the	  mean	  Z-­‐score	  among	  all	  the	  screening	  models	  has	  been	  applied	  
to	  rank	  the	  most	  potent	  genes	  across	  all	  of	  these	  PDAC	  relevant	  contexts	  (Fig.24).	  	  
2	   well-­‐known	   essential	   genes	   (PSMA1,	   RLP30)	   were	   inserted	   into	   the	   library	   as	   positive	  
controls	  and	  they	  scored	  among	  the	  top	  depleted	  hits.	  Interestingly,	  one	  of	  the	  top	  scoring	  
genes,	   PHF5A,	   has	   been	   proposed	   as	   a	   relevant	   key	   player	   in	   selectively	   sustaining	   RNA	  
splicing	   and	   survival	   of	   glioblastoma	   stem	   cells	   (GSCs)	   through	   a	   genome-­‐wide	   RNAi	  
screening	  approach204	  .	  
Among	   the	   cohesins	   (SMC1a,	   SMC3)	   and	   condensins	   (SMC2,	   SMC4),	   SMC2	   confirmed	   a	  
prominent	  role	  in	  sustaining	  PDAC	  cell	  proliferation,	   in	  line	  with	  previous	  findings205.	   In	  the	  
Figure	  23.	  Identification	  of	  depleted	  genes	  in	  human	  and	  mouse	  PDAC	  in	  vivo	  screens	  
Density	  plot	  of	  the	  p-­‐value	  associated	  to	  the	  mean	  Z-­‐score	  (fold-­‐change,	  average	  of	  the	  top	  3	  shRNAs)	  for	  each	  gene	  in	  MDA-­‐
PATX53	   and	  MDA.PATX43	   human	   PDAC	   screens	   and	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L,	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L	   senescence-­‐
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same	  direction,	  we	  identified	  BRD4	  in	  our	  top-­‐scoring	  gene	  list	  as	  expected	  by	  the	  very-­‐well	  
demonstrated	  PDAC	  cells	  sensitivity	  to	  BET	  inhibitors	  and	  BRD4	  interference206	  (Fig.24).	  
	  
In	   addition,	   an	   unsupervised	   clustering	   method,	   applied	   to	   all	   the	   genes	   in	   the	   library,	  
demonstrated	   not	   only	   the	   robustness	   of	   replicates	   from	   each	   PDAC	  model,	   but	   also	   the	  
possibility	   to	   inform	   on	   functional	   epigenetic	   networks	   in	   PDAC	   and	   identifying	   patient-­‐
specific	  dependent	  vulnerabilities	  (Fig.25).	  As	  expected,	  positive	  controls	  clustered	  together	  
and	  also	  leaded	  a	  very	  well	  defined	  sub-­‐group	  constituted	  by	  the	  most	  potent	  hits	  among	  all	  
the	  PDAC	  screened	  models.	  Negative	  controls	  clustered	  together	  as	  well	  and	  were	  at	  the	  top	  
of	   a	   bigger	   cluster	   containing	   genes	   that	  were	   inactive	   and	   genes	   that	   showed	   significant	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MDA$PATX53* p48$Cre,*KRAS*escaper* p48$Cre,*KINK* p48$Cre,*KP53*
Figure	  24.	  Top-­‐scoring	  e igenes	  in	  human	  and	  mouse	  PDAC	  in	  vivo	  screens	  
Heatmap	  of	  the	  top-­‐scoring	  hits	  identified	  applying	  a	  p-­‐value-­‐based	  cut-­‐off	  (p<0.05)	  associated	  to	  th 	  z-­‐scor 	  (fold-­‐change,	  average	  of	  
the	  top	  3	  shRNAs)	  for	  each	  gene.	  Genes	  were	  ranked	  calculating	  the	  mean	  z-­‐score	  among	  all	  the	  screened	  samples	  (T	  =	  tumor).	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Differently	  high-­‐ranked	  common	  hits	  (PHF5A,	  SMC2,	  WDR5)	  were	  individually	  validated	  with	  
2	  independent	  shRNA,	  aiming	  at	  linking	  target	  knock-­‐down	  level	  (72	  hours	  after	  infection),	  in	  
vivo	   xenotransplantation	   and	   in	   vitro	   colony	   formation	   assay	   (CFA).	   Down-­‐regulation	   of	  
these	   genes,	   confirmed	   by	  western	   blot,	   significantly	   impaired	   new	   colony	   formation	   and	  

































































































































































































































































































































































Figure	   25.	   Unbias	   clustering	   of	   human	   and	   mouse	   PDAC	   in	   vivo	   screens	   highlighted	   context-­‐dependent	  
lethalities	  
The	  heatmap	  was	  produced	  using	  unsupervised	  clustering	  analysis	  employing	  ”complete	  linkage”	  method	  with	  Euclidean	  distance	  
of	   the	   robust	  Z-­‐score	   (fold-­‐change,	   average	  of	   the	   top	  3	   shRNAs)	   for	  each	  gene	   in	   the	  Epi	   shRNA	   library,	  Replicates	   from	  each	  
sample	  (human	  or	  mouse	  PDAC)	  clustered	  together.	  Positive	  controls	  were	  higjlighted	  in	  green,	  negative	  controls	  in	  orange.	  	  
	  






Figure	  26.	  Validation	  of	  the	  top-­‐scoring	  hits	  identified	  by	  the	  in	  vivo	  shRNA	  screens	  for	  epigenetic	  vulnerabilities	  in	  
human	  and	  mouse	  PDAC	  models	  
(a)	  Western	  blot,	  xenotransplantation	  tumor	  size	  (mm3)	  and	  colony	  formation	  assay	  for	  xenograft-­‐derived	  PATX53	  cells	  infected	  with	  
2	   independent	   shRNAs	   against	   the	   top-­‐scoring	   hits:	  WDR5,	   PHF5A	   and	   SMC2	   (h=human);	   (b)	  Western	   blot,	   	   xenotransplantation	  
tumor	  size	  (mm3)	  and	  colony	  formation	  assay	  for	  the	  mouse	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  model	  infected	  with	  2	  independent	  shRNAs	  
against	  the	  top-­‐scoring	  hits:	  Wdr5,	  Phf5a	  and	  Smc2	  (m=mouse).	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4.	  WDR5	  is	  essential	  for	  PDAC	  establishment	  and	  maintenance	  	  
	  
Unbiased	   in	   vivo	   shRNA	   screens	   provide	   the	   opportunity	   to	   inform	   on	   novel	   genetic	  
associations	  and	  to	  query	  dependencies	  across	  common	  pathways,	  nodes,	  networks	  or	  even	  
multiprotein	  complexes	  in	  a	  disease-­‐relevant	  context.	  	  One	  of	  the	  strongest	  “hits”	  to	  emerge	  
across	   the	   multiple	   PDAC	   screens	   was	   the	   WD40	   protein	   WDR5,	   a	   core	   member	   of	   the	  




Recently,	  WDR5	  up-­‐regulation	  was	  detected	   in	  prostate	  and	  bladder	  cancers,	  where	   it	  also	  
demonstrated	   to	   be	   critical	   for	   cancer	   cells	   proliferation209,210.	   We	   first	   confirmed	  
deregulated	  expression	  of	  WDR5	   in	  human	  PDAC	  compared	   to	  normal	  control	  pancreas.	  A	  
Figure	  27.	  WDR5	  is	  over-­‐expressed	  in	  pancreatic	  cancer	  and	  essential	  for	  in	  vivo	  engraftment	  
(a)	   Box-­‐plot	   for	  WDR5	   intensity	   staining	   in	   human	   pancreatic	   ductal	   adenocarcinoma	   Tissue	  MicroArray	   (102	   cases	   total,	   42	   normal	  
pancreas,	   60	   PDAC,	   p<0.005).	   Representative	   images	   of	   PDAC	   and	   normal	   pancreas	   stained	   with	   WDR5	   (20x);	   (b)	   Non-­‐invasive	  
bioluminescence	   imaging	   depicts	   the	   luciferase	   expression	   in	   the	   pancreas	   (Day	   30)	   of	   representative	  mice	   injected	   with	   xenograft-­‐
derived	  MDA-­‐PATX53	  cells	  expressing	  shRNA	  targeting	  WDR5	  (Sh1	  hWDR5	  and	  Sh2	  hWDR5)	  and	  control	  (Sh	  NT).	  Percent	  survival	  of	  mice	  
transplanted	  with	  xenograft-­‐derived	  MDA-­‐PATX53	  cells	  expressing	   shRNA	  targeting	  WDR5	  (Sh1	  hWDR5	  and	  Sh2	  hWDR5)	  and	  control	  (Sh	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Tissue	  MicroArray	   (TMA)	   representing	   102	   specimens	   (46	  normal	   pancreas,	   60	   PDAC)	  was	  
stained	   for	  WDR5	  expression	  and	  an	   intensity	  score	   (0-­‐300,	  percentage	  of	  positive	  cells	  by	  
the	   intensity)	   was	   assigned	   by	   a	   pathologist	   to	   each	   sample	   (Fig.27a).	   PDAC	   specimens	  
showed	   a	   significant	   higher	   level	   of	   WDR5	   expression	   in	   comparison	   with	   the	   normal	  
pancreas	  (Student’s	  T-­‐test,	  p<0.005).	  To	  functionally	  validate	  the	  screen	  results,	  PDX-­‐derived	  
PDAC	   cells	   transduced	   with	   individual	   shRNAs	   targeting	   WDR5	   were	   orthotopically	  
implanted	  in	  the	  pancreas	  of	  NSG	  mice.	  In	  agreement	  with	  the	  above	  results,	  WDR5	  knock-­‐
down	  substantially	  delayed	  tumor	  growth	  and	  extended	  survival	  compared	  to	  non-­‐targeting	  
(NT)	  shRNA	  controls	  (Fig.27b).	  
These	  effects	  seemed	  specific	  as	  expression	  of	  a	  cDNA	  encoding	  the	  WDR5	  coding	  sequence	  
(ORF)	   lacking	   the	   3'	   UTR	   nucleotides	   rescued	   the	   observed	   effects	   upon	   targeting	   by	   the	  
shRNA	  (Fig.28a,b).	  	  
	  
	  
Figure	  28.	  Rescue	  experiments	  
of	   WDR5	   knock-­‐down	   in	  
human	  PDAC	  models	  
(a)	  Colony	  formation	  assay	  (CFA)	  of	  
MDA-­‐PATX53	   cells	   expressing	  
pHAGE-­‐GFP_IRES_GFP	   or	   pHAGE-­‐
WDR5_IRES_GFP	   and	   shRNA	  
targeting	   WDR5	   (sh1_WDR5)	   or	  
control	   (sh_NT),	  Protein	  expression	  
of	   WDR5,	   GFP	   and	   β-­‐actin;	   (b)	  
Colony	   formation	   assay	   (CFA)	   of	  
MDA-­‐PATX66	   cells	   expressing	  
pHAGE-­‐GFP_IRES_GFP	   or	   pHAGE-­‐
WDR5_IRES_GFP	   and	   shRNA	  
targeting	   WDR5	   (sh1_WDR5)	   or	  
control	   (sh_NT),	  Protein	  expression	  
of	  WDR5,	  GFP	  and	  β-­‐actin.	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Using	   a	   serum-­‐free	   3D	   culture,	  we	  were	   able	   to	   generate	   pancreatic	   cancer	   spheres	   from	  
either	   human	   or	   mouse	   PDAC	   samples211.	   WDR5	   knock-­‐down	   significantly	   impaired	   the	  
spherogenic	   potential	   of	   these	   cultures	   as	   demonstrated	   by	   calcein	   staining	   and	   spheroid	  
counts	  (Fig.29a,d).	  
	  
Next,	   we	   aimed	   to	   determine	   if	  WDR5	   was	   required	   for	   the	   in	   vivo	   growth	   of	   additional	  
patient-­‐derived	   PDAC	   models.	   Using	   our	   optimized	   ex	   vivo	   rapid	   culture	   conditions	   we	  
infected	  stabilized	  PDC	  cells	  with	  2	  independent	  shRNA	  for	  WDR5	  or	  control.	  Target	  knock-­‐
down	  was	  confirmed	  48	  hours	  after	  puromycin	  selection	  and	  NSG	  mice	  were	   transplanted	  
for	   each	   condition	   (n=5).	  Measuring	   the	   tumor	   size	   we	   were	   able	   to	   confirm	   that	  WDR5	  
knock-­‐down	  blocked	  tumor	  growth	  of	  transplanted	  PDAC	  samples	  (Fig.30).	  
Figure	   29.	   WDR5	   is	   essential	   to	   sustain	   growth	   of	   human	   and	  
mouse	  PDAC	  spheroids	  
(a)	   Adhesion-­‐independent	   spherogenic	   assay	   (Spheroids	   number)	   for	  
xenograft-­‐derived	  MDA-­‐PATX53	  cells	  expressing	  shRNA	  targeting	  WDR5	  (Sh1	  
hWDR5	   and	   Sh2	   hWDR5)	   and	   control	   (shNT);	   Calcein	   staining	   (Green)	  was	  
performed	   for	   visualizing	   and	   counting	   the	   spheroids	   encapsulated	   in	  
methylcellulose	   matrix;	   (b)	   Adhesion-­‐independent	   spherogenic	   assay	  
(Spheroids	   number)	   for	   p48-­‐Cre,	   KrasG12D_LSL/+	   senescence-­‐escaper	  
(quadruplicate),	   p48-­‐Cre,KrasG12D_LSL/+,p53L/L	   (quadruplicate)	   and	   p48-­‐Cre,	  
KrasG12D_LSL/+,	  Ink4aL/L	  (triplicate)	  cells	  expressing	  shRNA	  targeting	  WDR5	  (Sh1	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To	  evaluate	  whether	  WDR5	  would	  provide	  an	  essential	  function	  in	  tumor	  maintenance,	  we	  
infected	   PDX-­‐derived	   samples	   (MDA-­‐PATX53	   and	   MDA-­‐PATX66)	   with	   Tet-­‐inducible	   WDR5	  
shRNAs	  (Sh1	  WDR5i,	  Sh2	  WDR5i)	  or	  control	  shRNA	  (Sh	  NT)	  and	  sorted	  them	  for	  the	  top	  20%	  
RFP-­‐positive	  cells.	  WDR5-­‐inducible	  cells	  were	  grown	  using	  Tet-­‐free	  culturing	  media	  and	  the	  
protein	   knock-­‐down	   was	   confirmed	   after	   doxycycline	   addition	   (+	   DOX)	   by	   western	   blot	  
(Fig.31a-­‐c).	  Applying	  colony	  formation	  assay	  and	  supplementing	  with	  doxycycline	  upon	  cell	  
seeding	   (+	   DOX),	   we	   observed	   a	   significant	   arrest	   in	   colony	   growth,	   not	   detectable	  when	  
colonies	  were	   kept	   in	   absence	  of	   doxycycline	   (-­‐	  DOX)	   (Fig.32a).	   The	   same	  WDR5-­‐inducible	  
PDAC	  cells	  were	  transplanted	   into	  host	  mice	  and	  preliminarily	  monitored	  for	  their	  growing	  
ability	  in	  the	  absence	  of	  a	  doxycycline-­‐containing	  drinking	  water	  regimen	  (n=5).	  (Fig.32b).	  
Figure	  30.	  WDR5	  knock-­‐down	  impairs	  the	  engraftment	  potential	  of	  human	  xenograft-­‐derived	  PDAC	  models	  
Western	   blot	   for	   xenograft-­‐derived	   PDAC	   cells	   (MDA-­‐PATX66,	   MDA-­‐PATX77,	   MDA-­‐PATX80,	   MDA-­‐PATX92)	   infected	   with	   2	  
independent	   shRNAs	   against	  WDR5	   (Sh1	   hWDR5	   and	   Sh2	   hWDR5)	   or	   control	   (Sh	  NT),	   Protein	   expression	   of	  WDR5	   ans	  HSP90;	  
Tumor	  measurement	   (tumor	   size,	  mm3)	   of	   3	   primary	   PDAC	   xenograft-­‐derived	   cells	   (MDA-­‐PATX77,	  MDA-­‐PATX80,	  MDA-­‐PATX92)	  
expressing	  shRNAs	  targeting	  WDR5	  (sh1_WDR5,	  sh2_WDR5),	  and	  control	  (sh	  NT),	  Median	  (n	  =	  5,	  p<	  0.005).	  




We	  observed	  a	  significant	  arrest	  in	  the	  growth	  ability	  of	  the	  WDR5	  down-­‐regulated	  tumors	  
under	   doxycycline	   treatment	   (+	   DOX)	   that	   was	   maintained	   until	   the	   end	   of	   the	   study	  
(Student’s	  T-­‐test,	  p‹0.05)	  (Fig.32c).	  Immunohistochemistry	  staining	  confirmed	  in	  vivo	  WDR5	  
knock-­‐down	  associated	  with	  a	  reduction	  of	  the	  proliferation	  marker	  Ki67	  (Fig.32d).	  
	   	  
Figure	  31.	  Experimental	  details	  of	  WDR5-­‐inducible	  loss-­‐of-­‐function	  models	  	  
(a)	  MDA-­‐PATX53	  cells	  carrying	  Tet-­‐ON	  inducible	  WDR5	  shRNAs	  (Sh1	  hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  NT)	  were	  sorted	  by	  RFP	  
expression,	  RFP-­‐	  gate	  highlights	  the	  uninfected	  population,	  RFP+	  gate	  highlights	  the	  top	  20%	  RFP-­‐positive	  cells;	  (b)	  MDA-­‐PATX66	  cells	  
carrying	  Tet-­‐ON	  inducible	  WDR5	  shRNAs	  (Sh1	  hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  NT)	  were	  sorted	  by	  RFP	  expression,	  RFP-­‐	  gate	  
highlights	  the	  uninfected	  population,	  RFP+	  gate	  highlights	  the	  top	  20%	  RFP-­‐positive	  cells;	  (c)	  Western	  blot	  for	  MDA-­‐PATX53	  and	  MDA-­‐
PATX66	  cells	  carrying	  Tet-­‐ON	  inducible	  WDR5	  shRNAs	  (Sh1	  hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  NT)	  cultured	  for	  48h	  in	  presence	  
(+DOX)	  or	  absence	  (-­‐DOX)	  of	  doxycycline,	  Protein	  expression	  of	  WDR5	  and	  HSP90.	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Figure	  32.	  WDR5	  is	  essential	  for	  in	  
vitro	   and	   in	   vivo	   PDAC	  
maintenance	  	  
(a)	   Colony	   formation	   assay	   for	   sorted	  
MDA-­‐PATX53	   (left	   panel)	   and	   MDA-­‐
PATX66	   (right	   panel)	   cells	   carrying	   Tet-­‐
ON	   inducible	   WDR5	   shRNAs	   (Sh1	  
hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  
NT)	   cultured	   for	   10	   days	   in	   presence	  
(+DOX)	   or	   absence	   (-­‐DOX)	   of	  
doxycycline;	   (b)	   Tumor-­‐growth	   curve	  
(tumor	   size,	  mm3)	  of	  MDA-­‐PATX53	   (left	  
panel)	   and	   MDA-­‐PATX66	   (right	   panel)	  
cells	   carrying	   Tet-­‐ON	   inducible	   WDR5	  
shRNAs	   (Sh1	  hWDR5i	  and	  Sh2	  hWDR5i)	  
or	   control	   (shNT).	   Size	   measurements	  
performed	   in	   absence	   of	   doxycycline	  
every	   5	   days;	   (c)	   Tumor-­‐growth	   curve	  
(tumor	   size,	   mm3)	   of	   xenograft-­‐derived	  
MDA-­‐PATX53	   (left	   panel)	   and	   MDA-­‐
PATX66	   (right	   panel)	   cells	   carrying	   Tet-­‐
ON	   inducible	   WDR5	   shRNAs	   (Sh1	  
hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  
NT)	  (n=5,	  p<	  0.03).	  Mice	  were	  subjected	  
to	   doxycycline-­‐containing	   drinking	  
water	   regimen	   from	   day	   20	   (MDA-­‐
PATX53)	   or	   day	   55	   (MDA-­‐PATX66);	   (d)	  
Immunohistochemistry	   staining	  
(Hematoxylin	   and	   Eosin,	   Wdr5,	   Ki67,	  
10x)	   of	   sections	   collected	   from	   tumors	  
generated	   transplanting	   MDA-­‐PATX53	  
cells	   carrying	   Tet-­‐ON	   inducible	   WDR5	  
shRNA	  (Sh1	  hWDR5i)	  or	  control	  (sh	  NT).	  
Mice	   were	   sacrified	   72	   hours	   after	  
doxycycline	   supplementation	   in	   the	  
drinking	  water.	  	  
Figure	  32.	  WDR5	  is	  essential	  for	  in	  
vitro	   and	   in	   vivo	   PDAC	  
maintenance	  	  
(a)	   Colony	   formation	   assay	   for	   sorted	  
MDA-­‐PATX53	   (left	   panel)	   and	   MDA-­‐
PATX66	   (right	   panel)	   cells	   carrying	   Tet-­‐
ON	   inducible	   WDR5	   shRNAs	   (Sh1	  
hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  
NT)	   cultured	   for	   10	   days	   in	   presence	  
(+DOX)	   or	   absence	   (-­‐DOX)	   of	  
doxycycline;	   (b)	   Tumor-­‐growth	   curve	  
(tumor	   size,	  mm3)	  of	  MDA-­‐PATX53	   (left	  
panel)	   and	   MDA-­‐PATX66	   (right	   panel)	  
cells	   carrying	   Tet-­‐ON	   inducible	   WDR5	  
shRNAs	   (Sh1	  hWDR5i	  and	  Sh2	  hWDR5i)	  
or	   control	   (shNT).	   Size	   measurements	  
performed	   in	   absence	   of	   doxycycline	  
every	   5	   days;	   (c)	   Tumor-­‐growth	   curve	  
(tumor	   size,	   mm3)	   of	   xenograft-­‐derived	  
MDA-­‐PATX53	   (left	   panel)	   and	   MDA-­‐
PATX66	   (right	   panel)	   cells	   carrying	   Tet-­‐
ON	   inducible	   WDR5	   shRNAs	   (Sh1	  
hWDR5i	  and	  Sh2	  hWDR5i)	  or	  control	  (sh	  
NT)	  (n=5,	  p<	  0.03).	  Mice	  were	  subjected	  
to	   doxycycline-­‐containing	   drinking	  
water	   regimen	   from	   day	   20	   (MDA-­‐
PATX53)	   or	   day	   55	   (MDA-­‐PATX66);	   (d)	  
Immunohistochemistry	   staining	  
(Hematoxylin	   and	   Eosin,	   Wdr5,	   Ki67,	  
10x)	   of	   sections	   collected	   from	   tumors	  
generated	   transplanting	   MDA-­‐PATX53	  
cells	   carrying	   Tet-­‐ON	   inducible	   WDR5	  
shRNA	  (Sh1	  hWDR5i)	  or	  control	  (sh	  NT).	  
Mice	   were	   sacrified	   72	   hours	   after	  
doxycycline	   supplementation	   in	   the	  
drinking	  water.	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To	   demonstrate	   the	   role	   exerted	   by	   Wdr5	   in	   autochthonous	   pancreatic	   cancer,	   we	  
developed	   a	   Lentiviral	   based-­‐Somatic-­‐Mosaic	   system	   (pLSM5)	   allowing	   for	   tissue	   specific,	  
time	   restricted	   activation	   of	   a	   latent	   shRNA	   in	   a	   transplantation	   syngeneic	  GEM	  model	   of	  
PDAC.	  The	  system	  was	  designed	  to	  be	  modular,	  where,	  by	  combining	  in	  one	  vector	  the	  Cre-­‐
LoxP	   and	   Flpo-­‐Frt	   technologies,	   we	   were	   able	   to	   generate	   PDAC	   carrying	   a	   latent	   shRNA	  
allowing	  for	  the	  time	  restricted	  acute	  inactivation	  of	  a	  gene	  of	  interest	  in	  full	  blown	  tumors	  




Specifically,	   early	   epithelial	   progenitors	   cultures	   were	   established	   from	   KRasG12DLSL/+;	  
Trp53LoxP/LoxP;	   R26Cag-­‐FlpoERT2/+	   embryonic	   livers	   and	  expanded	  ex-­‐vivo.	   Cells	  were	   transduced	  
with	  the	  pLSM5	  system	  (where	  a	  Frt-­‐stop-­‐Frt	  cassette	  containing	  the	  Cre	  recombinase	  under	  
Figure	  33.	  Lentiviral-­‐based	  PDAC	  somatic	  model	  	  
(a)	  PDAC	  somatic	  mouse	  model	  experimental	  scheme	  (E13	  =	  Embryonic	  Day	  13);	  Specifically,	  early	  epithelial	  progenitors	  
cultures	   were	   established	   from	   KRasG12DLSL/+;	   Trp53LoxP/LoxP;	   R26Cag-­‐FlpoERT2/+	   embryonic	   livers	   and	   expanded	   ex-­‐vivo.	   Cells	  
were	   transduced	   with	   the	   pLSM5	   system	   and	   transplanted	   orthotopically	   in	   immunocompromised	   Rag2-­‐/-­‐	   mice	  
pretreated	  with	  caerulein;	  (b)	  Design	  of	  the	  lentiviral	  pLSM5	  vector	  applied	  for	  driving	  epithelial	  progenitors	  reprograming	  
(Krt19	  =	  Cytokeratin	  19	  promoter,	  Frt	  =	  Flp-­‐Frt	  recombination	  sites,	  NlsCre	  =	  Cre	  gene);	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the	  Krt19	  promoter	  was	  cloned	  between	  the	  U6	  promoter	  and	  the	  shRNA)	  and	  transplanted	  
orthotopically	  in	  immune-­‐compromised	  Rag2-­‐/-­‐	  mice	  pretreated	  with	  caerulein	  (Fig.33b).	  	  
Transplants-­‐derived	  tumors	  expressed	  the	  epithelial	  markers	  19	  and	  Sox9	  and	  the	  pancreatic	  
specific	   marker	   Pdx1	   suggesting	   that	   embryonic	   endodermal	   progenitors	   display	   a	  
remarkable	  plasticity	  and	  are	  able	  to	  originate	  bona	  fide	  pancreatic	  tumors	  (Fig.34a).	  
Figure	  34.	  Validation	  of	  the	  lentiviral-­‐based	  PDAC	  
somatic	  model	  	  
(a)	   Immunohistochemistry	   staining	   (Hematoxylin	   and	  
Eosin,	   Cytokeratin	   19,	   PDX1,	   Sox9,	   20x)	   for	   tumors	  
harvested	   from	   somatic	   models	   in	   the	   KRasG12DLSL/+;	  
Trp53L/L;	  R26Cag-­‐FlpoERT2/+	  background	  infected	  with	  pLSM5-­‐
K19	  (no	  shRNA);	  (b)	  Overall	  survival	  for	  somatic	  models	  in	  
the	  KRasG12DLSL/+;	  Trp53+/+;	   	  R26Cag-­‐FlpoERT2/+	  and	  KRasG12DLSL/+;	  
Trp53L/L;	  R26Cag-­‐FlpoERT2/+	  backgrounds	  infected	  with	  pLSM5-­‐
K19	   (no	   shRNA);	   (c)	   Immunohistochemistry	   staining	  
(Hematoxylin	   and	   Eosin,	   10x,	   GFP,	   20x)	   of	   sections	  
collected	   from	   normal	   pancreas	   of	   recipent	   mice	  
transplanted	   with	   Rosa26mTmG/+	   epithelial	   progenitors	  
(arrowheads	   highlight	   GFP	   postive	   acinar	   cells);	   (d)	  
Immunofluorescence	   staining	   (Amylase,	   GFP,	   DAPI,	  
Merge,	   20x)	   of	   sections	   collected	   from	   normal	   pancreas	  
of	  recipent	  mice	  transplanted	  with	  Rosa26mTmG/+	  epithelial	  
progenitors.	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Survival	   curves	   showed	   100%	   penetrance	   and	   a	   latency	   around	   40	   days	   for	   KRasG12DLSL/+;	  
Trp53LoxP/LoxP;	   R26Cag-­‐FlpoERT2/+	   mice,	   incomplete	   penetrance	   and	   prolonged	   survival	   was	  
instead	   detected	   for	   KRasG12DLSL/+;	   R26Cag-­‐FlpoERT2/+	   mice	   (Fig.34b).	   The	   mT/mG	   is	   a	   double-­‐
fluorescent	  Cre	  reporter	  mouse	  that	  expresses	  Tomato	  reporter	  (mT)	  prior	  to	  Cre-­‐mediated	  




Figure	  35.	  WDR5	  knock-­‐down	  arrests	  tumor	  growth	  of	  the	  lentiviral-­‐based	  PDAC	  somatic	  model	  	  
(a)	  Magnetic	   Resonance	   Imaging	   (RMI)	   for	   representative	  mice	   of	   the	   KRasG12DLSL/+;	   Trp53L/L	   background	   infected	  with	   pLSM5-­‐K19-­‐
shWDR5	   and	   treated	   for	   1	   week	   with	   4-­‐OHT	   (n=7)	   or	   Veh	   (n=9);	   (b)	  Weight	   of	   the	   tumors	   harvested	   from	   KRasG12DLSL/+;	   Trp53L/L	  
background	   mice	   infected	   with	   pLSM5-­‐K19-­‐shWDR5	   and	   treated	   for	   1	   week	   with	   4-­‐OHT	   (n=7)	   or	   Veh	   (n=9)	   (p<0.005);	   (c)	  
Immunohistochemistry	   staining	   (WDR5,	   Ki67,	   20x)	   for	   tumors	   harvested	   from	   the	   lentiviral-­‐based	   somatic	   PDAC	   models	   in	  
KRasG12DLSL/+;	  Trp53L/L	  background	  infected	  with	  pLSM5-­‐K19-­‐shWDR5	  and	  treated	  for	  1	  week	  with	  4-­‐OHT	  or	  vehicle	  (Veh).	  
	  	  	   74	  
Transplanting	  epithelial	  progenitors	  from	  Rosa26mTmG/+	  mice,	  upon	  infection	  with	  the	  pLSM5-­‐
K19	   lentiviral	   vector,	   we	   observed	   no	   tumor	   formation	   and	   differentiation	   in	   pancreatic	  
acini,	   as	   demonstrated	   by	   double	   positivity	   for	   GFP	   and	   Amylase	   of	   pancreatic	   sections	  
(Fig.34c,d).	  Mice	  were	  monitored	  for	  tumor	  formation	  by	  MRI	  imaging	  weekly.	  The	  FlpoERT2	  
was	   activated	   by	   repeated	   tamoxifen	   treatments	   to	   remove	   the	   stopper	   cassette	   and	  
activate	   the	   shRNA	   in	   advanced	   pancreatic	   tumors.	   In	   line	  with	   our	   previous	   findings,	   the	  
acute	   inactivation	   of	   Wdr5	   in	   vivo	   resulted	   in	   a	   delayed	   growth	   and	   in	   smaller	   lesions	  
(Fig.35a,b)	  characterized	  by	  a	  decrease	  in	  the	  numbers	  of	  Ki67	  positive	  cells	  (Fig.35c).	  These	  
data	  confirm	  a	  role	  for	  WDR5	  as	  a	  critical	  tumor	  dependency	  in	  human	  PDAC.	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5.	  WDR5	  complex	  protects	  PDAC	  cells	  from	  DNA	  damage	  and	  aneuploidy	  
stabilizing	  the	  DNA	  replication	  forks	  	  	  	  
The	  power	  of	  our	  approach	  was	  further	  demonstrated	  by	  the	  fact	  that	  we	  identified	  multiple	  
members	  of	  the	  COMPASS	  complex	  (ASH2L,	  MEN1,	  MLL1,	  MLL2)	  as	  "hits"	  in	  both	  the	  human	  
and	  mouse	  PDAC	  screens	  (Fig.36a).	  	  
	  
Figure	   36.	   COMPASS	   complex	  
dependencies	   and	   expression	   in	  
pancreatic	  cancer	  
(a)	  String	  of	  beads	  highlighted	  the	  behavior	  of	  
the	   COMPASS	   complex	   members	   in	   the	  
epigenetic	  screens	  of	  xenograft-­‐derived	  MDA-­‐
PATX53	  and	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  cells	  
(Each	   bead	   represents	   a	   gene	   in	   the	   Epi	  
library,	  mean	   Z-­‐score	   of	   3	   in	   vivo	   replicates);	  
(b)	   Immunohistochemistry	   staining	   (WDR5,	  
RBBP5,	   ASH2L,	   H3K4me3,	   20x)	   of	   sections	  
collected	   from	   secondary	   PDAC	   xenografts	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COMPASS	   and	   COMPASS-­‐like	   complexes	   are	   characterized	   by	   their	   unique	   subunit	  
composition,	   and	   individual	   subunits	   appear	   to	   dictate	   the	   biological	   functions	   of	   each	  
complex44,47,48.	  For	  example,	  even	  though	  both	  MLL1	  and	  MLL2	  are	  recruited	  to	  the	  Hox	  loci	  
through	  MEN1-­‐specific	  interactions,	  they	  also	  have	  non-­‐redundant	  functions	  as	  exemplified	  
by	   the	  MLL1	   and	  MLL2	   knock-­‐out	  mouse	  models.212	   Similarly,	  MLL3	   and	  MLL4	  may	   share	  
redundant	   functions	   in	   regulating	   the	   Hox	   genes,	   but	   they	   also	   interact	   with	   subunits	  
important	  for	  targeting	  nuclear	  receptors,	  such	  as	  PTIP48.	  In	  line	  with	  these	  data,	  MLL1	  and	  
MLL2	  seem	  to	  drive	  context-­‐specific	  essential	  functions	  also	  in	  PDAC,	  as	  shown	  by	  the	  non-­‐
overlapping	  results	  of	  our	  screens	  (Fig.36a).	  	  
	  
	  
Figure	   37.	   Additional	   COMPASS	   complex	   subunits	  
are	  required	  for	  PDAC	  cells	  proliferation	  
(a)	  Western	  blot	  for	  PDX-­‐derived	  MDA-­‐PATX53	  cells	  infected	  
with	  2	   independent	  shRNAs	  against	  WDR5	  (Sh1	  hWDR5	  and	  
Sh2	  hWDR5)	  or	  control	  (Sh	  NT),	  Protein	  expression	  of	  WDR5,	  
RBBP5,	   ASH2L	   and	   HSP90;	   (b)	   Protein	   expression	   of	   RBBP5	  
and	   ASH2L	   by	  WB	   for	   xenograft-­‐derived	  MDA-­‐PATX53	   (Left	  
panel)	  and	  MDA-­‐PATX66	  (right	  panel)	  cells	  expressing	  shRNA	  
targeting	   RBBP5	   (sh1	   hRBBP5,	   sh2	   hRBBP5),	   ASH2L	   (sh1	  
hASH2L,	   sh2	   hASH2L)	   and	   control	   (sh_NT);	   (c)	   Colony	  
formation	   assay	   (CFA)	   for	   xenograft-­‐derived	   MDA-­‐PATX66	  
and	   MDA-­‐PATX53	   cells	   expressing	   shRNA	   targeting	   RBBP5	  
(sh1	  hRBBP5,	  sh2	  hRBBP5),	  ASH2L	  (sh1	  hASH2L,	  sh2	  hASH2L),	  
MLL	  (sh1hMLL,	  sh2	  hMLL)	  and	  control	  (sh_NT).	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The	  WDR5-­‐RBBP5-­‐ASH2L	  (WAR)	  core	  showed	  high	  protein	  expression	  level	   in	  human	  PDAC	  
xenografts	   (Fig.36b).	   The	   functional	   non-­‐redundant	   role	   of	   WAR	   complex	   in	   PDAC	   was	  
proven	  by	  the	  significant	   impairment	  of	  colony	  formation	  ability	  we	  observed	  when	  ASH2L	  




Figure	  38.	  H3K4me3	  ChIP-­‐seq	  experiments	  in	  human	  and	  mouse	  PDAC	  models	  upon	  WDR5	  knock-­‐down	  	  
(a)	  Mapping	  of	   tri-­‐methylation	  profiles	  with	  human	  or	  mouse	   genomes	   (Genome	  Browser,	  UCSC)	   in	   relation	   to	   the	  distance	   from	   the	  
transcription	   start	   sites	   (TSSs)	   in	   MDA-­‐PATX53,	   MDA-­‐PATX66	   and	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L	   upon	   WDR5	   knock-­‐down	   with	   2	  
independent	  shRNAs	  or	  control	   (sh	  NT);	  (b)	  Venn	  diagrams	  highlighted	  the	  H3K4me3	  common	  peaks	  associated	  to	  the	  TSSs	  between	  2	  
independent	  WDR5	  shRNAs	  in	  MDA-­‐PATX53,	  MDA-­‐PATX66	  and	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  cells;	  (c)	  Table	  for	  number	  of	  H3K4me3	  peaks	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The	  methyltransferase	   subunit	   of	   the	   COMPASS	   complex	   is	   catalyzing	   the	   methylation	   of	  
lysine	   4	   on	   histone	   H3,	   a	   validated	   marker	   of	   open-­‐chromatin	   conformation	   and	   active	  
transcription44,213.	  Knock-­‐down	  of	  WDR5	  in	  both	  human	  and	  mouse	  PDAC	  cell	  lines	  induced	  a	  
modest	  overall	   reduction	   in	  global	  methylation	   levels	  as	  confirmed	  by	  anti-­‐H3K4me3	  ChIP-­‐
Seq	  experiments	   (Fig.38a).	  Mapping	  of	   tri-­‐methylation	  profiles	  with	   functional	  elements	  of	  
the	   genome	   confirmed	   that	   only	   a	   small	   fraction	   (4-­‐20%)	   of	   the	   significantly	   altered	  
methylation	   regions	  were	   in	  proximity	   (‹1kb)	  of	   transcriptional	   start	   sites	   (TSSs)	  and	   these	  
peaks	  were	  statistically	  significant	  (Fig.38b,c).	  	  
In	   addition,	   the	   WAR	   tripartite	   complex	   has	   been	   reported	   to	   execute	   additional	   H3K4	  
methylation-­‐independent	  functions,	  as	  the	  enhancement	  of	  the	  transcriptional	  activation	  of	  
nuclear	  hormone	   receptor-­‐responsive	   genes214.	  We	  next	  performed	  RNA-­‐Seq	   to	   inform	  on	  
transcriptional	   changes	   conferred	  upon	  WDR5	  knock-­‐down	  with	  2	   independent	   shRNAs.	  A	  
consistent	  number	  of	  genes	  displayed	  modification	  in	  mRNA	  expression	  level	  with	  both	  the	  
shRNAs	   for	   WDR5	   (1%	   FDR,	   1.5	   FC)	   and	   crossing	   results	   from	   human	   and	   mouse	   PDAC	  
models	   we	   robustly	   identified	   a	   common	   set	   of	   genes	   affected	   by	   WDR5	   silencing	   in	  
pancreatic	   cancer	   (Fig.39a,b).	   Remarkably,	   genes	   for	   which	   a	   reduction	   in	   the	   level	   of	  
H3K4me3	  was	  detected	  in	  the	  promoter	  regions	  showed	  a	  significant	  association	  with	  down-­‐
regulation	  at	  the	  transcription	  level	  upon	  WDR5	  knock-­‐down,	  in	  accordance	  with	  the	  role	  of	  
the	   COMPASS	   complex	   as	   activator	   of	   transcription	   (data	   not	   shown).	   However,	   gene	   set	  
enrichment	   analysis	   (GSEA)	   identified	   up-­‐regulated	   genes	   involved	   in	   the	   control	   of	   DNA	  
replication	   and	   progression	   through	   the	   different	   phases	   of	   the	   cell	   cycle	   in	   all	   the	   PDAC	  
models	   (Fig.39c,d).	   The	   increase	   in	   transcriptional	   levels	   of	   genes	   essential	   for	   supporting	  
replicative	  mechanisms	   and	   cell	   proliferation	   could	   be	   explained	   as	   compensatory	   events	  
carried	  out	  by	  the	  PDAC	  cells	  to	  counteract	  the	  WDR5	  loss	  of	  function.	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Figure	  39.	  RNA-­‐Seq	  experiments	  in	  human	  and	  mouse	  PDAC	  models	  upon	  WDR5	  knock-­‐down	  	  
(a)	  Number	  of	  genes	  differentially	  expressed	  (Up-­‐	  or	  Down-­‐regulated)	  in	  MDA-­‐PATX53,	  MDA-­‐PATX66	  and	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  	  
(KP53)	  cells	  comparing	  2	  independent	  WDR5	  shRNAs	  (sh1	  and	  sh2)	  with	  control	  (Sh	  NT)	  (FDR	  =	  False	  Discovery	  Rate,	  FC	  =	  Fold-­‐Change);	  
(b)	   Venn	   diagram	   of	   the	   genes	   differentially	   expressed	   in	   human	   (MDA-­‐PATX53,	   MDA-­‐PATX66)	   and	   mouse	   (p48-­‐Cre,	   KrasG12D_LSL/+,	  
p53L/L)	   PDAC	   models	   upon	  WDR5	   knockdown	   (RNA-­‐Seq	   replicates,	   FC>1.5,	   FDR	   1%);	   (c)	   Gene	   Set	   Enrichment	   Analysis	   (GSEA)	   for	  
pathways	   significantly	   enriched	   and	   in	   common	   between	  MDA-­‐PATX53,	  MDA-­‐PATX66	   and	   p48-­‐Cre,	   KrasG12D_LSL/+,	   p53L/L	   	   (KP53)	   cells	  
comparing	  2	  independent	  WDR5	  shRNAs	  (sh1	  and	  sh2)	  with	  control	  (Sh	  NT),	   (d)	  Table	  for	  NES,	  p-­‐value	  and	  false	  discovery	  rate	  (FDR)	  
associated	  with	  significantly	  enriched	  pathways	  in	  MDA-­‐PATX53,	  MDA-­‐PATX66	  and	  p48-­‐Cre,	  KrasG12D_LSL/+,	  p53L/L	  	  (KP53)	  cells	  comparing	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PATX53*
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MDA:
PATX66*
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P48:Cre,$
KP53*
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REACTOME_G1_S_TRANSITION* 1.66* 0.001* 0.124*
REACTOME_LAGGING_STRAND_SYNTHESIS* 1.65* 0.009* 0.104*
PATX66* NES$ p:value$ FDR$
REACTOME_MITOTIC_G1_G1_S_PHASES* 1.98* 0* 0.001*
REACTOME_G1_S_TRANSITION* 2.01* 0* 0.001*
REACTOME_LAGGING_STRAND_SYNTHESIS* 1.41* 0.091* 0.183*
PATX53* NES$ p:value$ FDR$
REACTOME_MITOTIC_G1_G1_S_PHASES* 2.15* 0* 0*
REACTOME_G1_S_TRANSITION* 2.21* 0* 0*
REACTOME_LAGGING_STRAND_SYNTHESIS* 1.76* 0.006* 0.025*
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Figure	   40.	   WDR5	   protects	   PDAC	   cells	  
from	   replicative	   defects	   and	  
aneuploidy	  	  
(a)	   DNA	   content	   analysis	   (DAPI)	   by	   flow	  
cytometry	   for	   PDX-­‐derived	   MDA-­‐PATX53	  
cells	   with	   2	   independent	   shRNA	   targeting	  
WDR5	   or	   shNT	   (72	   and	   120	   hrs	   after	  
selection);	  (b)	  DNA	  content	  analysis	  (DAPI)	  by	  
flow	   cytometry	   for	   PDX-­‐derived	   MDA-­‐
PATX66	   cells	   with	   2	   independent	   shRNA	  
targeting	   WDR5	   or	   shNT	   (72	   and	   120	   hrs	  
after	   selection);	   (c)	   Flow	   cytometry	   analysis	  
of	   BrdU	  uptake	   (2h	  pulse)	   and	  DNA	   content	  
in	   MDA-­‐PATX53	   cells	   infected	   with	   2	  
independent	   shRNA	   targeting	   WDR5	   (Sh1	  
hWDR5	  and	  Sh2	  hWDR5)	  or	  sh	  NT	  (72	  or	  120	  
hrs	   after	   infection),	   Gates	   highlight	   the	  
different	   phases	   of	   the	   cell-­‐cycle	   (Sub-­‐G1,	  
G0/G1,	  S,	  G2/M)	  and	  cells	  with	  extra	  amount	  
of	   DNA	   content	   (>4n	   Brd+,	   >4n	   Brd-­‐);	   (d)	  
Flow	   cytometry	   analysis	   of	   BrdU	   uptake	   (2h	  
pulse)	  and	  DNA	  content	  in	  MDA-­‐PATX66	  cells	  
infected	  with	  2	  independent	  shRNA	  targeting	  
WDR5	   (Sh1	   hWDR5	   and	   Sh2	   hWDR5)	   or	   sh	  
NT	   (72	   or	   120	   hrs	   after	   infection),	   Gates	  
highlight	   the	   different	   phases	   of	   the	   cell-­‐
cycle	   (Sub-­‐G1,	   G0/G1,	   S,	   G2/M)	   and	   cells	  
with	   extra	   amount	   of	   DNA	   content	   (>4n	  













































































































Figure	   40.	   WDR5	   protects	   PDAC	   cells	  
from	   replicative	   defects	   and	  
aneuploidy	  	  
(a)	   DNA	   content	   analysis	   (DAPI)	   by	   flow	  
cytometry	   for	   PDX-­‐derived	   MDA-­‐PATX53	  
cells	   wi h	   2	   independent	   shRNA	   targeting	  
WDR5	   or	   shNT	   (72	   and	   120	   hrs	   after	  
selection);	  (b)	  DNA	  content	  analysis	  (DAPI)	  by	  
flow	   cytometry	   for	   PDX-­‐derived	   MDA-­‐
PATX66	   cells	   with	   2	   independent	   shRNA	  
targeting	   WDR5	   or	   shNT	   (72	   and	   120	   hrs	  
after	   selection);	   (c)	   Flow	   cytometry	   analysis	  
of	   BrdU	  uptake	   (2h	  pulse)	   and	  DNA	   content	  
in	   MDA-­‐PATX53	   cells	   infected	   with	   2	  
independent	   shRNA	   targeting	   WDR5	   (Sh1	  
hWDR5	  and	  Sh2	  hWDR5)	  or	  sh	  NT	  (72	  or	  120	  
hrs	   after	   infection),	   Gates	   highlight	   the	  
different	   phases	   of	   the	   cell-­‐cycle	   (Sub-­‐G1,	  
G0/G1,	  S,	  G2/M)	  and	  cells	  with	  extra	  amount	  
of	   DNA	   content	   (>4n	   Brd+,	   >4n	   Brd-­‐);	   (d)	  
Flow	   cytometry	   analysis	   of	   BrdU	   uptake	   (2h	  
pulse)	  and	  DNA	  content	  in	  MDA-­‐PATX66	  cells	  
infected	  with	  2	  independent	  shRNA	  targeting	  
WDR5	   (Sh1	   hWDR5	   and	   Sh2	   hWDR5)	   or	   sh	  
NT	   (72	   or	   120	   hrs	   after	   infection),	   Gates	  
highlight	   the	   different	   phases	   of	   the	   cell-­‐
cycle	   (Sub-­‐G1,	   G0/G1,	   S,	   G2/M)	   and	   cells	  
with	   extra	   amount	   of	   DNA	   content	   (>4n	  
Brd+,	  >4n	  Brd-­‐).	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To	  further	  inform	  on	  a	  functional	  role	  of	  the	  WAR	  complex	  in	  regulating	  DNA	  replication	  we	  
performed	  BrdU-­‐labeling	  studies	  in	  PDAC	  cells.	  Consistent	  with	  the	  observed	  transcriptional	  
changes,	   knock-­‐down	   of	   WDR5	   resulted	   in	   reduction	   of	   BrdU	   incorporation,	   with	   a	  
paradoxical	   increase	   in	   overall	   DNA	   content	   suggesting	   failure	   to	   sustain	   DNA	   replication	  
checkpoint	  or	  mitotic	  defects	  (Fig.40a-­‐d).	  First	  of	  all,	  we	  designed	  a	  single	  guide	  RNA	  (sgRNA)	  
guide	  specific	  for	  targeting	  WDR5	  with	  the	  CRISPR/CAS9	  lentiviral	  system	  to	  interrogate	  the	  
origin	  of	  the	  aneuploidy	  as	  a	  consequence	  of	  WDR5	  silencing	  (Fig.41a).	  	  
	  
This	  approach	  gave	  us	   the	  possibility	   to	   investigate	  early	  events	  and	   the	   first	  mitosis	  upon	  
WDR5	  withdrawal.	  PDAC	  cells	  infected	  with	  the	  CRISPR/CAS9	  construct	  for	  WDR5	  displayed	  
a	  significant	  increase	  in	  defective	  mitosis	  (multipolar	  mitotic	  spindles)	  and	  cytokinesis,	  as	  we	  















































Figure	  41.	  WDR5	   loss-­‐of-­‐function	  
drives	   accumulation	   of	   mitotic	  
defects	  in	  PDAC	  cells	  
(a)	  Western	  blot	  for	  MDA-­‐PATX53	  cells	  
infected	  with	   2	   different	   CRISPR/CAS9	  
construct	   for	  WDR5	  /hWDR5	  CRISPR1,	  
hWDR5	   CRISPR2).	   Protein	   lysates	  
collected	   from	   MDA-­‐PATX53	   cells	  
infected	   with	   WDR5	   shRNA	   (Sh1	  
WDR5)	  or	  non-­‐targeting	  shRNA	  (Sh	  NT)	  
were	   respectively	   loaded	   as	   positive	  
and	   negative	   control.	   Protein	  
expression	   of	   WDR5	   and	   β-­‐Actin;	   (b)	  
Percentage	   of	   MDA-­‐PATX53	   cells	  
displaying	   mitotic	   defects	   upon	  
infection	   with	   WDR5	   CRISPR/CAS9	  
construct	   (hWDR5	  CRISPR1)	  or	  control	  
(Sh	  NT).	  100	  mitosis	  were	  counted	  per	  
each	  condition	  24	  hours	  after	  infection	  
(p<0.03);	  (c)	   Immunofluoresce	  staining	  
(α-­‐Tubulin,	   ACA,	   DAPI,	   20x)	   for	   MDA-­‐
PATX53	   infected	   with	   WDR5	  
CRISPR/CAS9	   construct	   (hWDR5	  
CRISPR1)	  or	  control	  (Sh	  NT).	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High	   sensitivity	   of	   tumor	   cells	   to	   S-­‐phase	   defects	   was	   associated	   with	   an	   increase	   in	   the	  
number	   of	   active	   replication	   forks	   and	   concomitant	   frequent	   alterations	   in	   arresting	   G1	  
checkpoints215.	   In	   line	   with	   these	   data,	   PDAC	   cells	   with	   defects	   in	   G1-­‐checkpoint	   showed	  
accumulation	   of	   replicative	   damage	   when	   treated	   with	   a	   specific	   ATR	   inhibitor	   (VE-­‐821)	  
(Fig.42a,b).	  The	  accumulation	  of	  deregulated	  genetic	  materials	  observed	   in	  PDAC	  cells	  was	  
associated	  with	  the	  induction	  of	  DNA	  damage	  (phospho-­‐H2AX	  staining)	  upon	  WDR5	  silencing	  
that	   accompanied	   the	   deregulated	   DNA	   replication	   events	   (Fig.36d).	   The	   excessive	   DNA	  
content	   and	   the	   accumulation	   of	   phospho-­‐H2AX	  were	   not	   detected	   in	   the	  wild-­‐type	  MEF	  
upon	  WDR5	  knock-­‐down	  or	  ATR	  inhibition	  (Fig.42c,d	  and	  data	  not	  shown).	  
These	  findings	  indicated	  a	  critical	  role	  for	  WDR5	  in	  sustaining	  the	  proper	  execution	  of	  DNA	  
replication	   in	  PDAC	  cells	  The	  assembly	  of	  a	  proficient	  and	  active	  replication	  machinery	   is	  a	  
multistep	   process	   strictly	   regulated	   during	   G1-­‐	   and	   S-­‐phases	   of	   the	   cell	   cycle	   through	   the	  
involvement	   of	   CDKs	   and	   CDK	   inhibitors	   (CDKIs)213.	   The	   licensing	   of	   the	   replication	   origins	  
happens	   in	  G1	  with	  the	  assembly	  of	  the	  pre-­‐replication	  complex	  (pre-­‐RC),	  characterized	  by	  
ORC1-­‐6,	  MCM2-­‐7,	  CDC6	  and	  CDT1.	  Signals	  promoting	  the	  entering	  into	  the	  S-­‐phase	  start	  the	  
firing	   of	   the	   replication	   origins	   and	   the	   formation	   of	   the	   pre-­‐initiation	   complex	   (pre-­‐IC).	  
Features	  of	  this	  critical	  step	  are	  the	  disassociation	  from	  the	  pre-­‐replication	  complex	  of	  CDC6	  
and	  CDT1,	  upon	  phosphorylation,	  and	  the	  recruitment	  of	  CDC45	  and	  GNIS	  at	  the	  replication	  
forks216,217.	  
In	  this	  direction,	  the	  subcellular	  protein	  fractionation	  of	  PDAC	  cells	  upon	  WDR5	  knock-­‐down	  
demonstrated	  a	  significant	  reduction	  of	  CDC45	  recruitment	  on	  the	  chromatin,	   in	   front	  of	  a	  
CDT1	   accumulation	   (Fig.43a).	   Displacement	   of	   CDC45	   from	   the	   pre-­‐initiation	   complex	  
suggested	  that	  the	  origin	  of	  the	  DNA	  damage	  we	  observed	  in	  PDAC	  cells	  could	  be	  related	  to	  
a	  prolonged	  stalling	  and	  further	  collapse	  of	  the	  replications	  forks.	  
	  





Figure	  42.	  PDAC	  cells	  are	  sensitive	  to	  replicative	  defects	  and	  accumulate	  DNA	  damage	  upon	  WDR5	  knock-­‐down	  
(a)	  DNA	  content	  analysis	  (DAPI)	  by	  flow	  cytometry	  for	  PDX-­‐derived	  MDA-­‐PATX53	  cells	  treated	  with	  ATR	  inhibitor	  VE-­‐821	  (0.5	  μM	  and	  
1	  μM)	  or	  vehicle	  (96	  hrs,	  left	  panel),	  DNA	  content	  analysis	  (DAPI)	  by	  flow	  cytometry	  for	  wild-­‐type	  mouse	  embryo	  fibroblast	  (MEF)	  cells	  
treated	  with	  ATR	  inhibitor	  VE-­‐821	  (0.5	  μM	  and	  1	  μM)	  or	  vehicle	  (96	  hrs,	  right	  panel);	   (b)	  Western	  blot	  for	  MDA-­‐PATX53	  cells	  treated	  
for	  72	  hours	  with	  2	  different	  concentrations	  (0.5	  μM	  and	  1	  μM)	  of	  the	  ATR	  inhibitor	  VE-­‐821	  or	  vehicle,	  protein	  expression	  of	  phospho-­‐
Chk1	   (Ser345),	  phospho-­‐Chk2	   (Thr68),	  phospho	  H2AX	   (γH2AX)	  and	  Vinculin;	   (c)	  DNA	  content	  analysis	   (DAPI)	  by	   flow	  cytometry	   for	  
wild-­‐type	  mouse	  embryo	  fibroblast	  (MEF)	  cells	  infected	  with	  2	  independent	  shRNA	  targeting	  WDR5	  or	  shNT	  (120	  hrs	  after	  selection);	  
(d)	  Western	  blot	  for	  MDA-­‐PATX53	  cells	  (left	  panel)	  or	  wild-­‐type	  MEF	  (right	  panel)	  expressing	  shRNA	  targeting	  WDR5	  (sh1	  hWdr1)	  and	  
control	   (shNT)	   at	   different	   time-­‐points	   after	   infection	   (48,	   72,	   96,	   120h,	   NI=not	   infected).	   Protein	   expression	   of	   phospho-­‐H2AX	  
(γH2AX),	  WDR5	  and	  HSP90;	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The	   recent	   finding	  of	   a	   direct	   interaction	  between	  WDR5	  and	   c-­‐Myc	   and	   the	   reduction	  of	  
chromatin-­‐bound	   c-­‐Myc	   upon	   WDR5	   silencing	   open	   the	   possibility	   that	   WDR5	   may	   be	  
recruited	   to	   replication	   origins	   to	   sustain	   replication	   stress	   and	   tumorigenicity	   in	   PDAC	  
cells218.	  These	  results	  demonstrated	  a	  critical	  role	  of	  WDR5	  in	  stabilizing	  the	  replication	  forks	  
in	  the	  presence	  of	  replicative	  stress	  (Fig.43b).	  	  	  
	  
	   	  
Figure	  43.	  WDR5	  is	  essential	  to	  stabilize	  replication	  forks	  in	  PDAC	  cells	  
(a)	   Subcellular	   protein	   fractionation	   (Cytoplasmic	   and	   Chromatin-­‐bound	   fractions)	   of	  MDA-­‐PATX53	   cells	   infected	  with	   2	   independent	  
shRNA	  for	  WDR5	  (Sh1	  hWDR5,	  Sh2	  hWDR5)	  or	  control	  (Sh	  NT).	  Protein	  expression	  of	  CDC45,	  c-­‐Myc,	  WDR5,	  CDT1,	  MCM2	  and	  GAPDH;	  (b)	  
Model	  for	  WDR5	  dependency	  of	  PDAC	  cells:	  i)	  Replication	  origin	  licensing	  is	  a	  strictly	  regulated	  process	  in	  normal	  cells	  starting	  only	  upon	  
stimulation	  by	  mitogenic	  signals.	  In	  this	  context,	  WDR5	  partecipates	  in	  the	  assembly	  of	  replication	  machinaries	  potentially	  recruiting	  c-­‐
Myc	   (left	  panel);	   ii)	  Oncogene	  activation	   (as	  KRAS	  mutation	   in	  PDAC)	  and	  G1-­‐checkpoint	  alterations	   (as	   loss	  of	  p53	  and	  p16	   in	  PDAC)	  
induce	  replication	  stress	  characterized	  by	  an	  increase	  in	  the	  origin	  activation	  and	  in	  the	  number	  of	  replication	  forks	  contemporary	  active.	  
Up-­‐regulation	   of	  WDR5	   is	   essential	   to	   stabilize	   them	   (middle	   panel);	   (iii)	  WDR5	   knock-­‐down	   in	   PDAC	   cells	   arrests	   the	   progression	   of	  
activated	  replication	  forks	  (collapsed	  forks)	  driving	  the	  accumulation	  of	  massive	  DNA	  damage	  and	  lethal	  mitotic	  defects.	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Summary	  of	  results	  	  	  
• Adaptation	  of	  the	  pancreatic	  cancer	  PDX	  models	  to	  in	  vivo	  functional	  studies	  
	  
• New	  barcode-­‐based	  TIC	   frequency	  tool	   for	  a	  sample-­‐by-­‐sample	  rapid	  estimation	  of	  
the	  minimum	  required	  coverage	  of	  complex	  libraries	  
	  
• In	  vivo	  loss-­‐of-­‐function	  screens	  in	  human	  PDX	  and	  mouse	  models	  to	  inform	  on	  new	  
epigenetic	  context-­‐dependent	  vulnerabilities	  in	  PDAC	  
	  
• Integration	   of	   the	   top-­‐scoring	   “hits”	   in	   a	   comprehensive	   triage	   pipeline	   for	   target	  
prioritization	  
	  
• Establishment	  of	  a	  new	  somatic	  model	  of	  PDAC	  able	  to	  recapitulate	  the	  progression	  
of	  the	  disease	  
	  
• WDR5	   over-­‐expression	   in	   PDAC	   is	   associated	  with	   cell-­‐cycle	   functions	   essential	   to	  
sustain	  tumor	  proliferation	  and	  maintenance	  	  
	  
• WDR5	  inhibition	  selectively	  promotes	  DNA	  damage	  accumulation	  in	  PDAC	  cells	  with	  
p53	   and	   p16	   alterations	   (G1	   checkpoint-­‐deficiency),	   potentially	   destabilizing	   the	  
DNA	  replication	  forks	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Discussion	  and	  future	  directions	  
	  
Large-­‐scale	   genomics	   efforts	   have	   provided	   the	   opportunity	   to	   access	   a	   comprehensive	  
catalog	  of	  genetic	  alterations	   in	  multiple	  cancers.	  They	  have	  also	  highlighted	  both	  the	  high	  
frequency	   at	   which	   alterations	   are	   detected	   and	   the	   significant	   intra-­‐	   and	   inter-­‐tumor	  
heterogeneity	  of	  the	  diseases.	   It	  has	  also	  become	  apparent	  that	  very	  few	  driver	  mutations	  
are	   emerging	   and	   as	   a	   consequence	  of	   that,	   limited	  opportunities	   exist	   to	   target	  mutated	  
oncogenic	  proteins.	  It	  is	  imperative	  therefore	  to	  develop	  alternative	  approaches	  to	  therapy	  
that	  can	  leverage	  the	  selective	  vulnerabilities	  of	  tumor	  cells	  resulting	  from	  the	  engagement	  
of	  abnormal	  pathway	  connectivity.	  These	  can	  be	  best	  exploited	   in	  vivo,	   in	  a	  context	  that	   is	  
closer	   to	   the	   environment	   tumors	   strive	   in143,149,150.	   To	   identify	   new	   relevant	   actionable	  
dependencies	   we	   have	   developed	   a	   system	   for	   rapid	   identification	   and	   validation	   of	  
potential	  therapeutic	  targets	  in	  PDX	  tumor	  cells.	  By	  optimizing	  primary	  rapid	  tumor	  explant	  
and	  expansion,	  determination	  of	  tumor	  initiating	  cell	  frequency	  through	  retroviral-­‐mediated	  
transduction,	  next	  generation	  sequencing	  and	  bioinformatics,	  we	  have	  been	  able	  to	  identify	  
a	   first	  set	  of	   factors	  that	  are	  dramatically	   impacting	  pancreatic	  cancer	   in	  a	  most	  resistance	  
disease	  context	  (activating	  mutation	  of	  KRAS	  and	  p53/p16	  inactivations).	  	  	  
Biology-­‐applied	   robotics	   and	   small-­‐scale	   optimizations	   had	   started	   the	   so-­‐called	   “high-­‐
throughput	   screening	   era”.	   Despite	   its	   tremendous	   potential,	   the	   very	   high	   percentage	   of	  
gene	   candidates	   failing	   the	   in	   vitro-­‐in	   vivo	   step	   rapidly	   unmasked	   the	   intrinsic	  weak	   spot:	  
non-­‐physiological	  conditions.	   In	  the	  last	  few	  years,	  many	  laboratories	  endeavored	  to	  find	  a	  
way	  to	  couple	  the	  high-­‐throughput	  techniques	  with	  the	   in	  vivo	  models.	  So	  far,	  the	  majority	  
of	   performed	   in	   vivo	   screens	  were	   focused	   on	   the	   identification	   of	   cooperating	   factors	   in	  
cancer	   mouse	   models125,126,127.	   Opportunities	   for	   translation	   of	   these	   valuable	   tools	   to	  
identify	  new	  actionable	  functionalities	   in	  human	  contexts	  have	  been	  hampered	  by	  the	  fact	  
that	   tumor-­‐initiating	   cells	   (TICs)	   are	   rare	   in	   many	   human	   cancers168-­‐172.	   TIC	   frequency	  
assessment	   is	   traditionally	   based	   on	   serial	   transplantation	   in	   limiting	   dilution,	   a	   time-­‐
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consuming	   and	   imprecise	   method202,203.	   Recently,	   Possemato	   and	   colleagues	   showed	   the	  
first	  pooled-­‐shRNA	  in	  vivo	  screen	  on	  a	  human	  breast	  cancer	  cell	   line	  (MCF10DCIS.com)	  and	  
relied	   on	   the	   statistical	   power	   of	   the	   average	   between	   eleven	   replicates	   for	   hits	  
identification132.	   In	   our	   study,	   we	   propose	   a	   loss-­‐of-­‐function	   in	   vivo	   screen	   on	   patient-­‐
derived	   samples	   from	   one	   of	   the	   most	   aggressive	   solid	   tumors,	   the	   pancreatic	   ductal	  
adenocarcinoma,	   adjusted	   for	   the	   effective	   number	   of	   tumor	   initiating	   cells.	   A	   complexity	  
study	  using	  thousands	  of	  molecular	  barcodes	  demonstrated	  to	  be	  a	  useful	  tool	  to	   increase	  
the	   sensitivity	   of	   the	   method	   and	   to	   rapidly	   optimize	   conditions	   for	   shRNA	   library	  
transduction	  reducing	  the	  number	  of	  required	  animals.	  The	  integration	  of	  this	  approach	  with	  
barcoded	  on-­‐target	   shRNA	   libraries	   in	  exactly	   the	   same	  experimental	   setting	  established	  a	  
flexible	   format	   that	   can	   take	   into	   account	   tumor	   variability	   between	   patients.	   This	   point	  
acquires	  even	  more	   relevance	   taking	   into	  account	   the	  adaptation	  of	  our	  barcode	  platform	  
into	   a	   context	   of	   patient-­‐derived	   xenografts	   (PDXs).	   So	   far,	   limitations	   of	   extensive	   use	   of	  
PDX	   models	   for	   functional	   genomic	   studies	   were	   intrinsically	   related	   to	   the	   extreme	  
variability	  observed	  in	  establishing	  stable	  in	  vitro	  cultures134,135.	  Our	  new	  protocol,	  optimized	  
in	   each	   one	   of	   the	   involved	   steps	   (single	   cell	   isolation,	   cell	   seeding	   and	   culturing	  media),	  
displayed	  100%	  rate	  of	  success	  (7/7).	  The	  potential	  caveat	  of	  genetic	  biases	  introduced	  by	  a	  
prolonged	   in	   vitro	   culture	  was	   limited	   in	  our	   approach	   restricting	   the	  number	  of	   passages	  
before	  transplantation.	   In	  vivo	  expansion	  of	  the	  tumor	  cell	  population	  in	  primary	  xenograft	  
and	  cell	  seeding	  at	  high	  confluency	  further	  guaranteed	  the	  possibility	  to	  obtain	  the	  required	  
number	  of	  cells	  for	  performing	  drop-­‐out	  screens	  in	  a	  short	  period	  of	  time.	  Interestingly,	  the	  
extension	  of	  our	  in	  vivo	  screening	  platform	  to	  other	  medical	  indications	  with	  longer	  survival	  
expectations	   compared	   to	   PDAC	   (ex.	   Melanoma,	   Triple-­‐Negative	   Breast	   Cancer)	   will	  
potentially	   allow	   for	   identification	   of	   selective	   vulnerabilities	   in	   time	   to	   impact	   treatment	  
recommendations.	  
To	  increase	  the	  stringency	  of	  our	  studies,	  we	  chose	  to	  perform	  parallel	  screens	  in	  human	  and	  
mouse	  PDAC	  cells,	  using	  shRNA	  sets	  specific	  for	  either	  context.	  This	  increased	  the	  chance	  to	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find	   cancer	   vulnerabilities	   related	   to	   a	   specific	   context	   dependency	   and	   allowed	   the	  
application	  of	  functional	  and	  structural	  criteria	  for	  hits	  prioritization.	  The	  robustness	  of	  our	  
analytics	   pipeline	  was	   proven	   by	   the	   absence	   of	   false	   positive	   hits	   among	   the	   top-­‐scoring	  
genes,	   as	   confirmed	   by	   the	   experiments	   with	   independent	   shRNAs.	   Developing	   a	   high-­‐
throughput	   validation	   scheme	   to	   triage	   hits	   emerged	   from	   each	   screen	   we	   were	   able	   to	  
enroll	   the	   most	   promising	   candidates	   in	   functional	   and	   clinico-­‐pathological	   studies	   to	  
determine	   the	   highest	   priority	   targets.	   The	   idea	   of	   proving	   the	   efficacy	   of	   our	   in	   vivo	  
screening	  platform	  applying	  a	  set	  of	  shRNA	  specific	  for	  chromatin-­‐remodeling	  enzymes	  was	  
dictated	  by	  the	  very	  low	  mutation	  frequency	  of	  these	  genes	  in	  PDAC,	  in	  front	  of	  a	  consistent	  
deregulation	  at	  the	  protein	  level.	  Focusing	  on	  different	  PDAC	  genetic	  backgrounds,	  with	  the	  
common	  denominator	   of	  mutant	   KRAS,	  we	   increased	   the	   chance	   of	   identifying	   actionable	  
epigenetic	  dependencies	  to	  overcome	  actual	  KRAS	  “undruggability”.	  
Genetic	  lesions	  in	  chromatin	  regulators	  have	  been	  identified	  in	  a	  variety	  of	  cancers	  and	  new	  
epigenetic	   cancer	   dependencies	   are	   emerging	   as	   intriguing	   actionable	   vulnerabilities32,219.	  
Chromosomal	   translocations	   involving	   MLL	   gene	   are	   frequent	   events	   characterizing	   the	  
Mixed	  Lineage	  Leukemia.	  In	  this	  disease,	  it	  has	  been	  shown	  that	  fusion	  events	  with	  a	  variety	  
of	  different	  partners	  compromise	   the	  MLL	  methyltransferase	  activity220.	  However,	  multiple	  
members	   of	   the	  MLL	   family	   could	   be	   deregulated	   via	   different	   oncogenic	   mechanisms	   in	  
PDAC,	  as	  the	  genetic	  alterations	  in	  MLL2	  (amplification)	  and	  MLL3	  (mutation)	  suggested34,221.	  
Therefore,	  a	  deeper	  understanding	  of	  genes	  and	  pathways	  regulated	  by	  each	  MLL	  subunit	  in	  
the	  context	  of	  PDAC	  will	  be	  critical	  to	  elucidate	  the	  molecular	  dynamics	  of	  this	  disease	  better	  
and	  to	  identify	  additional	  key	  points	  of	  vulnerability.	  Experiments	  with	  the	  MM-­‐401	  peptide,	  
able	  to	  selectively	  disrupt	  the	   interaction	  between	  MLL1	  and	  WDR5	  without	   impacting	  the	  
other	   MLL	   subunits,	   could	   be	   performed	   to	   dissect	   these	   specific	   PDAC	   context	  
dependencies222.	  
In	   this	   study	  we	   identified	   the	  core	  different	   subunits	  of	   the	  COMPASS	  complexes	   (WDR5,	  
ASH2L,	  RBBP5)	  as	  broad	  relevant	  players	   in	  sustaining	  PDAC	  progression	  and	  maintenance,	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while	   the	   dependency	   on	   the	   MLL	   subunits	   appears	   to	   be	   more	   context-­‐dependent	   and	  
potentially	  consequent	  to	  specific	  genetic	  alterations.	  These	  findings	  were	  further	  enforced	  
by	   minimal	   overlap	   between	   transcriptionally	   regulated	   gene	   sets	   in	   3	   different	   PDAC	  
models	   upon	   COMPASS	   complex	   depletion,	   as	   proved	   by	   the	   intersection	   between	  
expression	  profiles	  and	  promoter	  methylation.	  However,	  our	  actual	  analysis	  was	   limited	  to	  
the	  methylation	  level	  of	  the	  promoter	  regions	  and	  can	  not	  exclude	  a	  relevant	  contribution	  of	  
enhancer	   regions	   in	   PDAC	   transcriptional	   regulation.	   So,	   we	   propose	   to	   investigate	   the	  
contribution	   of	   these	   distal	   genomic	   regions	   in	   sustaining	   essential	   PDAC	   mechanisms	  
crossing	  our	  H3K4	  methylation	  profiles	  with	  the	  span	  of	  H3K27	  acetylation,	  a	  histone	  mark	  
associated	  to	  the	  active	  enhancers223.	  Moreover,	  Blobel	  and	  colleagues	  recently	  proposed	  an	  
intriguing	   hypothesis	   for	   the	   COMPASS	   role	   in	   mitosis	   as	   a	   positional	   bookmark	   for	  
transcriptional	   reactivation	   of	   immediate	   early	   genes	   (IEGs)	   after	   mitotic	   exit224.	   In	   this	  
scenario,	   it	   could	   be	   valuable	   investigating	   COMPASS	   regulation	   of	   IEGs	   in	   PADC	   contexts	  
where	  mutant	  KRAS	   imposes	  a	  higher	  requirement	  of	  their	  associated	  transcription	  factors	  
(TFs),	  as	  previously	  demonstrated	  by	  Fos.	  
Different	  works	  clearly	  demonstrated	  a	  cell-­‐cycle	  regulated	  expression	  of	  COMPASS	  complex	  
members	   and	   presented	   as	   peaks	   at	   the	   G1–S	   and	   G2–M	   transitions.	   The	   interactions	  
between	  MLL1/MLL2	   complexes	   and	   E2F	   proteins	   are	   unique,	   or	   partially	   redundant,	   and	  
may	   activate	   or	   repress	   E2F	   cell	   cycle	   target	   genes	   in	   addition	   to	   cyclins	   and	   cyclin-­‐
dependent	   kinase	   (CDK)	   inhibitors	   (CDKIs)213.	   Along	   the	   same	   line,	   a	   COMPASS	   complex	  
methylation-­‐independent	  role	  was	  recently	  proposed	  as	  a	  mechanism	  to	  regulate	  cell-­‐cycle	  
execution	  in	  U2OS	  osteosarcoma	  cell	  line56.	  Another	  possibility	  is	  a	  direct	  control	  of	  the	  cell-­‐
cycle	  mechanism,	  as	  demonstrated	  in	  yeast	  by	  a	  cross-­‐talk	  between	  histone	  and	  non-­‐histone	  
methylations,	   controlled	   by	   the	   Set1-­‐containing	   complex	   and	   able	   to	   influence	   the	  
kinetochore	  subunit	  Dam1225.	  So,	  our	  results	  are	  helping	  to	  clarify	  the	  hijacked	  functions	  of	  
the	  COMPASS	  complex	   in	  solid	  tumors,	  as	  demonstrated	  by	  the	  fact	  that	  PDAC	  cells	  under	  
the	  constant	  stimulus	  of	  a	  potent	  oncogene	  are	  not	  able	  to	  repair	  DNA	  damages	  upon	  WDR5	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silencing.	   The	   analysis	   of	   the	   early	   events	   is	   suggesting	   potential	   defects	   starting	   in	   G1-­‐S	  
phases	  of	  the	  cell-­‐cycle	  that	  cannot	  be	  counteracted	  during	  chromosome	  segregation	  or	  cell	  
division	   and	   are	   relentlessly	   driving	   cells	   to	   aneuploidy	   and	   mitotic	   catastrophe.	   These	  
observations	  are	  further	  intriguing	  taking	  into	  account	  the	  prominent	  role	  of	  ATR	  and	  MLL	  in	  
S-­‐phase	  checkpoint	  activation	  and	  premature	  chromosome	  condensation	  (PCC)	  escaping	   in	  
the	  presence	  of	  damaged	  DNA55,215.	  In	  this	  direction,	  the	  COMPASS	  complex	  could	  represent	  
a	   new	  weakness	   point	   for	   PDAC	   tumors	  with	  G1-­‐checkpoint	   alterations	   and	   compromised	  
cell	   cycle-­‐arrest	  checkpoints.	  Tumor	  cells	  possess	  an	   increased	  number	  of	   replication	   forks	  
and	   endure	   elevated	   levels	   of	   replication	   stress	   compared	   to	   normal	   cells,	   opening	   the	  
intriguing	  possibility	  that	  WDR5	  over-­‐expression	  in	  tumors	  may	  be	  required	  to	  stabilize	  the	  
replication	  machinery.	  Whether	  this	  is	  a	  direct	  effect	  of	  WDR5	  (or	  a	  WDR5	  complex)	  binding	  
or	  an	   indirect	  effect	   (possibly	  mediated	   through	   transcriptional	  control	  by	  a	  COMPASS-­‐like	  
complex),	   cannot	   be	   determined	   from	   our	   current	   studies.	   The	   recent	   finding	   of	   a	   direct	  
interaction	  between	  WDR5	  and	  c-­‐Myc	  could	   imply	  a	  further	  possibility,	  that	  WDR5	  may	  be	  
recruited	   to	   replication	   origins	   to	   regulate	   c-­‐Myc	   association	   with	   the	   replication	  
machinary218.	  Dominguez-­‐Sola	  and	  colleagues	  have	  recently	  demonstrated	  a	  direct	  role	  of	  c-­‐
Myc	   in	   the	   initiation	   of	   DNA	   replication	   that	   is	   independent	   from	   the	   transcriptional	  
regulation226.	   More	   than	   that,	   in	   this	   study,	   WDR5,	   MCM2,	   MCM4	   and	   c-­‐Myc	  
coimmunoprecipitated	   as	   part	   of	   the	   same	   complex	   enforcing	   the	   hypothesis	   of	   WDR5-­‐
mediated	   c-­‐Myc	   recruitment	   at	   the	   replicative	   forks.	   Direct	   confirmation	   of	   this	   physical	  
interaction	  at	  the	  replication	  origins	  of	  PDAC	  contexts	  will	  open	  the	  possibility	  to	  think	  new	  
inhibitors	  selectively	  oriented	  towards	  the	  transcription-­‐independent	  function	  of	  c-­‐Myc	  and	  
not	  at	  the	  interaction	  with	  Max.	  So,	  our	  findings	  are	  proposing	  a	  new	  layer	  of	  complexities	  in	  
trapping	   the	   COMPASS	   complexes	   during	   tumor	   development	   and	   unmasking	   unexplored	  
directions	  for	  new	  therapeutic	  opportunities.	  
Taken	  together,	  our	  data	  highlight	  this	  in	  vivo	  screening	  platform	  as	  a	  powerful	  new	  tool	  to	  
identify	  genetic	  vulnerabilities	  using	  patient-­‐derived	  tumor	  samples.	  This	  system	  can	  also	  be	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enabled	  in	  syngeneic	  mouse	  models	  where	  one	  can	  probe	  the	  effects	  of	  target	  inhibition	  in	  
the	   context	   of	   an	   intact	   immune	   response,	   and	   in	   the	   presence	   of	   immune	   checkpoint	  
activators.	  As	  initial	  proof	  of	  concept	  of	  the	  validity	  of	  our	  approach,	  we	  identify	  WDR5	  as	  a	  
new	   regulator	   of	   PDAC	   development	   and	   maintenance,	   and	   illuminate	   therapeutic	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Materials	  and	  Methods	  	  	  
Antibodies,	   plasmids	   and	   chemical	   reagents.	   Primary	   antibodies	   used	   for	   flow	   cytometry,	  
immunohistochemistry	  and	  immunoblotting	  were:	  Cytokeratin	  19	  (Proteintech,	  14965-­‐1-­‐AP),	  
Vimentin	   (Cell	  Signaling	  Technologies,	  D21H3),	  HLA	  A	   (Abcam,	  ab52922),	  phospho-­‐ERK	  (Cell	  
Signaling	  Technologies,	  D10),	  WDR5	  (Cell	  Signaling	  Technologies,	  D9E1I),	  SMC2	  (Cell	  Signaling	  
Technologies,	   D91E3),	   PHF5A	   (Santa	   Cruz	   Biotechnology,	   V-­‐12),	   Vinculin	   (Cell	   Signaling	  
Technologies,	   E1E9V),	   β-­‐Actin	   (sc-­‐1615,	   Santa	   Cruz),	   HSP90	   (Cell	   Signaling	   Technologies,	  
C45G5),	   ASH2L	   (Cell	   Signaling	   Technologies,	   D93F6),	   RBBP5	   (Cell	   Signaling	   Technologies,	  
D3I6P),	   phospho-­‐H2AX	   (Cell	   Signaling	   Technologies,	   20E3),	   H432),	   p53	   (Santa	   Cruz	  
Biotechnology,	   FL-­‐393),	   p16	   (Proteintech,	   10883-­‐1-­‐AP),	   SMAD4	   (Abcam,	   ab40759),	   Ki67	  
(Thermo	   Scientific),	   Sox9	   (Millipore),	   Pdx1	   (Santa	   Cruz	   Biotechnology,	   A-­‐17),	   H3K4me3	  
(Abcam,	   ab8580),	   H3	   (Abcam,	   ab12079),	   GFP	   (Abcam,	   ab290),	   APC-­‐conjugated	   BrdU	   (BD	  
Biosciences,	   552598),	   CDC45	   (Cell	   Signaling	   Technologies,	   D7G6),	   c-­‐Myc	   (Santa	   Cruz	  
Biotechnology,	   9E10),	   CDT1	   (Cell	   Signaling	   Technologies,	   D10F11),	   MCM2	   (Cell	   Signaling	  
Technologies,	  D7G11),	  GAPDH	  (Cell	  Signaling	  Technologies,	  14C10),	  APC-­‐conjugated	  HLA-­‐ABC	  
(BD	   Biosciences,	   555555),	   PE-­‐conjugated	   H-­‐2Kd	   (BD	   Biosciences,	   553566).	   Plasmids:	   pLKO	  
WDR5	   shRNAs	   (Sigma,	   Human	   sh1	   TRCN0000118047,	   sh2	   TRCN0000118049;	   Mouse	   sh1	  
TRCN0000034415;	   sh2	   TRCN0000034416),	   pLKO	   RBBP5	   shRNAs	   (Sigma,	   Human	   sh1	  
TRCN0000166086,	   sh2	   TRCN0000165777),	   pLKO	   ASH2L	   shRNAs	   (Sigma,	   Human	   sh1	  
TRCN0000019274,	   sh2	   TRCN0000019275),	   pLKO	   PHF5A	   shRNAs	   (Sigma,	   Human	   sh1	  
TRCN0000286156,	   sh2	   TRCN0000286158),	   pLKO	   SMC2	   shRNAs	   (Sigma,	   Human	   sh1	  
TRCN0000291366,	  sh2	  TRCN0000291367),	  pLKO	  Non-­‐Targeting	  (Sigma,	  SHC007),	  pLX304	  was	  
a	   gift	   from	   D.Root	   (Addgene	   plasmid	   ♯25890	   ),	   Tet-­‐inducible	   pRSIT16	   WDR5	   shRNAs	  
(Cellecta,,	   Human	   sh1	   shhWDR5	   251,	   sh2	   shhWDR5	   1000),	   Tet-­‐inducible	   pRSIT16	   Non-­‐
Targeting	   (Cellecta,	   shNT),	   CRISPR/Cas9	   WDR5	   constructs	   (Cellecta,	   pRSGC1).	   Full-­‐length,	  
sequence-­‐verified	   cDNA	   for	   WDR5	   (Clone♯IOH4895)	   was	   obtained	   from	   the	   Ultimate	   ORF	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collection	  (Invitrogen)	  and	  transferred	  by	  Gateway	  cloning	  into	  a	  modified	  pHAGE-­‐EF1a-­‐IRES-­‐
EGFP	   lentiviral	   vector	   (generously	   provided	  by	  D.Kotton,	   BU	   School	   of	  Medicine).	  Chemical	  
reagents:	   VE-­‐821	   (Selleck	   Chemicals),	   Hydroxyurea	   (Sigma	   Aldrich),	   Doxycycline	  
Hydrochloride	  (RPI	  Corp.)	  
	  
Somatic	   lentiviral	   vectors	   and	   other	   plasmids.	   pLSM5:	   a	   synthetic	   cassette	   (Geneart,	   Life	  
Technologies)	   containing	   the	   U6	   promoter	   and	   the	   Cre	   recombinase	   sequence	   under	   the	  
human	   Keratin	   19	   promoter	   (-­‐1114,	   +141)	   flanked	   by	   2	   TATA-­‐Frt	   sites	   (XbaI-­‐U6-­‐TATA-­‐Frt-­‐
EcoRI-­‐hKrt19-­‐NheI-­‐Cre-­‐TATA-­‐Frt-­‐HpaI)	   was	   cloned	   into	   the	   XbaI/HpaI	   site	   of	   the	   pSICO	  
vector.	  A	  DNA	  fragment	  was	  liberated	  by	  XbaI/KpnI	  digestion	  and	  cloned	  into	  the	  XbaI	  KpnI	  
sites	  of	  the	  pLB	  vector	  32.	  The	  introduction	  of	  the	  TATA	  box	  into	  the	  Frt	  sites	  was	  designed	  
according	   to	   Ventura	   et	   al.	   All	   the	   constructs	   were	   verified	   by	   restriction	   digestion	   and	  
sequencing.	  The	  pSICO	  and	  pSICO-­‐Flpo	  were	  made	  by	  Dr.	  Tyler	  Jacks227.	  The	  pLB	  vector	  was	  
created	  by	  Dr.	  Stephan	  Kissler.	  All	  plasmids	  were	  obtained	  through	  Addgene.	  
	  
Mouse	  strains.	  KrasLSL_G12D/+	  mice	  were	  generated	  by	  Dr.	  Tyler	  Jacks	  and	  obtained	  through	  the	  
Jackson	   Laboratory.228	   The	   p48Cre/+,	   the	   Ink4aLoxP/LoxP	   and	   the	   Trp53LoxP/LoxP	   strains	   were	  
donated	  by	  Dr.	  Ronald	  DePinho.	  The	  R26Cag-­‐FlpoERT2	  was	  generated	  by	  Dr.	  Alexandra	  Joyner	  and	  
obtained	   from	   the	   Jackson	   Laboratory229.	   The	   Cag-­‐FlpER	   allele	   was	   kindly	   donated	   by	   Dr.	  
Susan	  Dymecki230.	  R26mTmG	  strain	  was	  generated	  by	  Dr.	  Liqun	  Luo	  and	  obtained	  through	  the	  
Jackson	   Laboratory13. The	   strains	   were	   kept	   in	   a	   mix	   C57BL/6	   and	   129Sv/Jae.	   All	   animal	  
studies	  and	  procedures	  were	  approved	  by	  the	  UTMDACC	   Institutional	  Animal	  Care	  and	  Use	  
Committee.	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Tumor	  cell	  isolation	  and	  culture	  from	  human	  PDXs.	  	  Tumors	  from	  human	  primary	  xenografts	  
(Xenograft	  I)	  were	  harvested	  in	  HBSS	  (Gibco).	  Isolation	  of	  pancreatic	  adenocarcinoma	  tumor	  
xenograft	  (PATX)	  cells	  was	  performed	  by	  a	  combination	  of	  enzymatic	  (Tumor	  Dissociation	  Kit,	  
human,	  Miltenyi	  Biotec)	  and	  mechanical	  (mincing	  the	  tumor	  tissue	  in	  very	  small	  pieces	  with	  
sterile	  scissors)	  dissociation	  protocols.	  Erythrocytes	  were	  removed	  through	  RBC	  Lysis	  Buffer	  
1X	  (eBioscience).	  The	  single	  cell	  populations	  were	  seeded	  at	  high-­‐confluency	  on	  collagen	  IV-­‐
coated	  plates	   (Corning)	   in	  DMEM/F12	  (Gibco)	  supplemented	  with	  10%	  FBS	  (Gibco),	  1%	  BSA	  
(Fisher	   Scientific),	   0.5	   μM	   Hydrocortisone	   (Sigma	   Aldrich),	   10	  mM	  HEPES	   (Invitrogen),	   100	  
ng/mL	   Cholera	   Toxin	   (Sigma	   Aldrich),	   5	   mL/L	   Insulin-­‐Transferrin-­‐Selenium	   (BD),	   100IU/mL	  
Penicillin	   (Gibco),	   100	   μg/mL	   Streptomycin	   (Gibco).	   In	   order	   to	   get	   rid	   of	   the	   murine	  
fibroblasts	   in	   the	   culture	   we	   performed	   brief	   trypsinization	   cycles	   (0.25%	   Trypsin-­‐EDTA,	  
Gibco)	  before	  each	  round	  of	  splitting.	  The	  enrichment	  for	  human	  components	  was	  confirmed	  
by	  flow	  cytometry	  comparing	  the	  percentage	  of	  cells	  expressing	  human	  (HLA-­‐ABC)	  or	  mouse	  
(H-­‐2Kd)	   histocompatibility	   complex	   antigens.	   The	   isolated	   human	   cells	   were	  maintained	   in	  
culture	   for	   a	   maximum	   of	   three	   passages	   before	   being	   transplanted	   in	   a	   secondary	   host	  
(Xenograft	   II).	   Primary	   xenograft	   isolated	   cells	  were	  also	   kept	   in	   culture	  as	   spheres	   in	   semi	  
solid	  media.	  Single	  cell	  suspensions	  were	  plated	  in	  DMEM	  (Gibco)	  supplemented	  with	  2	  mM	  
Glutamine	   (Invitrogen),	   10%	   FBS	   (Gibco),	   40	   ng/mL	   hEGF	   (PeproTech),	   20	   ng/mL	   hFGF	  
(PeproTech),	  5	  μg/mL	  h-­‐Insulin	   (Roche),	  0.5	  μM	  Hydrocortisone	   (Sigma	  Aldrich),	  100	  μM	  β-­‐
Mercaptoethanol	   (Sigma	   Aldrich),	   4	   μg/mL	   Heparin	   (Sigma	   Aldrich),	   100IU/mL	   Penicillin	  
(Gibco),	  100	  μg/mL	  Streptomycin	   (Gibco).	  Methocult	   (StemCell	  Technologies)	  was	  added	   to	  
SCM	   (0.8%	   final)	   to	   keep	   cells	   growing	   as	   clonal	   spheres	   versus	   aggregates.	   Fully	   formed	  
spheres	  were	  collected	  and	  digested	  with	  0.25%	  trypsin-­‐EDTA	  (Gibco)	  to	  single	  cells	  and	  re-­‐
plated25.	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Tumor	   cell	   isolation	   and	   culture	   from	   GEM	   models.	   For	   isolation	   of	   cells	   from	   primary	  
pancreatic	   tumors	   see	   Viale	   et	   al.211.	   Single	   cells	   derived	   from	   GEM	   tumors	   were	   kept	   in	  
culture	   as	   adherent	   cells	   or	   spheres	   in	   semi-­‐solid	  media.	   Briefly,	   tumors	   were	   digested	   at	  
37°C	   for	   1h	   with	   a	   Collagenase	   IV-­‐Dispase	   mix	   (4	   mg/mL,	   Invitrogen)	   soon	   after	   explant.	  
Single	   cell	   suspensions	  were	  plated	   in	  DMEM	   (Gibco)	   supplemented	  with	  2	  mM	  Glutamine	  
(Invitrogen),	   10%	   FBS	   (Gibco),	   40	   ng/mL	   hEGF	   (PeproTech),	   20	   ng/mL	   hFGF	   (PeproTech),	   5	  
μg/mL	  h-­‐Insulin	  (Roche),	  0.5	  μM	  Hydrocortisone	  (Sigma	  Aldrich),	  100	  μM	  β-­‐Mercaptoethanol	  
(Sigma	   Aldrich),	   4	   μg/mL	   Heparin	   (Sigma	   Aldrich),	   100IU/mL	   Penicillin	   (Gibco),	   100	   μg/mL	  
Streptomycin	   (Gibco).	  Methocult	   (StemCell	  Technologies)	  was	  added	  to	  SCM	  (0.8%	  final)	   to	  
keep	  cells	  growing	  as	  clonal	  spheres	  versus	  aggregates.	  Fully	  formed	  spheres	  were	  collected	  
and	   digested	  with	   0.25%	   trypsin-­‐EDTA	   (Gibco)	   to	   single	   cells	   and	   re-­‐plated.	   For	   2-­‐D	   tumor	  
culture	   cells	   were	   maintained	   in	   DMEM	   supplemented	   with	   10%	   FBS	   (Gibco),	   100IU/mL	  
Penicillin	  (Gibco),	  100	  μg/mL	  Streptomycin	  (Gibco).	  
	  
Tumor	  transplantation,	  transplantation	  in	  limiting	  dilution	  and	   in	  vivo	  studies.	  Tumor	  cells	  
were	   isolated	   from	  PDX	   tumors	  or	  GEMM	  models	   and	   stabilized	   in	   culture	   (see	  Tumor	   cell	  
isolation	   and	   culture).	   Usually,	   106	   or	   105	   tumor	   cells	   were	   respectively	   used	   for	   routine	  
transplantation	   from	   PDX	   or	   GEMM	   models.	   For	   the	   experiments	   with	   the	   Tet-­‐inducible	  
shRNAs	   when	   the	   tumors	   reached	   a	   volume	   of	   100-­‐130	   mm3,	   mice	   were	   put	   under	   a	  
doxycycline-­‐containing	   (1	   mg/mL)	   drinking	   water	   regimen	   and	   tumor	   size	   was	   measured	  
every	  5	  days.	  Tumor	  volume	  was	  calculated	  using	   the	   formula:	  V=l2*L/2	   (l	   length;	   L	  width).	  
For	  transplantation	  in	   limiting	  dilution	  were	  used	  104,	  103,	  102	  or	  10	  cells.	  Tumor	  cells	  were	  
suspended	   in	   PBS	   (Gibco)	   and	   Matrigel	   (BD	   Biosciences)	   (1:1	   dilution)	   and	   injected	  
subcutaneously	   into	   the	   flank	  of	   4-­‐	   to	  6-­‐week-­‐old	   female	   immunodeficient	  mice	   (NSG,	   The	  
Jackson	   Laboratory).	   Tumor-­‐initiating	   cell	   (TIC)	   frequencies	   and	   95%	   confidence	   intervals	  
were	  determined	  by	  the	  Extreme	  Limiting	  Dilution	  Analysis	  (ELDA)	  software202.	  For	  orthotopic	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end	  point	  survival	  studies,	  6-­‐9	  weeks	  old	  ncr/Nude	  female	  mice	  were	  injected	  with	  2x105	  PDX	  
cells	   resuspended	   in	   a	   1:1	   solution	   of	   PBS	   (Gibco)	   and	   Matrigel	   (BD	   Biosciences).	   All	  
manipulations	  were	  performed	  under	  IACUC-­‐approved	  protocols.	  
	  
Libraries	  design	  and	  construction.	  A	  custom	  library	  constituted	  by	  2410	  shRNAs	  focused	  on	  
chromatin	   remodeling	   enzymes	   was	   constructed	   by	   using	   chip-­‐based	   oligonucleotide	  
synthesis	  and	  cloned	  into	  the	  pRSI16	  lentiviral	  vector	  (Cellecta)	  as	  a	  pool.	  The	  shRNA	  library	  
targeted	   236	   genes	   with	   a	   coverage	   of	   10	   shRNAs/gene.	   The	   shRNA	   includes	   2	   G/U	  
mismatches	   in	   the	   passenger	   strand,	   a	   7	   nucleotides	   loop	   and	   a	   21	   nucleotides	   targeting	  
sequence.	  Targeting	   sequences	  were	  designed	  using	  a	  proprietary	  algorithm	   (Cellecta).	  The	  
oligo	   corresponding	   to	   each	   shRNA	  was	   synthesized	   with	   a	   unique	  molecular	   barcode	   (18	  
nucleotides)	  for	  measuring	  representation	  by	  NGS.	  The	  12.5k	  barcoded	  library	  applied	  for	  the	  
TIC	  covering	  studies	  was	  constructed	  using	  the	  same	  technology	  and	  cloned	  as	  a	  pool	  into	  the	  
pRSI17	  lentiviral	  plasmid	  (Cellecta).	  	  	  
	  
In	  vivo	  TIC	  coverage	  studies.	  The	  volume	  of	  virus	  required	  to	  give	  a	  percentage	  of	  infection	  
around	  30%	  or	  below	  was	  determined	  sample	  by	  samples	  using	  a	  3	  points	  dose	  response	  in	  
the	  presence	  of	  8	  μg/mL	  polybrene	  (Millipore):	  0.15,	  0.3	  and	  0.6	  transducing	  unit	  (TU)/cell	  for	  
the	  human	  PDX	  cells;	  0.3,	  0.6	  and	  1.2	  TU/cell	   for	  the	  GEMM-­‐derived	  cells	   (See	  Suppl.Fig.2).	  
Infectivity	  was	  determined	  as	  the	  %	  of	  RFP	  positive	  cells	  2	  days	  after	   infection	  as	  measured	  
by	  FACS	  analysis.	  	  In	  vivo	  TIC	  covering	  studies	  were	  performed	  al	  least	  in	  replicate.	  For	  large	  
scale	  infection	  of	  human	  PDX	  cells,	  60	  million	  cells	  were	  plated	  in	  T-­‐175	  flasks	  (Corning)	  with	  
fresh	  media	  containing	  8	  μg/mL	  polybrene	  and	  sufficient	  virus	  to	  guarantee	  a	  25%	  infection	  
rate	  based	  on	  precedent	   calculations.	   For	   infection	  of	  GEMM-­‐derived	   cells,	   20	  million	   cells	  
were	   plated	   in	   T-­‐75	   flasks	   (Corning)	   with	   fresh	   media	   containing	   8	   μg/mL	   polybrene	   and	  
sufficient	  virus	  to	  guarantee	  a	  15%	  infection	  rate	  based	  on	  precedent	  calculations.	  24	  hours	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after	   infection,	   the	   culture	   media	   was	   replaced	   with	   fresh	   media	   containing	   puromycin	  
(Gibco).	  For	  each	  cell	  line	  the	  optimal	  puromycin	  dose	  to	  achieve	  more	  than	  95%	  cell	  killing	  in	  
72	  hours	  was	  determined	  by	  measuring	  cell	  viability	  with	  a	  Cell	  Titer	  Glo	  assay	  (Promega)	  for	  
a	  6	  points	  dose	  response	  ranging	  from	  0	  to	  8	  μg	  of	  puromycin.	  72	  hours	  following	  puromycin	  
addiction,	  cells	  were	   trypsinized,	  pooled	   together	  and	  counted.	  A	   representative	  portion	  of	  
the	  total	  cells	  (normally	  1/3	  or	  1/4)	  was	  collected	  as	  Reference	  Cells	  and	  immediately	  frozen	  
as	   pellet	   at	   -­‐80°C.	   The	   cells	   for	   the	   in	   vivo	   studies	  were	   separated	   into	   independent	   tubes	  
(replicates	  or	   triplicates),	   suspended	   in	  200	  μl	  of	  a	  PBS:Matrigel	   (1:1)	   solution	  and	   injected	  
subcutaneously	   into	   the	   flank	  of	   4-­‐	   to	  6-­‐week-­‐old	   female	   immunodeficient	  mice	   (NSG,	   The	  
Jackson	   Laboratory).	   The	   experiments	   with	   the	   GEMM-­‐derived	   cells	   were	   performed	  
transplanting	  106	  cells	  per	  mouse	  ensuring	  an	  in	  vivo	  representation	  of	  ≈80	  cells/barcode.	  For	  
the	  human	  PDX	  experiments,	  each	  injection	  was	  performed	  with	  5x106	  cells	  to	  guarantee	  an	  
in	   vivo	   coverage	   of	   	   ≈400	   cells/barcode.	   Specifically,	   the	   TIC	   in	   vivo	   study	   with	   the	  MDA-­‐
PATX53	   to	   modulate	   the	   appropriate	   coverage	   in	   the	   human	   models	   was	   executed	   in	  
triplicate	  with	  106,	  3x106	  and	  5x106	  cells	  from	  the	  same	  infection.	  Mice	  were	  monitored	  every	  
5	  days	  and	  euthanized	  when	  the	  tumors	  reached	  a	  volume	  around	  750	  mm3	  as	  determined	  
by	  caliper	  measurement.	  Tumor	  volume	  was	  calculated	  using	  the	  formula:	  V=l2*L/2	  (l	  length;	  
L	  width).	  The	  whole	  tumor	  was	  collected	  from	  each	  mouse	  under	  sterile	  conditions,	  weighed	  
and	  snap-­‐frozen	  in	  liquid	  nitrogen.	  
	  
In	  vivo	  shRNA	  screens.	  Infectivity	  was	  determined	  sample	  by	  sample	  as	  the	  %	  of	  GFP	  positive	  
cells	  2	  days	  after	  infection	  as	  measured	  by	  FACS	  analysis	  (see	  In	  vivo	  TIC	  covering	  studies).	  In	  
vivo	  shRNA	  screens	  were	  performed	  al	   least	   in	  replicate.	  For	   large	  scale	   infection	  of	  human	  
PDX	  cells,	  60	  million	  cells	  were	  plated	  in	  T-­‐175	  flasks	  (Corning)	  with	  fresh	  media	  containing	  8	  
μg/mL	  polybrene	  and	  sufficient	  virus	  to	  guarantee	  a	  25%	  infection	  rate	  based	  on	  precedent	  
calculations.	  For	   infection	  of	  GEMM-­‐derived	  cells,	  20	  million	  cells	  were	  plated	  in	  T-­‐75	  flasks	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(Corning)	  with	  fresh	  media	  containing	  8	  μg/mL	  polybrene	  and	  sufficient	  virus	  to	  guarantee	  a	  
15%	   infection	   rate	   based	   on	   precedent	   calculations.	   24	   hours	   after	   infection,	   the	   culture	  
media	  was	   replaced	  with	   fresh	  media	   containing	  puromycin.	  72	  hours	   following	  puromycin	  
addiction,	  cells	  were	   trypsinized,	  pooled	   together	  and	  counted.	  A	   representative	  portion	  of	  
the	  total	  cells	  (normally	  1/3	  or	  1/4)	  was	  collected	  as	  Reference	  Cells	  and	  immediately	  frozen	  
as	  pellet	   at	   -­‐80°C.	   The	   cells	   for	   the	   in	   vivo	   screens	  were	   separated	   into	   independent	   tubes	  
(replicates	  or	   triplicates),	   suspended	   in	  200	  μl	  of	  a	  PBS:Matrigel	   (1:1)	   solution	  and	   injected	  
subcutaneously	   into	   the	   flank	  of	   4-­‐	   to	  6-­‐week-­‐old	   female	   immunodeficient	  mice	   (NSG,	   The	  
Jackson	   Laboratory).	   The	   experiments	   with	   the	   GEMM-­‐derived	   cells	   were	   performed	  
transplanting	  106	  cells	  per	  mouse	  ensuring	  an	   in	  vivo	   representation	  of	  ≈400	  cells/barcode.	  
For	  the	  human	  PDX	  experiments,	  each	  injection	  was	  performed	  with	  5x106	  cells	  to	  guarantee	  
an	   in	   vivo	   coverage	   of	   	   ≈2000	   cells/barcode.	   Mice	   were	   monitored	   every	   5	   days	   and	  
euthanized	  when	   the	   tumors	   reached	  a	   volume	  around	  750	  mm3	  as	  determined	  by	   caliper	  
measurement.	  Tumor	  volume	  was	  calculated	  using	  the	  formula:	  V=l2*L/2	  (l	   length;	  L	  width).	  
The	   whole	   tumor	   was	   collected	   from	   each	   mouse	   under	   sterile	   conditions,	   weighed	   and	  
snap-­‐frozen	  in	  liquid	  nitrogen.	  
	  
Genomic	  DNA	  extraction	   and	  PCR	   for	  NGS	   library	   production.	   Frozen	   tumors	   from	   in	  vivo	  
experiments	  were	  minced	  to	  small	  pieces	  through	  mechanical	  procedure	  with	  sterile	  scalpels	  
and	   suspended	   in	   buffer	   P1	   (QIAGEN,	   1	  mL	  Buffer/100	  mg	   tumor)	   supplemented	  with	   100	  
μg/mL	  RNase	  A	  (Promega).	  The	  dissociation	  step	  was	  performed	  in	  disposable	  gentleMACS	  M	  
tubes	   (Miltenyi	   Biotech)	   with	   the	   gentleMACS	   dissociator	   (Miltenyi	   Biotec).	   The	   cell	   pellet	  
obtained	  from	  the	  Reference	  Cells	  was	  suspended	  in	  1	  mL	  buffer	  P1/RNAse	  A.	  Samples	  were	  
transferred	  in	  a	  15	  mL	  polypropylene	  tube	  (Falcon)	  and	  lysed	  adding	  1/20	  volume	  of	  10%	  SDS	  
(Promega).	  After	  mixing,	  the	  Reference	  Cells	  lysates	  were	  incubated	  at	  RT	  for	  5	  minutes	  and	  
the	   tumors	   for	   20	  minutes.	   Genomic	   DNA	  was	   sheared	   by	   passing	   the	   lysate	   10-­‐15	   times	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through	  a	  22-­‐gauge	  syringe	  needle.	  Then,	  a	  first	  genomic	  DNA	  extraction	  step	  was	  executed	  
adding	   1	   volume	   of	   Phenol:Chloroform	  pH	   8.0	   (Sigma	  Aldrich).	   After	   centrifugation	   (12000	  
rpm,	  12	  minutes),	  the	  upper	  phase	  was	  moved	  to	  a	  new	  tube	  and	  a	  second	  extraction	  step	  
with	  Chloroform	  (Sigma	  Aldrich)	  was	  performed.	  Again,	  the	  upper	  phase	  was	  transferred	  to	  a	  
new	   tube	   and	   added	   with	   0.1	   volumes	   of	   3M	   NaCl	   (Sigma	   Aldrich)	   and	   0.8	   volumes	   of	  
isopropanol	   (Fisher	   Scientific)	   to	   precipitate	   the	   genomic	   DNA.	   Centrifugation	   of	   tumor	  
samples	  was	  performed	  at	  12000	  rpm	  for	  20	  minutes,	  the	  samples	  from	  Reference	  Cells	  were	  
stored	  over-­‐night	  at	  -­‐20°C	  before	  centrifugation.	  DNA	  pellet	  was	  washed	  once	  in	  70%	  ethanol	  
(Fisher	   Scientific)	   and	   centrifuged	   again	   for	   5	   minutes	   at	   12000	   rpm.	   The	   DNA	   pellet	   was	  
finally	   air-­‐dried	   and	   dissolved	   over-­‐night	   in	   UltraPure	   distilled	  water	   (Invitrogen).	   The	   final	  
DNA	   concentration	  was	   assessed	  by	  NanoDrop	  2000	   (Thermo	  Scientific)	   quantification.	   For	  
NGS	   libraries	   generation,	   the	   barcodes	   were	   amplified	   starting	   from	   the	   total	   amount	   of	  
genomic	  DNA	  in	  2	  rounds	  of	  PCR	  using	  the	  Titanium	  Taq	  DNA	  polymerase	  (Clontech-­‐Takara)	  
and	  pooling	  together	  the	  total	  material	  from	  the	  first	  PCR	  before	  proceeding	  with	  the	  second	  
run.	  The	  first	  PCR	  reactions	  were	  performed	  for	  16	  cycles	  with	  the	  common	  primer	  13K_R2	  
(5’-­‐	  AGTAGCGTGAAGAGCAGAGAA-­‐3’)	  and	  the	  specific	  primers	  for	  in	  vivo	  TIC	  covering	  studies,	  
FHTS3	   (5’-­‐TCGGATTCAAGCAAAAGACGGCATA-­‐3’)	   or	   in	   vivo	   screens,	   13K_F2	   (5’-­‐
TCGGATTCGCACCAGCACGCTA-­‐3’).	   The	   second	   PCR	   reactions	  were	   performed	   for	   12	   cycles	  
with	   the	   common	   primer	   P5_NR2	   (5-­‐
AATGATACGGCGACCACCGAGACGAGCACCGACAACAACGCAGA-­‐3’)	  and	  the	  specific	  primers	  for	  
in	   vivo	   TIC	   covering	   studies,	  Gx1_Bp	   (5’-­‐TCAAGCAGAAGACGGCATACGAAGACA-­‐3’)	   or	   in	   vivo	  
screens,	   P7_NF2	   (5’-­‐CAAGCAGAAGACGGCATACGATTCGCACCAGCACGCCTACGCA-­‐3’).	   The	  
primers	   for	   the	   second	   PCR	   reactions	   were	   optimized	   in	   order	   to	   introduce	   the	   required	  
adapters	  for	   Illumina	  NGS	  technology.	  The	  PCR	  amplifications	  were	  analyzed	  by	  agarose	  gel	  
electrophoresis	  (2.5%,	  Lonza)	  to	  check	  for	  the	  expected	  262	  bp	  (in	  vivo	  TIC	  covering	  studies)	  
or	  272	  bp	  (in	  vivo	  screens)	  products.	  Amplified	  PCR	  products	  from	  2	  replicates	  of	  the	  second	  
PCR	   reactions	  were	  pooled	   together	   and	  extracted	   from	  agarose	   gel	  with	   the	  QIAquick	   gel	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purification	  kit	  (QIAGEN).	  The	  amount	  of	  purified	  PCR	  product	  was	  quantified	  using	  the	  High	  
Sensitivity	   DNA	   Assay	   (Agilent	   Technologies)	   for	   the	   Agilent	   2100	   Bioanalyzer.	   Barcode	  
representation	   was	   measured	   by	   Next	   Generation	   Sequencing	   on	   an	   Illumina	   HiSeq	   2000	  
with	   a	   common	   sequencing	   primer	   for	   both	   the	   libraries,	   13K_Seq	   (5’-­‐
AGAGGTTCAGAGTTCTACAGTCCGAA-­‐3’).	  
	  
Bioinformatic	   data	   analysis.	   Read	   Counting:	   Illumina	   base	   calls	   were	   processed	   using	  
CASAVA	  (version	  1.8.2)	  and	  resulting	  reads	  were	  processed	  using	  our	  in-­‐house	  pipeline.	  Raw	  
FASTQ	  files	  are	  filtered	  for	  a	  4	  base	  pair	  spacer	  (CGAA)	  starting	  at	  18th	  base	  allowing	  for	  one	  
mismatch	   to	   account	   for	   sequencing	   errors,	   such	   that	   only	   reads	   amplified	   using	   above	  
mentioned	   PCR	   reactions	   are	   used	   for	   further	   processing.	  We	   then	   extract	   23-­‐40bp	   of	   the	  
above	  reads	  for	  targeting	  libraries,	  and	  1-­‐18	  bp	  for	  non-­‐targetting	  library.	  These	  are	  further	  
aligned	  using	  Bowtie	  (2.0.2)	  to	  their	  respective	  libraries	  (2.4k	  mouse	  Epigenome,	  2.4k	  human	  
Epigenome	   and	   12.5k	   non-­‐targetting	   scramble)231.	   We	   then	   use	   samtools	   to	   count	   the	  
number	  of	  reads	  aligned	  to	  each	  barcode232.	  
Complexity	   Analysis:	   Read	   counts	   are	   normalized	   for	   the	   amount	   of	   sequencing	   reads	  
retrieved	  for	  each	  sample,	  using	  library	  size	  normalization	  (to	  100	  million	  reads).	  
Hit	  Analysis:	  A	  similar	  approach	  was	  employed	  as	  with	  complexity	  analysis,	  described	  above.	  
Using	  normalized	  counts,	  each	  sample	  is	  then	  compared	  with	  its	  respective	  reference	  and	  a	  
Log2	  Fold	  Change	  is	  calculated.	  This	  is	  further	  normalizing	  using	  a	  robust	  Z-­‐Score	  defined	  by:	  
(FC_i	   –	   Median)/Median	   absolute	   deviation	   (MAD)233.	   To	   summarize	   the	   effect	   of	   knock-­‐
down	  at	  gene	  level	  we	  employed	  RSA,	  to	  score	  each	  gene234.	  
	  
Patient-­‐derived	   samples.	   Patient-­‐derived	   samples	   were	   obtained	   from	   consented	   patients	  
under	   an	   Institutional	   Review	   Board	   (IRB)-­‐approved	   protocol	   LAB07-­‐0854	   chaired	   by	   J.B.F.	  
(UTMDACC).	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shRNA	   expression	   and	   gene	   down-­‐regulation.	   Human	   PDX	   or	   GEMM	   tumor	   cells	   were	  
transduced	   with	   independent	   pLKO	   shRNA	   from	   concentrated	   or	   fresh	   virus	   (see	   Virus	  
preparation)	   in	   the	   presence	   of	   8	   μg/mL	   polybrene.	   24	   hours	   after	   infection	   the	   culture	  
media	  was	  replaced	  with	  a	   fresh	  media	  supplemented	  with	  puromycin.	  Down-­‐regulation	  of	  
the	  target	  was	  evaluated	  by	  western	  blot	  at	  72hs	  after	  shRNA	  selection.	  The	  same	  infection	  
procedure	  was	  applied	  for	  the	  Tet-­‐inducible	  shRNAs.	  The	  top	  20%	  RFP-­‐expressing	  cells	  were	  
sorted	   72	   hours	   after	   selection.	   48	   hours	   after	   reseeding,	   doxycycline	   was	   added	   to	   the	  
culture	  to	  induce	  shRNA	  expression.	  Down	  regulation	  of	  the	  target	  was	  evaluated	  by	  western	  
blot	   at	   72	  hours	   after	   shRNA	   induction.	   For	   the	   in	   vivo	   experiments	  with	   the	   Tet-­‐inducible	  
shRNAs,	  72	  hours	  after	  the	  initiation	  of	  the	  doxycycline-­‐containing	  (1	  mg/mL)	  drinking	  water	  
regimen	   mice	   were	   euthanized	   and	   tumor	   collected	   to	   confirm	   shRNA	   induction	   by	  
immunohistochemistry	  analysis.	  
	  
Flow	   cytometry,	   cell	   sorting,	   immunohistochemistry,	   immunoblotting	   analysis	   and	  
subcellular	  protein	  fractionation	  
Flow	   cytometry.	   Single	   cells	   isolated	   from	   PDX	  were	   stained	  with	   primary	   antibodies	   after	  
blocking	   with	   10%	   BSA	   and	   5%	   rat	   serum.	   HLA-­‐ABC	   (BD	   Biosciences)	   and	   H-­‐2Kd	   (BD	  
Biosciences)	  staining	  were	  performed	  according	  to	  manufacturer’s	  instructions.	  To	  study	  the	  
cell	  cycle	  of	  PDX	  tumor	  cells,	  BrdU	  Flow	  Kit	  (BD	  Pharmingen)	  was	  used	  according	  to	  datasheet	  
specifications.	   DAPI	   (Invitrogen)	   was	   used	   to	   stain	   DNA	   content	   or	   to	   exclude	   dead	   cells	  
depending	  on	  the	  experiment.	  After	  staining,	  samples	  were	  acquired	  using	  a	  BD	  FACSCantoII	  
flow	  cytometer	  and	  BD	  LSRFortessa	  analyzer.	  Cell	  sorting	  of	  the	  top	  20%	  RFP-­‐expressing	  cells	  
infected	  with	  Tet-­‐inducible	  shRNAs	  was	  performed	  using	  BD	  FACSAria	  II	  cell	  sorter.	  Data	  were	  
analyzed	  by	  BD	  FACSDiva	  or	  FlowJo	  (Tree	  Star).	  	  
ImmunoHistoChemistry.	  Tumor	  samples	  were	  fixed	   in	  4%	  formaldehyde	  for	  2	  to	  4	  hours	  on	  
ice,	  moved	   in	   70%	   ethanol	   for	   12	   hours,	   and	   then	   embedded	   in	   paraffin	   (Leica	   ASP300S).	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After	   cutting	   (Leica	   RM2235),	   baking	   and	   deparaffinization,	   slides	  were	   treated	  with	   Citra-­‐
Plus	   Solution	   (BioGenex)	   according	   to	   specifications.	   For	   IHC	   staining,	   endogenous	  
peroxidases	  were	   inactivated	   by	   3%	   hydrogen	   peroxide.	   Non-­‐specific	   signals	   were	   blocked	  
using	  3%	  BSA,	  10%	  goat	   serum	  and	  0.1%	   triton.	  Tumor	   samples	  were	   stained	  with	  primary	  
antibodies.	   For	   IHC,	   ImmPress	   and	   ImmPress-­‐AP	   (Vector	   Lab)	   were	   used	   as	   secondary	  
antibodies	  and	  Nova	  RED	  and	  DAB	  were	  used	  for	  detection	  (Vector	  Lab).	  Images	  (10X	  or	  20X	  
magnification)	   were	   captured	   with	   a	   Nikon	   DS-­‐Fi1	   digital	   camera	   using	   a	   wide-­‐field	   Nikon	  
EclipseCi	  microscope.	  
Immunoblotting.	   Protein	   lysates	  were	   resolved	   on	   5-­‐15%	   gradient	   polyacrylamide	   SDS	   gels	  
and	   transferred	   onto	   Nitrocellulose	   membranes	   according	   to	   standard	   procedures.	  
Membranes	   were	   incubated	   with	   indicated	   primary	   antibodies,	   washed,	   and	   probed	   with	  
HRP-­‐conjugated	   secondary	   antibodies.	   The	   detection	   of	   bands	   was	   carried	   out	   upon	  
chemiluminescence	  reaction	  followed	  by	  film	  exposure.	  	  
Subcellular	  protein	  fractionation.	  Separation	  and	  preparation	  of	  cytoplasmic	  and	  chromatin-­‐
bound	   protein	   extracts	   were	   performed	   applying	   the	   Subcellular	   Protein	   Fractionation	   Kit	  
(Thermo	  Scientific)	  according	  to	  vendor’s	  specifications.	  
	  
In	  vitro	  studies.	  Cell	  viability	  was	  measured	  using	  MTT	  assay	  (Sigma	  Aldrich)	  or	  Cell	  Titer	  Glo	  
(Promega)	   at	   various	   time	   points.	   Colony	   Formation	   Assay	   (CFA)	   was	   carried	   out	   seeding	  
2000/cells	  in	  a	  6	  well	  plate	  in	  replicate.	  After	  10-­‐15	  days	  colonies	  were	  visualized	  by	  staining	  
with	  Crystal	  Violet.	  For	  the	  experiment	  with	  the	  Tet-­‐inducible	  shRNAs,	  cells	  were	  treated	  with	  
0	   or	   200	   ng/mL	   of	   Dox	   after	   plating.	   The	   cells	  were	   incubated	   in	   the	   presence	   of	   the	   ATR	  
inhibitor	   (VE-­‐821)	   or	   Vehicle	   (0.1%	   DMSO)	   for	   the	   whole	   period	   of	   the	   experiment.	  
Replication	   inhibitor	   Hydroxyurea	   (HU)	   was	   used	   at	   a	   concentration	   2	  mM	   and	   cells	   were	  
harvested	   1	   hour	   after	   drug	   application.	   Experiments	   with	   the	   CRISPR/Cas9	   system	   were	  
performed	   using	   a	   single	   lentiviral	   vector	   (Cellecta,	   pRSGC1)	   carrying	   both	   the	   sgRNA	   for	  
WDR5	  and	  the	  Cas9	  nuclease.	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RNA-­‐Seq	  and	  data	  analysis.	  RNA	  profiling	  was	  performed	  at	  the	  UTMDACC	  Sequencing	  and	  
Microarray	  Facility.	  RNA	  was	  isolated	  72	  hours	  after	  puromycin-­‐selection	  from	  PDX	  or	  GEMM	  
tumor	  cells	  infected	  with	  constitutive	  WDR5	  shRNAs	  or	  control	  (shNT)	  using	  RNeasy	  Mini	  Kit	  
(Qiagen)	  according	  to	  technical	  specifications.	  Raw	  reads	  from	  PATX53	  and	  PATC66	  cells	  were	  
aligned	   to	   the	   hg19	   assembly	   of	   the	   Human	   genome	   using	   STAR	   aligner235.	   The	   raw	   reads	  
from	   the	   p48-­‐Cre,	   KP53	   cells	   were	   aligned	   to	   XX	   assembly	   of	   Mouse	   genome	   using	   STAR	  
aligner.	   Gene	   annotations	   from	   the	   ENSEMBL	   were	   used	   to	   quantify	   gene	   expression	  
information	  using	  HTSeq	  pipeline236.	  The	  raw	  read	  matrix	  was	  filtered	  with	  median	  absolute	  
deviation	   threshold	   and	   differential	   expression	   was	   carried	   out	   using	   edgeR	   Bioconductor	  
package237.	   As	   the	   sequencing	   was	   carried	   out	   in	   two	   different	   batches,	   we	   checked	   the	  
possibility	   of	   presence	   of	   the	   batch	   effect.	   No	   batch	   effect	  was	   found.	  We	   used	   ENSEMBL	  
annotations	  to	  identify	  1:1	  orthologs	  from	  Human	  and	  Mouse	  using	  biomaRt	  package.	  Genes	  
with	  at	  least	  1.5	  fold-­‐change	  and	  1%	  false	  discovery	  rate	  (FDR)	  were	  considered	  differentially	  
expressed	   for	   overlap	   analysis.	   To	   identify	   functional	   enrichment,	   we	   used	   -­‐10*log10(p-­‐
values)	   of	   differential	   expression	   and	  direction	  of	   fold	   change	   to	   generate	   ranked	   lists	   and	  
pathway	  information	  from	  mSigDB	  with	  GSEA	  algorithm238.	  
	  
ChIP-­‐Seq	   and	   data	   analysis.	   For	   characterization	  of	   genome-­‐wide	  binding	  profiles,	   the	   raw	  
reads	   were	   aligned	   to	   hg19	   and	   mm9	   genome	   assemblies	   using	   Bowtie2	   aligner	   and	   the	  
enriched	   peaks	   were	   identified	   using	   MACS	   algorithm239,240.	   The	   MACS	   algorithm	   was	   run	  
with	   the	   combination	  of	   control	   and	  WDR5-­‐shRNA	   treated	   samples	   that	  were	  enriched	   for	  
H3K4me3.	  Therefore,	   the	  peaks	   identified	   in	  such	  analysis	  would	  be	  those	   lost	  upon	  WDR5	  
knock-­‐down.	  Next,	  ChIPPeakAnno	  bioconductor	  package	  was	  used	  with	  ENSEMBL	  gene	  TSS	  
annotations	   to	   assign	   target	   genes	   with	   a	   distance	   threshold	   of	   +/-­‐	   5kb	   to	   the	   enriched	  
peak241.	  To	  integrate	  loss	  of	  genome	  wide	  binding	  of	  H3K4me3	  with	  gene	  expression	  profiles,	  
we	   define	   promoter	   enriched	   H3K4me3	   peaks	   as	   a	   gene	   signature.	   We	   then	   checked	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enrichment	  of	  these	  signatures	  with	  the	  ranked	  gene	  lists	  defined	  using	  RNA-­‐seq	  profiles	  of	  
control	  to	  WDR5	  knock-­‐down	  experiments	  in	  GSEA	  software.	  
	  
Virus	   preparation,	   Lentiviral-­‐based	   Somatic	   Mosaic	   model,	   Surgical	   procedures.	   Virus	  
preparation.	  Viral	  particles	  were	  produced	  using	  2nd	  generation	  packaging	  plasmids	  psPAX2	  
and	   pMD2.G	   generated	   by	   Didier	   Trono	   Lab	   and	   obtained	   by	   Addgene.	   293T	   cells	   (ATCC)	  
were	   cultured	   in	   DMEM	   supplemented	  with	   10%	   FBS	   (Gibco),	   100IU/mL	   Penicillin	   (Gibco),	  
100μg/mL	   Streptomycin	   (Gibco),	   4mM	   Caffeine	   (Sigma	   Aldrich)	   and	   transfected	   using	   the	  
Polyethylenimine	   (PEI).	   Supernatant	   was	   collected	   48-­‐72	   hours	   after	   transfection,	   filtered	  
through	   0.45μm	   low-­‐protein	   binding	   filters	   (Corning)	   and	   concentrated	   100X	   in	   sterile	   PBS	  
(Gibco)	  after	  ultracentrifugation	  at	  23000	  rpm	  for	  2	  hours.	  Concentrated	  virus	  was	  used	  fresh	  
or	  stored	  at	  -­‐80°C	  for	  further	  applications.	  	  
	  
Lentiviral	   Somatic	   Mosaic	   GEM	   model.	   Embryonic	   liver	   progenitors	   (E12.5/E13)	   were	  
isolated	  and	  cultured	  according	  to	  Zender	  et	  al.125.	  Cells	  were	  infected	  24	  hours	  after	  seeding	  
with	  the	  pLSM5	  virus	  and	  2x105	  cells	  were	  injected	  in	  the	  tail	  of	  the	  pancreas	  of	  Rag2-­‐/-­‐	  mice.	  
Before	   cell	   injection,	   Rag2-­‐/-­‐	  mice	   approximately	   8	   to	   10	  weeks	   old	   received	   7	   consecutive	  
(one	   each	   day)	   intraperitoneal	   injections	   of	   10μg/Kg	   caerulein.	   Animals	   were	   monitored	  
weekly	   for	   tumor	   formation.	   Tumor	   bearing	   mice	   were	   treated	   with	   tamoxifen	   (5x	   100ul	  
injections,	  15mg/ml)	  and	  tumor	  volume	  was	  measured	  by	  MRI	  (see	  below).	  
	  
Orthotopic	   injections.	   Mice	   were	   anesthetized	   using	   a	   Ketamine/Xylazine	   solution	   (150	  
mg/Kg,	  10	  mg/Kg).	  Shaved	  skin	  was	  disinfected	  with	  Betadine	  and	  Ethanol.	   Incisions	   (1	  cm)	  
were	  performed	  through	  the	  skin/subcutaneous	  and	  muscular/peritoneal	  layers.	  The	  spleen	  
and	   tail	   of	   the	   pancreas	   were	   exposed	   and	   cells	   were	   directly	   injected	   in	   the	   tail	   of	   the	  
pancreas.	  The	  muscular/peritoneal	  planes	  were	  closed	  by	  continuous	  resorbable	  sutures.	  The	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skin/subcutaneous	   planes	   were	   closed	   by	   interrupted	   resorbable	   sutures.	   Analgesia	   was	  
achieved	  with	  Buprenorphine	  (0.1	  mg/Kg	  BID).	  	  	  
	  
MRI	   and	   Ivis	   imaging.	   Animals	   were	   imaged	   on	   a	   4.7T	   Bruker	   Biospec	   (Bruker	   BioSpin,	  
Billerica)	   equipped	  with	  6	   cm	   inner	  diameter	   gradients	   and	  35	  mm	   inner	  diameter	   volume	  
coil.	  Multi-­‐slice	   T2-­‐weighted	   images	  were	   acquired	   in	   coronal	   and	   axial	   geometries	   using	   a	  
rapid	  acquisition	  with	  relaxation	  enhancement	  (RARE)	  sequence	  with	  TR/TE	  of	  2000/38	  ms,	  
matrix	   size	   256x192,	   0.75	   mm	   slice	   thickness,	   0.25	   mm	   slice	   gap,	   4x3	   cm	   FOV,	   101	   kHz	  
bandwidth,	  3	  NEX.	  Axial	  scan	  sequences	  were	  gated	  to	  reduce	  respiratory	  motion.	  Detection	  
of	   luciferase	  activity	  was	  performed	   in	  an	   IVIS-­‐100	   imaging	   system.	  Mice	  were	   injected	   i.p.	  
with	   the	   D-­‐Luciferin	   bioluminescence	   substrate	   (Perkin	   Elmer)	   5	   minutes	   before	   the	  
procedure,	   according	   to	  manufacturer’s	   instruction.	   The	   Living	   Image	   4.3	   software	   (Perkin	  
Elmer)	  was	  used	  for	  analysis	  of	  the	  images	  post-­‐acquisition.	  
	  
Statistical	   Analysis.	   In	   vitro	   and	   in	   vivo	   data	   are	   presented	   as	   the	   mean	   ±	   s.d.	   (standard	  
deviation).	   Statistical	   analyses	   were	   performed	   using	   a	   two-­‐tailed	   Student’s	   t-­‐test.	   Results	  
from	  survival	  experiments	  were	  analyzed	  with	  a	  Log-­‐rank	  (Mantel-­‐Cox)	  test	  and	  expressed	  as	  
Kaplan–Meier	  survival	  curves.	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